Prelims final.qxd
12/18/2006
15:07
Page i
Surgery for Ovarian Cancer Principles and Practice
Prelims final.qxd
12/18/2006
15:07
Page iii
Surgery for Ovarian Cancer Principles and Practice
Edited by Robert E Bristow
MD
Associate Professor and Director The Kelly Gynecologic Oncology Service The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
and Beth Y Karlan
MD
Director Women’s Cancer Research Institute Division of Gynecologic Oncology Cedars-Sinai Medical Center; Professor, Obstetrics and Gynecology Geffen School of Medicine at UCLA, Los Angeles, California, USA
Prelims final.qxd
12/18/2006
15:07
Page iv
© 2006 Taylor & Francis, an imprint of the Taylor & Francis Group First published in the United Kingdom in 2006 by Taylor & Francis, an imprint of the Taylor & Francis Group, 2 Park Square, Milton Park Abingdon, Oxon OX14 4RN, UK Second printing 2007 Tel: +44 (0)20 7017 6000 Fax: +44 (0)20 7017 6699 Email:
[email protected] Website: http://www.tandf.co.uk/medicine All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention. British Library Cataloguing in Publication Data Data available on application Library of Congress Cataloging-in-Publication Data Data available on application ISBN10: 1-84214-165-1 ISBN13: 9-78-1-84214-165-6 Distributed in North and South America by Taylor & Francis 2000 NW Corporate Blvd Boca Raton, FL 33431, USA Within Continental USA Tel: 800 272 7737; Fax: 800 374 3401 Outside Continental USA Tel: 561 994 0555; Fax: 561 361 6018 E-mail:
[email protected] Distributed in the rest of the world by Thomson Publishing Services Cheriton House North Way Andover, Hampshire SP10 5BE, UK Tel: +44 (0) 1264 332424 E-mail:
[email protected] Composition by Parthenon Publishing Printed and bound by Replika Press Pvt. Ltd.
Prelims final.qxd
12/18/2006
15:07
Page v
Contents
List of contributors
vii
Chapter 1
Epidemiology, staging and clinical characteristics Christina S Chu, Stephen C Rubin
1
Chapter 2
Preoperative preparation and surgical instrumentation Marcela G del Carmen, Robert E Bristow, Linda R Duska
39
Chapter 3
Management of early-stage ovarian cancer Anil K Sood, David M Gershenson
57
Chapter 4
Cytoreductive surgery: principles and rationale Christine H Holschneider, Jonathan S Berek
87
Chapter 5
Cytoreductive surgery: pelvis Robert E Bristow, Leo D Lagasse
127
Chapter 6
Cytoreductive surgery: abdominal retroperitoneum and adenopathy Jason D Wright, Thomas J Herzog
171
Chapter 7
Cytoreductive surgery: intestinal tract and omentum Yukio Sonoda, Dennis S Chi, Richard R Barakat
195
Chapter 8
Cytoreductive surgery: right upper abdomen Robert L Giuntoli II, Robert E Bristow, Richard D Schulick
227
Chapter 9
Cytoreductive surgery: left upper abdomen Krishnansu S Tewari, Michael L Berman
261
Chapter 10
Second-look surgery Ilana Cass, Beth Y Karlan
289
v
Prelims final.qxd
12/18/2006
15:07
Page vi
SURGERY FOR OVARIAN CANCER
Chapter 11
Secondary cytoreductive surgery Robert L Coleman, Adnan Munkarah, Robert E Bristow
305
Chapter 12
Laparoscopic surgery David E Cohn, Inbar Ben-Shachar, Jeffrey M Fowler
331
Chapter 13
Palliative surgery for ovarian cancer Laura J Havrilesky, Daniel L Clarke-Pearson
351
Chapter 14
Postoperative management Lee-may Chen
375
Index
413
vi
Prelims final.qxd
12/18/2006
15:07
Page vii
List of contributors
Richard R Barakat Gynecology Service Department of Surgery Memorial Sloan-Kettering Cancer Center 1275 York Avenue New York, NY 10021 USA
Robert E Bristow The Kelly Gynecologic Oncology Service Department of Gynecology and Obstetrics The Johns Hopkins Medical Institutions 600 North Wolfe Street, Phipps 281 Baltimore, MD 21287 USA
Inbar Ben-Shachar Division of Gynecologic Oncology James Cancer Hospital and Solove Research Institute The Ohio State University College of Medicine and Public Health 320 West 10th Avenue M-210 Starling Loving Hall Columbus, OH 43210 USA
Ilana Cass Division of Gynecologic Oncology Department of Obstetrics and Gynecology Cedars-Sinai Medical Center 8700 Beverly Boulevard, Suite 290W Los Angeles, CA 90048–1865 USA
Jonathan S Berek Department of Obstetrics and Gynecology Division of Gynecologic Oncology David Geffen School of Medicine at UCLA 10833 LeConte Avenue Los Angeles, CA 90095–1740 USA Michael L Berman Division of Gynecologic Oncology Chao Family Comprehensive Cancer Center University of California, Irvine Medical Center 101 The City Drive Orange, CA 92868 USA
Lee-may Chen Division of Gynecologic Oncology UCSF Comprehensive Cancer Center 1600 Divisadero Street 4th Floor San Francisco, CA 94115–1702 USA Dennis S Chi Gynecology Service Department of Surgery Memorial Sloan-Kettering Cancer Center 1275 York Avenue New York, NY 10021 USA
vii
Prelims final.qxd
12/18/2006
15:07
Page viii
SURGERY FOR OVARIAN CANCER
Christina S Chu Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Pennsylvania Health System 3400 Spruce Street Philadelphia, PA 19104 USA
Linda R Duska Division of Gynecologic Oncology Wayne State University/Karmanos Cancer Institute Harper Hospital 3990 John R Street, 2 Webber Detroit, MI 48201 USA
Daniel L Clarke-Pearson Division of Gynecologic Oncology Duke University Medical Center 3713 Benson Drive Durham, NC 27710 USA
Jeffrey M Fowler Division of Gynecologic Oncology James Cancer Hospital and Solove Research Institute The Ohio State University College of Medicine and Public Health 320 West 10th Avenue M-210 Starling Loving Hall Columbus, OH 43210 USA
David E Cohn Division of Gynecologic Oncology James Cancer Hospital and Solove Research Institute The Ohio State University College of Medicine and Public Health 320 West 10th Avenue M-210 Starling Loving Hall Columbus, OH 43210 USA Robert L Coleman Department of Obstetrics and Gynecology University of Texas, Southwestern Medical Center 5323 Harry Hines Boulevard, J7.124 Dallas, TX 75390–9032 USA Marcela G del Carmen Division of Gynecologic Oncology Vincent Memorial Obstetrics and Gynecology Massachusetts General Hospital Harvard Medical School Boston, MA 02114 USA
viii
David M Gershenson Department of Gynecologic Oncology The University of Texas MD Anderson Cancer Center 1515 Holcombe Boulevard, Unit 440 Houston, TX 77030 USA Robert L Giuntoli II The Kelly Gynecologic Oncology Service Department of Gynecology and Obstetrics The Johns Hopkins Medical Institutions 600 North Wolfe Street, Phipps 281 Baltimore, MD 21287 USA Laura J Havrilesky Division of Gynecologic Oncology Duke University Medical Center 3713 Benson Drive Durham, NC 27710 USA
Prelims final.qxd
12/18/2006
15:07
Page ix
LIST OF CONTRIBUTORS
Thomas J Herzog Division of Gynecologic Oncology Department of Obstetrics and Gynecology Columbia University 622 West 168th Street, PH 16 New York, NY 10032 USA
Richard D Schulick The Kelly Gynecologic Oncology Service Department of Gynecology and Obstetrics The Johns Hopkins Medical Institutions 600 North Wolfe Street, Phipps 281 Baltimore, MD 21287 USA
Christine H Holschneider Department of Obstetrics and Gynecology Division of Gynecologic Oncology David Geffen School of Medicine at UCLA 10833 LeConte Avenue Los Angeles, CA 90095–1740 USA
Yukio Sonoda Gynecology Service Department of Surgery Memorial Sloan-Kettering Cancer Center 1275 York Avenue New York, NY 10021 USA
Beth Y Karlan Women’s Cancer Research Institute Division of Gynecologic Oncology Cedars-Sinai Medical Center 8700 Beverly Boulevard, Suite 290W Los Angeles, CA 90048–1865 USA
Anil K Sood Department of Gynecologic Oncology and Cancer Biology The University of Texas MD Anderson Cancer Center 1515 Holcombe Boulevard, Unit 1362 Houston, TX 77030–1439 USA
Leo D Lagasse UCLA School of Medicine Division of Gymecologic Oncology Cedars-Sinai Medical Center 8635 West 3rd Street 160-W Los Angeles, CA 90048 USA Adnan Munkarah Division of Gynecologic Oncology Wayne State University/Karmanos Cancer Institute Harper Hospital 3990 John R Street, 2 Webber Detroit, MI 48201 USA
Krishnansu S Tewari Division of Gynecologic Oncology The Chao Family Comprehensive Cancer Center University of California, Irvine Medical Center 101 The City Drive Orange, CA 92868 USA Jason D Wright Division of Gynecologic Oncology Department of Obstetrics and Gynecology Washington University School of Medicine 4911 Barnes Hospital Plaza St Louis, MO 63110 USA
Stephen C Rubin Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Pennsylvania Health System 3400 Spruce Street Philadelphia, PA 19104 USA
ix
Prelims final.qxd
12/18/2006
15:07
Page x
Dedication
This book is dedicated to our spouses, Michelle and Scott; our children, Jackson and Chloe Bristow, and Matthew and Jocelyn Karlan; and our colleagues and mentors from whom we have been fortunate enough to learn and alongside whom we have faced the many challenges of gynecologic oncology and life – you have our deepest gratitude for your patience, support and guidance. Also, to our friend, colleague and mentor Rick Montz with a special note of remembrance. This book was inspired by our respect and admiration for all women with ovarian cancer, whose courage and determination will always motivate us to improve care until cures are discovered. Robert E Bristow Beth Y Karlan
x
Prelims final.qxd
12/18/2006
15:07
Page xi
Preface
Ovarian cancer is a significant cause of morbidity and mortality, and represents one of the most pressing problems in women’s health care today. Perhaps more than any other gynecologic malignancy, effective treatment of ovarian cancer requires an integrative model of multidisciplinary care that includes gynecologic, medical, surgical and radiation oncologists, pathologists, oncology nurses, psychologists and basic scientists among others. Recent advances in molecular biology, diagnostic imaging, chemotherapy, supportive care and targeted treatment strategies have contributed to an improved overall outcome for women with ovarian cancer. Nevertheless, complete and effective surgical intervention remains the cornerstone of ovarian cancer diagnosis and treatment. As surgical instrumentation and operative techniques have evolved, it has become increasingly apparent that special training is necessary in order to practice surgery for ovarian cancer beyond the fundamentals that are typically learned during postgraduate residency education. Formal fellowship training in gynecologic oncology is the preferred method of learning the myriad of individualized surgical approaches to women with ovarian cancer. In reality, however, many surgeons must acquire such expertise under less favorable circumstances. Admittedly, postgraduate training can only provide a foundation. Proficient ovarian cancer surgical skills are further developed through continued experience, challenge and self-instruction. Many surgical texts and atlases address the complexities of gynecologic and pelvic cancer surgery as a general topic, yet no single work has been devoted exclusively to the rational and effective operative management of ovarian cancer. The authors have attempted to fill this void with a
text that emphasizes the practical applicability of important procedures. The basic topics of ovarian cancer epidemiology and preoperative preparation are covered initially, followed by a section addressing the operative management of early-stage disease. The majority of the text, however, is devoted to the technical aspects of cytoreductive surgery, since this is where we perceive that the greatest need for extended training exists. The chapters on cytoreductive surgery are divided according to anatomic regions and include the relevant anatomical considerations, the surgical challenges specific to each region and the operative approaches and techniques favored by the authors. Chapters on laparoscopy, second-look surgery, secondary cytoreduction and palliative surgery follow. The final section discusses the unique postoperative care issues common to ovarian cancer surgical patients. This text is intended for all clinicians caring for women with ovarian cancer including attending surgeons, fellows and residents in the disciplines of gynecologic oncology, pelvic surgery, surgical oncology and general surgery. Ultimately, the optimal surgical management of the ovarian cancer patient is dependent on multiple factors including her age and general medical condition, the extent and biological aggressiveness of her disease, available access to an appropriately skilled multidisciplinary care team, and the preparedness of the surgeon to put forth the maximum operative effort. This text was conceived and prepared with this latter factor in mind.
Robert E Bristow Beth Y Karlan
xi
Ch 01 final.qxd
12/18/2006
15:08
Page 1
CHAPTER 1
Epidemiology, staging and clinical characteristics Christina S Chu, Stephen C Rubin
EPIDEMIOLOGY Overview Epithelial ovarian cancer is responsible for the majority of gynecologic cancer deaths, though it is only the second most common gynecologic neoplasm, accounting for approximately one-quarter of gynecologic cancer diagnoses.1,2 In 2003, the American Cancer Society estimated that 25 400 women would be diagnosed with ovarian cancer in the USA, and that 14 300 would die of their disease.3 A woman’s lifetime risk of ovarian cancer is about 1 in 70. Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the USA, following cancer of the lung, breast, colon and pancreas.3 Most women are diagnosed in advanced stages and eventually die of progressive, chemotherapy-resistant disease. Overall 5-year survival is approximately 53%.3 Malignant tumors of the ovary occur at all ages. Malignant germ cell tumors are most commonly found in adolescents and young women under the age of 20. In contrast, epithelial ovarian cancer is seen primarily in patients over the age of 50, with most women diagnosed between the ages of 60 and 64. Older patients have a significantly worse prognosis. Yancik et al. noted that those over the age of 65 were more likely to be diagnosed with advanced disease.4 Similarly, the National Cancer Institute reported that, while younger patients had a mortality rate of 1.0 per 100 000, those over the age of 50 demonstrated a mortality rate of 25.5 per 100 000.5
Etiologic theories and risk factors While the exact cause of epithelial ovarian cancer is unknown, several theories have been proposed. The most common theory of ‘incessant ovulation’ postulates that ovulatory trauma to the surface epithelium of the ovary may predispose to malignant transformation. In support of this theory, women who ovulate regularly, such as nulliparous patients,6 or women with a higher number of lifetime ovulatory events, such as those undergoing early menarche or late menopause,7 appear to have a higher risk for the development of epithelial ovarian cancer. Others have noted that ovulation-inducing drugs such as clomiphene citrate may also increase the risk of ovarian cancer.8,9 In contrast, multiparous women, and those with a history of breastfeeding or oral contraceptive use, appear to have a lower risk. Casagrande et al.10 reported that the use of oral contraceptives may decrease the risk by approximately 40%. This protective effect is maximized with 10 years of use and persists up to 15 years after discontinuation. Another theory suggests that chemical carcinogens introduced via the vulva and vagina with subsequent migration to the peritoneum via the uterus and Fallopian tubes may promote development of ovarian cancer. Both Keal11 and Newhouse et al.12 noted that women with occupational exposure to asbestos had a higher rate of intra-abdominal carcinomatosis resembling ovarian cancer. In animal models, other investigators noted that abnormal changes in the ovarian epithelium could be induced after exposure to asbestos.13,14 Talc particles have also been found in
1
Ch 01 final.qxd
12/18/2006
15:08
Page 2
SURGERY FOR OVARIAN CANCER
benign and malignant ovarian tumors.13,14 In 1979, Longo and Young15 suggested that talc could be introduced to the upper genital tract via dusting on sanitary napkins, and 10 years later, Venter16 used technetium-99m-labeled human albumin microspheres to prove that particles in the lower genital tract could in fact migrate to reach the ovaries. Despite this finding, the effect of talc on ovarian cancer risk is controversial. Several studies have failed to find an association between talc or asbestos and the development of ovarian cancer.17–19 However, Cramer et al.20 examined 215 women with epithelial ovarian cancer compared to 215 controls and noted that 43% of the women with cancer used talc as a dusting powder on the perineum or sanitary napkins compared to only 28% of controls, yielding a relative risk of 1.9. Similarly, Cook et al.21 noted a relative risk of 1.6 for women using talc on the perineum. Racial trends
The incidence of ovarian cancer varies with country of origin, as well as race. Residents of industrialized and affluent areas, such as North America and Western Europe, appear to incur the highest rates of occurrence. The incidence of ovarian malignancies has been reported to be 14.9 per 100 000 for residents of Sweden and 13.3 per 100 000 for residents of the USA compared to only 4.6 per 100 000 for residents of India and 2.7 per 100 000 for residents of Japan.22 Some have speculated that differences in parity may account for variations in incidence rates between industrialized and non-industrialized nations,23 while others suggest that changes in family size due to the introduction of oral contraceptives with their inherent protective effect may be responsible for the differences.24 Within the USA, ovarian cancer appears more frequently among White women than Black women (14.2 per 100 000 vs. 9.3 per 100 000, respectively).25 Of note, although the incidence among native-born Japanese is only 3.2 per 100 000, after one to two generations of residence in the USA, Japanese immi-
2
grants develop ovarian cancer at the same rate as other native-born Americans.26 These racial differences appear to affect survival as well. For the period 1973–77, the National Cancer Institute reported the age-adjusted mortality rate to be 8.7 per 100 000 for White women versus only 6.9 for Black women.25 Similarly, in more recently gathered data, other non-White women also displayed lower mortality rates – 7.3 per 100 000 for American Indians, 4.8 for Hispanics and 3.4 for Filipinos.27 Radiation exposure, viral infection and dietary factors
Investigators have examined several other risk factors associated with the development of epithelial ovarian cancer, although the evidence is mixed (see Table 1.1). The effect of radiation exposure on subsequent ovarian cancer risk is controversial. Annegers et al. have reported a relative risk of 1.8 for those individuals exposed to radiation,28 although others have noted no significant difference in risk.12 Viruses have been purported to affect the incidence of ovarian cancer. Although rubella and influenza infection6 have been occasionally reported to exert an effect, most speculation has centered on mumps infection. Some investigators have noted a protective effect for mumps,29 although this phenomenon may be related to reproductive factors: women exposed to mumps are more likely to come from families with more children and, in turn, produce more children themselves.30,31 In contrast, reports by Menczer et al.32 and Cramer et al.33 found that mumps infection may be associated with an increased risk for ovarian cancer. These authors noted that patients with ovarian cancer often demonstrated subclinical mumps infection, which they theorized might lead to early ovarian failure with subsequent elevation of gonadotropins, stimulating ovarian epithelial growth, ultimately leading to an elevated risk for cancer. Dietary factors have also been reported to affect the risk for developing ovarian cancer. In particular, a diet high in fat and meat has been noted to increase the risk for malignancy.30 Accordingly, obesity has also been reported to be associated with increased risk.30
Ch 01 final.qxd
12/18/2006
15:08
Page 3
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
Table 1.1 Suggested risk factors for the development of epithelial ovarian cancer Race White European Jewish descent Age > 50 years Residence in industrialized nation (except Japan) Diet high fat high coffee low fiber low vitamin A Environmental exposure talc asbestos radiation Reproductive early menarche late menopause nulliparity Viral mumps rubella Familial family history BRCA1, BRCA2 mutation DNA mismatch repair gene mutation
However, some have linked dietary risk with residence in industrialized nations.34 Cramer et al.35 examined the relationship between a high fat–high galactose diet and ovarian cancer risk in those populations lacking the enzyme galactose-1-phosphate uridyltransferase, which converts galactose to glucose. In these populations, increased levels of galactose are associated with increased gonadotropin levels, which are hypothesized to lead to elevated ovarian cancer risk. The authors reported a significantly lower level of enzyme activity in patients with ovarian cancer. Other dietary factors such as coffee consumption have been examined. Based on the observation that residents of Sweden have both the highest per capita
consumption of coffee and the highest incidence of ovarian cancer,36 Trichopoulos et al.37 conducted a case–control study confirming that patients with ovarian cancer did indeed consume more coffee than controls. However, other authors38,39 found no such correlation. The effect of other dietary factors is also controversial. Byers et al.38 noted an increased risk for patients with diets low in vitamin A and fiber. In contrast, a case–control study from Slattery et al.40 did not detect an association between ovarian cancer risk and intake of protein, fat, fiber, vitamin A, vitamin C, or total calories. In the largest prospective study to date, Fairfield et al. followed more than 80 000 women in the Nurses’ Health Study and found no association between intake of vitamins A, C and E and specific carotenoids, as well as fruit and vegetable intake, in relation to ovarian cancer risk.41
Familial syndromes The greatest single risk factor for the development of epithelial ovarian cancer is a family history of breast and/or ovarian cancer. In 1989, case–control studies by Koch et al.42 and Hartge et al.43 noted an increase in the risk for ovarian cancer in the setting of a family history of ovarian cancer, as well as a personal history of breast cancer. While the lifetime risk for developing ovarian cancer in the general population is between 1 and 2%, women with one family member suffering from ovarian cancer have their risk increased to 4–5%. With two affected family members, the risk increases to 7%.10,44 Approximately 5–10% of ovarian cancers occur in patients with a familial history of breast cancer, ovarian cancer or other adenocarcinoma.45–49 In many of these families, cancer risk appears to be transmitted in an autosomal dominant fashion.31 Two major syndromes of familial ovarian carcinoma have been described: hereditary breast–ovarian cancer and hereditary non-polyposis colon cancer (HNPCC).31,50 Specific genetic mutations involved in each syndrome are delineated in Table 1.2. Hereditary breast–ovarian cancer syndrome is usually seen in families with a history of cancer affecting
3
Ch 01 final.qxd
12/18/2006
15:08
Page 4
SURGERY FOR OVARIAN CANCER
first- and second-degree relatives. Women from these families tend to develop breast and/or ovarian cancer at a young age, and breast cancer may occur in both breasts. Over 90% of familial ovarian cancer cases are caused by germline mutations in the BRCA1 gene, with mutations in the BRCA2 gene being linked to most of the remaining cases.51 BRCA1, located on the long arm of chromosome 17, was initially cloned in 1994,52 and a year later, BRCA2 was isolated on the long arm of chromosome 13.53 Although the exact function of these genes is not known, BRCA1 and BRCA2 are felt to act as tumor suppressor genes, possibly involved in the repair of DNA damage54,55 and in regulation of gene expression.56–60 BRCA1 and 2 appear to be important genes in familial ovarian cancer, but not sporadic cancers. Mutations are transmitted in an autosomal dominant fashion with high penetrance. Mutations in BRCA1 have been reported to occur in 3–6% of all patients with epithelial ovarian carcinoma.61,62 Although only 1 in 800 people in the general population carries a mutation in BRCA1, the prevalence of mutations may be as high as 2.5% in individuals of Ashkenazi Jewish heritage,63,64 where three specific founder mutations, including the 185delAG and 5382insC mutations in BRCA1 and the 6174delT mutation in BRCA2, account for 90% of the cases of hereditary breast–ovarian cancer. Not all patients carrying mutations in BRCA1 and BRCA2 will develop cancer. Penetrance varies and
may be affected by age and the specific mutation inherited. In large families carrying mutations in BRCA1 studied by the Breast Cancer Linkage Consortium, the risk of developing breast cancer was approximately 82–87% by the age of 70, compared to only 11% in the general population.65 In these families, the risk for developing ovarian cancer by age 70 was approximately 44–63%, in contrast to the risk in the general population of only 1.4%. Overall, high penetrance of BRCA1 mutations in these families conveyed a greater than 90% lifetime risk of developing either breast or ovarian cancer. In similar studies of BRCA2 families, the risk of developing breast or ovarian cancer by age 70 was noted to be 84% and 27%, respectively.66 Overall, by the age of 70, the risk of developing either breast or ovarian cancer was estimated to be 88%. Mutation carriers in the general population may demonstrate lower penetrance. In a study of 120 Ashkenazi Jewish patients unselected for family history carrying one of the three founder mutations in BRCA1 and BRCA2, risks for developing breast cancer or ovarian cancer by age 70 were estimated to be 56% and 16%, respectively.67 BRCA1 and BRCA2 mutation carriers appear to exhibit a distinct clinical course. Rubin et al.68 reported on 53 ovarian cancer patients with germline mutations in BRCA1, and noted significantly improved survival compared to patients with sporadic cancers. The actuarial median survival for the 43 patients with advanced disease was 77 months compared to only 29
Table 1.2 Genes associated with hereditary ovarian cancer syndromes Gene
Syndrome
Location
Percentage of ovarian cancer
BRCA1
Breast and ovarian cancer
17q21
4.1
BRCA2
Breast and ovarian cancer
13q12
3.3
Mismatch repair genes MSH2 MLH1 MSH6 PMS2 PMS1
Hereditary non-polyposis colorectal cancer
4
2.9 2p22-p21 3p21 2p16-p15 7p22 2q31-q33
Ch 01 final.qxd
12/18/2006
15:08
Page 5
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
months for age- and stage-matched controls (p < 0.001). In 2000, Boyd et al.69 confirmed these findings. They examined 88 Jewish ovarian cancer patients with BRCA1 or BRCA2 mutations and noted that, compared to controls, mutation carriers had both longer median time to recurrence (7 months vs. 14 months, p < 0.001) and increased survival (p = 0.004). Among patients with stage III tumors, after adjustment for age and residual disease, BRCA mutation status was noted to be an independent prognostic factor, conferring a 25% reduction in the relative risk of death when compared to sporadic cancers. HNPCC, or Lynch II syndrome, occurs in families affected by a combination of early-onset colon cancer and cancers of the ovary, endometrium and other gastrointestinal sites. This syndrome is a less common cause of familial ovarian cancer, accounting for only about 2% of cases. HNPCC has been linked to multiple genetic mutations in the DNA mismatch repair (MMR) genes.70,71 Mutations in these genes result in the loss of the ability to correct mismatched DNA nucleotides, causing microsatellite instability. Accumulation of genetic replication errors in tumor suppressor genes and oncogenes ultimately leads to carcinogenesis. While five different mutations in the MMR genes have been noted to cause HNPCC, mutations in MLH1 on chromosome 3 and MSH2 on chromosome 2 account for 45% and 49% of cases, respectively.72 Most of the remainder occur in PMS2 on chromosome 7, while mutations in PSM1 and MSH6 are noted only sporadically. Although little is known about the prevalence of MMR gene mutations, one large study conducted in Finland estimated the overall carrier frequency of mutations in MLH1 and MSH2 to be 1 in 660.73 Penetrance for HNPCC carriers also varies. By age 65, approximately 70% of carriers will develop colorectal cancer.74,75 The frequency of non-colonic cancers varies among families. The majority of HNPCC carriers who develop colon cancer will also develop a second primary, usually a synchronous or metachronous colon cancer or endometrial cancer. Endometrial, gastric and biliary tract carcinoma are
the most common extracolonic primaries, with lifetime risks of 43–60%, 13–19% and 18%, respectively.74 The cumulative lifetime risk for the development of ovarian cancer is approximately 9–12%,74 and is usually associated with mutations in MSH2. Screening
Because of the low prevalence of mutations, genetic screening is not appropriate for the general population. The American Society of Clinical Oncology recommends testing for individuals with a strong family history of early-onset disease, when results of testing will affect medical management.76 Obtaining an accurate family history is crucial to identify patients at risk for genetic mutation. A careful three-generation family history should be initially assessed and updated at each visit. Based on history, certain patients may benefit from genetic testing for BRCA1 and BRCA2 mutations. These include individuals having a personal or family history of breast cancer diagnosed before age 50 and ovarian cancer diagnosed at any age; a first-degree relative with a known mutation; a family history of two or more cases of breast cancer diagnosed before age 50; a family history of two or more cases of ovarian cancer; a personal or family history of bilateral breast cancer; a family history of male breast cancer; or Ashkenazi Jewish ancestry in the setting of a personal or family history of breast or ovarian cancer.76 For individuals at risk for HNPCC mutations, the Amsterdam and Bethesda criteria are used to identify those likely to benefit from genetic screening.75 The Amsterdam criteria recommend testing for individuals with a family history of at least two successive generations affected by colorectal cancer; diagnosis of a family member before the age of 50; colon cancer diagnosed in at least three relatives; or an increased incidence of other cancers (such as ovarian, endometrial, gastric, urinary tract and biliary). The Bethesda criteria designate that individuals with either two cases of colon cancer (in very small families) or two first-degree relatives with colon cancer, combined with a third relative with either early-onset colon
5
Ch 01 final.qxd
12/18/2006
15:08
Page 6
SURGERY FOR OVARIAN CANCER
cancer or endometrial cancer should undergo genetic testing. Prevention strategies
No method exists which can reliably identify patients with early ovarian cancer,77 but attempts have been made to screen populations of women at elevated risk. In 1994, the National Cancer Institute Consensus Statement on Ovarian Cancer78 recommended annual or semiannual bimanual pelvic examination, transvaginal ultrasonography (TVUS) and CA-125 measurement to screen high-risk women. Similarly, in 1997, the Cancer Genetics Studies Consortium recommended annual or semiannual TVUS and CA-125 testing starting at the age of 25–35 in women known to be BRCA1 or BRCA2 mutation-positive.75 Despite the recommendations, these methods have limitations. While relatively sensitive in its ability to detect small potentially curable ovarian tumors,79 TVUS may miss ovarian cancers in the setting of normal-sized ovaries or primary peritoneal cancers, and cannot necessarily distinguish between benign and malignant tumors, which may lead to unnecessary invasive procedures. While CA-125 is the most commonly used tumor marker to screen for ovarian cancer, the value is elevated in only 80% of cases. For patients with clinically diagnosed stage I disease, potentially the most curable patients, only half exhibit elevations.80 Again, false positives may lead to unneeded surgical intervention. The National Cancer Institute acknowledged that no definitive evidence exists to show that these tests can improve the survival of women ultimately diagnosed with the disease.78 In regards to increased breast cancer risk, the Cancer Genetics Studies Consortium recommends monthly self-examinations of the breast, beginning at the age of 18, and annual mammography beginning at age 25–35 for BRCA mutation carriers. Because of the difficulty in reading mammograms in younger women, annual or semiannual clinical breast examinations are also advised.75 For HNPCC mutation carriers, the Cancer Genetics Studies Consortium81 also
6
recommends screening for colon and endometrial cancers. Recommendations include colonoscopy every 1–3 years beginning at age 25, and either annual endometrial biopsy and/or TVUS beginning at age 25–35. In addition to increased vigilance, medical intervention may decrease the risk for ovarian cancer. Oral contraceptive use was noted to reduce the risk of ovarian cancer in the general population by as much as 40% as early as 1979.10 Use of chemoprophylaxis for BRCA1 and BRCA2 mutation carriers was not examined until 1998, when Narod et al.82 conducted a case–control study comparing 207 women with BRCA1 and BRCA2 mutation-related ovarian cancer with 161 of their cancer-free sisters. The authors found that any past use of oral contraceptives conferred a 50% reduction in risk for both BRCA1 and BRCA2 mutation carriers. No difference in breast cancer risk was noted. However, other researchers have found conflicting results. Modan et al.83 conducted a large population-based case–control study examining 840 Jewish women in Israel with ovarian cancer and 751 controls. All women were tested for the three founder mutations in BRCA1 and BRCA2, and the effect of oral contraceptive use on ovarian cancer risk was assessed. The use of oral contraceptives only appeared to reduce the risk in women without mutations. Among mutation carriers, the reduction in risk was only 0.2% per year of use. Ness et al.84 examined 727 women with ovarian cancer and 1360 controls in relation to use of various types of contraception including oral contraceptive pills, intrauterine devices, barrier methods, tubal ligation and vasectomy. The authors noted that nulligravid women did not derive reduction in cancer risk from any method, whereas multigravid women improved their risk with all contraceptive methods. They concluded that the risk reduction afforded by oral contraceptives may be due to mechanisms unrelated to hormonal or ovulatory status. Narod et al.85 confirmed that, among BRCA1 mutation carriers, tubal ligation decreased risk, as did the combination of tubal ligation and oral
Ch 01 final.qxd
12/18/2006
15:08
Page 7
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
contraceptive use. The same effects were not seen for BRCA2 mutation carriers. The results of prospective chemoprevention trials are necessary to resolve the question of the effectiveness of oral contraceptives for ovarian cancer risk reduction. However, it appears that mutation carriers may use oral contraceptives without increase in their breast cancer risk. The most definitive method for preventing ovarian cancer in high-risk women is surgical extirpation of the ovaries. Because prophylactic oophorectomy may usually be accomplished laparoscopically on an outpatient basis, the potential morbidity and mortality of the procedure is low enough to counter the elevated risk of developing ovarian cancer in mutation carriers. However, aside from surgical risks and issues associated with early menopause, it is important that the physician counsel prospective patients that the procedure is not entirely protective. Streuwing et al.86 concluded that prophylactic oophorectomy may confer only a 50% reduction in risk of ovarian or primary peritoneal cancer. Primary peritoneal carcinoma (PPC), which is histologically indistinguishable from ovarian cancer, has been documented to occur with increased frequency in women susceptible to hereditary ovarian cancer. Tobacman et al.87 reported on three cases (11%) of intra-abdominal carcinomatosis resembling metastatic ovarian cancer among 28 women from high-risk families who had undergone prophylactic oophorectomy. Similarly, Piver et al.31 examined data from the Gilda Radner Familial Ovarian Cancer Registry and identified six cases (1.85%) of primary peritoneal cancer in 324 high-risk women who had undergone previous prophylactic oophorectomy from 1 to 27 years earlier. Because of these risks, both thorough exploration of the abdominopelvic cavity at the time of prophylactic surgery and meticulous histologic examination of even normal-appearing ovaries must be performed in order to exclude the presence of an occult malignancy. Care should also be taken to remove the fallopian tubes entirely, in order to decrease the risk of tubal carcinoma.
PATTERNS OF SPREAD AND STAGING BY THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS Overview of anatomy The pelvis is divided by a fold of peritoneum named the broad ligament, which runs transversely across the cavity. The uterus and fallopian tubes are situated between the anterior and posterior leaves of the broad ligament, with the free ends of the fallopian tubes opening into the peritoneal cavity. The round ligament runs within the leaves of the broad ligament, extending from a point anterior to the uterotubal junction to the pelvic sidewall, through the internal inguinal ring, to merge with the subcutaneous tissues of the labia majora. The ovaries are suspended from the posterior surface of the uterus by the uteroovarian ligaments and are attached to the broad ligament via the mesovarium. Blood and lymphatic vessels supplying the ovary course through a peritoneal fold (called the infundibulopelvic ligament, or suspensory ligament of the ovary) from the ovary to the pelvic wall. The ovaries are not covered by the peritoneum, but are suspended freely within the peritoneal cavity (Figure 1.1). The ovaries are supplied by the ovarian arteries, which arise from the aorta near the level of the L2 vertebra. The ovarian arteries then course along the posterior abdominal wall and cross over the external iliac vessels at the pelvic brim to enter the infundibulopelvic ligament. The ovarian artery supplies the ovary through the mesovarium and continues to course along the fallopian tube and uterus, eventually to anastomose with the uterine artery. The ovarian veins typically follow the course of the ovarian arteries, with the right ovarian vein usually draining directly into the inferior vena cava to the renal vein, and the left ovarian vein draining into the left renal vein. Most lymphatic drainage from the ovary, as well as some from the fallopian tube and uterus, forms a plexus in the mesovarium. The lymphatic channels then course through the infundibulopelvic ligament
7
Ch 01 final.qxd
12/18/2006
15:08
Page 8
SURGERY FOR OVARIAN CANCER
Urinary bladder Deep inguinal ring Round ligament Fundus of uterus Utero-ovarian ligament Broad ligament
Fallopian tube Body (corpus) of uterus Cervix of uterus Sigmoid colon
Mesovarium Ovary Rectouterine pouch (cul-de-sac of Douglas) External iliac vessels Uterosacral ligament Infundibule pelvic ligament (contains ovarian vessels)
Sacral promontory Middle sacral vessels
Abdominal aorta
Figure 1.1 Anatomy of the pelvis
with the ovarian vessels out of the pelvis. At the level of the lower pole of the kidney, the lymphatics join the aortic lymphatic chain. Some direct lymphatic channels also drain from the ovary to the common iliac chain. In addition, some lymphatic fluid may travel through the leaves of the broad ligament to the pelvic sidewall, and eventually drain to the external iliac, internal iliac and obturator lymph nodes.88
Routes of spread Epithelial ovarian cancers generally arise in cysts from the germinal epithelium of the ovary. When the tumor’s growth penetrates the ovarian capsule, spread occurs mainly through peritoneal and lymphatic dissemination (Table 1.3). Once the tumor reaches the surface of the ovary, malignant cells may exfoliate to float freely in the peritoneal cavity. As these malignant cells are circulated by the normal flow of peritoneal fluid up the right paracolic gutter to the under-
8
Table 1.3 Routes of spread Peritoneal dissemination Direct extension Lymphatic spread Hematogenous spread
surface of the right hemidiaphragm, implantation on any abdominopelvic surface may occur, causing diffuse seeding of the peritoneal cavity, which may manifest as either microscopic or macroscopic tumor nodules. Commonly, implants may occur on the uterus, adnexae, bowel, omentum, hemidiaphragms and liver capsule (Figure 1.2). It is important to note that peritoneal spread may occur even in the absence of gross capsular infiltration.89 Formation of ascites occurs in more than two-thirds of patients. Ascites may result from both decreased plasma oncotic pressure, which
Ch 01 final.qxd
12/18/2006
15:08
Page 9
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
Diaphragm
Liver Serosal bowel implants Colon
Pleura
Stomach
Omentum
Nodes
Ovaries Pelvic peritoneal implant
Figure 1.2 Routes of spread
favors third-spacing of fluid into the pertioneal cavity, and the increased production of fluid by damaged peritoneal surfaces. Decreased absorption of fluid may occur as a result of tumor obstruction of lymphatic channels.90,91 Another common route of spread is lymphatic dissemination. As discussed previously, ovarian lymphatics predominantly drain to the para-aortic, iliac and obturator lymph nodes. Autopsy studies have demonstrated lymph node metastases in up to 80% of ovarian cancer patients.92,93 At the time of diagnosis, Burghardt et al.94 examined 180 patients of various stages and noted that, in patients with apparent stage I disease, 24% had positive lymph nodes. This number increased to 50% for those with apparent stage II disease, and to more than 70% for those with apparent stage III or IV disease. Of 105 patients who underwent both pelvic and para-aortic lymphadenectomy, 12% had positive pelvic but negative para-aortic nodes, while 9% had positive para-aortic but negative pelvic nodes. In addition to these routes, ovarian cancer may spread by direct extension, as ovarian tumor masses grow to engulf and invade the adnexa and surrounding structures. Hematogenous spread may also
occur, and manifest as brain or parenchymal lung and liver metastases.
Staging by the International Federation of Gynecology and Obstetrics Staging is performed to define the extent of tumor spread. Staging for ovarian cancer is accomplished surgically, with laparotomy generally serving the dual purpose of staging and primary treatment via surgical cytoreduction. Table 1.4 defines the International Federation of Gynecology and Obstetrics (FIGO) staging schema. Assignment of the patient’s stage of disease is based on findings at the time of surgery. An adequate staging procedure (Table 1.5) begins with a vertical midline incision large enough to allow full examination of the pelvis and abdomen. Unfortunately, most patients present in late stages (Table 1.6) with diffuse abdominal disease, and stage is ascertained by gross examination rather than by surgical sampling. In the absence of widespread disease, pelvic and abdominal washings are first obtained for cytologic analysis. A thorough examination of all pelvic and abdominal surfaces is then carried out. In addition to
9
Ch 01 final.qxd
12/18/2006
15:08
Page 10
SURGERY FOR OVARIAN CANCER
Table 1.4 FIGO staging of ovarian cancer Stage
Definition
Stage I IA
Growth limited to the ovaries Growth limited to one ovary; no ascites present containing malignant cells; no tumor on the external surfaces; capsule intact Growth limited to both ovaries; no ascites present containing malignant cells; no tumor on the external surfaces; capsules intact Tumor stage IA or IB, but with tumor on the surface of one or both ovaries; or with capsule ruptured; or with ascites present containing malignant cells, or with positive peritoneal washings
IB IC Stage II IIA IIB IIC
Growth involving one or both ovaries with pelvic extension Extension and/or metastases to the uterus and/or tubes Extension to other pelvic tissues Tumor stage IIA or IIB but with tumor on the surface of one or both ovaries; or with capsule(s) ruptured; or with ascites present containing malignant cells, or with positive peritoneal washings
Stage III
Tumor involving one or both ovaries with peritoneal implants outside the pelvis and/or positive retroperitoneal or inguinal nodes; superficial liver metastasis equals stage III; tumor is limited to the true pelvis but with histologically verified malignant extension to small bowel or omentum Tumor grossly limited to the true pelvis with negative nodes with histologically confirmed microscopic seeding or abdominal peritoneal surfaces Tumor of one or both ovaries; histologically confirmed implants of abdominal peritoneal surfaces, none exceeding 2 cm in diameter; nodes negative Tumor of one or both ovaries; histologically confirmed implants of abdominal peritoneal surfaces, none exceeding 2 cm in diameter; nodes negative
IIIA IIIB IIIC Stage IV
Growth involving one or both ovaries with distant metastasis; if pleural effusion is present, there must be positive cytologic test results to allot a case to stage IV; parenchymal liver metastasis equals stage IV
Table 1.5 Elements of ovarian cancer staging Adequate vertical incision Abdominal and pelvic washings Inspection and palpation of all abdominal and pelvic surfaces Random peritoneal biopsies Biopsy/resection of peritoneal adhesions Removal of affected ovary Removal of remaining ovary, uterus and tubes* Total abdominal hysterectomy and bilateral salpingooophorectomy Omentectomy Appendectomy Pelvic and para-aortic lymph node sampling * May be forgone in selected patients
10
the pelvic organs, the entire abdominal cavity must be adequately inspected, including the bowel, liver, mesentery, omentum and undersurfaces of the diaphragm. Biopsies are taken from multiple random sites, as well as from any adhesions or suspicious locations. Omentectomy is also performed to rule out occult metastases. In the absence of gross upper abdominal disease greater than 2 cm in diameter (stage IIIC), sampling of the pelvic and para-aortic lymph nodes to rule out nodal metastases is indicated. In general, a total abdominal hysterectomy with bilateral salpingo-oophorectomy is performed. When disease is limited to the pelvis, great care must be taken to avoid rupture of the neoplasm during removal to prevent possible intraoperative spread of tumor. Certain patients may forgo hysterectomy, depending on age, reproductive desires, tumor type and the
Ch 01 final.qxd
12/18/2006
15:08
Page 11
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
Table 1.6 Stage at initial diagnosis and survival by stage (all histologic classes). From reference 226
rare neoplasms of uncertain origin that may involve the ovary (Table 1.8). A summary of the incidence of tumor bilaterality is found in Table 1.9.
Patients Stage
n
%
5-Year survival (%)
I
1639
27
79
II
748
12
60
III
2440
40
22
IV
1291
21
14
Total
6118
100
31
extent of disease. Young patients who desire future childbearing with certain unilateral germ cell, sex cord–stromal, or suspected borderline tumors may undergo surgical staging with removal of only the affected ovary and preservation of the contralateral ovary and uterus. Accurate assignment of stage is crucial to assessment of prognosis. The need for thorough surgical staging cannot be overstated: evidence suggests that, in cases where disease appears limited to the ovary (apparent stage I disease), 30% of patients may have occult nodal metastases (actual stage IIIC disease).94 Upon examination of multiple series of apparent early-stage ovarian cancer, occult metastases may occur in 7–10% of peritoneal biopsies.95 While the overall 5-year survival of patients with ovarian cancer is approximately 50%, survival varies by stage (Table 1.6), ranging from 79% for those with stage I disease, to 14% for those with stage IV disease.
CLASSIFICATION AND CLINICAL CHARACTERISTICS OF OVARIAN CANCER The current classification of ovarian tumors is based on the schema delineated by the World Health Organization (WHO) in 1999 (Table 1.7).96 The system is based on the histogenesis of the normal ovary and includes tumors of epithelial, germ cell, sex cord–stromal type, as well as metastases and other
Epithelial ovarian cancer Epithelial ovarian tumors are the most common type of ovarian cancer, accounting for approximately 90% of all malignancies in women. These lesions are thought to arise from the surface epithelium of the ovary, which is derived from the mesothelial lining of the celomic cavity. During embryonic development, this mesothelial lining also gives rise to the Müllerian ducts which form the uterus, fallopian tubes and upper vagina. Epithelial inclusion cysts of the ovary may undergo neoplastic transformation to display different types of Müllerian differentiation (Table 1.10). Serous tumors are the most common, followed by mucinous, endometrioid and clear cell tumors. Brenner tumors, which resemble transitional cell epithelium, are another potential type of differentiation. Epithelial ovarian tumors may be benign, malignant, or of low malignant potential. Malignant epithelial ovarian cancer is treated by surgical extirpation, followed by platinum- and taxane-based chemotherapy. Patients with stage IA grade 1 or 2 tumors may be treated with surgery alone. Each subtype will be briefly discussed. Serous
Serous adenocarcinomas comprise the majority of ovarian epithelial malignancies (Figure 1.3). The mean age at presentation is 56 years.97 About onethird of stage I tumors are bilateral, while more advanced lesions are bilateral in about two-thirds of cases. Grossly, these tumors are composed of both cystic and solid components. Microscopically, serous malignancies display cells resembling fallopian tube epithelium. Psammoma bodies are present in 30% of cases.98 Serous tumors may also produce extracellular mucin. Well-differentiated, grade 1 lesions may display well-formed glands and papillary fronds, occasionally showing ciliated cells. Moderately differentiated, grade 2 lesions display sheets of tumor cells in
11
Ch 01 final.qxd
12/18/2006
15:08
Page 12
SURGERY FOR OVARIAN CANCER
Table 1.7 WHO histologic classification of ovarian neoplasms. From reference 96
I.
E. Unclassified F. Steroid (lipid) cell tumors 1. Stromal luteoma 2. Leydig cell tumor 3. Steroid cell tumor, not otherwise specified
Surface epithelial tumors A. Serous tumors B. Mucinous tumors 1. Endocervical-like 2. Intestinal type C. Endometrioid tumors D. Clear cell tumors E. Transitional cell tumors F. Squamous cell tumors G. Mixed epithelial tumors H. Undifferentiated and unclassified carcinoma
II. Sex cord–stromal tumors A. Granulosa–stromal cell tumors 1. Granulosa cell tumors (adult and juvenile) 2. Tumors in the thecoma–fibroma group a. Thecoma b. Fibroma c. Cellular fibroma d. Fibrosarcoma e. Sclerosing stromal tumor B. Sertoli–stromal cell tumors 1. Sertoli cell tumors 2. Sertoli–Leydig cell tumors C. Sex cord tumors with annular tubules D. Gynandroblastoma
III. Germ cell tumors A. Dysgerminoma B. Yolk sac tumor (endodermal sinus tumor) C. Embryonal carcinoma D. Polyembryoma E. Choriocarcinoma F. Teratoma 1. Immature 2. Mature 3. Struma ovarii 4. Carcinoid tumors G. Mixed germ cell tumors IV. Gonadoblastoma V. Miscellaneous A. Small cell carcinoma B. Malignant lymphomas, leukemias, plasmacytomas C. Unclassified D. Metastatic tumors
Table 1.8 Distribution of types of ovarian malignancies. From
Table 1.9 Incidence of bilaterality of various ovarian cancers.
reference 97
From references 115, 227 and 228
Histologic type
Frequency (%)
Epithelial
86
Germ cell
6
Sex cord–stromal
4
Metastatic
3
addition to areas with defined papillae. Poorly differentiated, grade 3 lesions predominantly exhibit sheets of malignant cells. Approximately half of serous carcinomas are grade 3. Grade of the tumor has been found to correlate with stage and prognosis.
12
Tumor type
% Bilateral
Epithelial serous mucinous endometrioid clear cell
33–66 10–20 13–30 12–39
Germ cell immature teratoma dysgerminoma other malignant germ cell tumors
2–5 10–15 rare
Sex cord–stromal thecoma Sertoli–Leydig cell tumor granulosa–theca cell tumor
rare rare rare
Ch 01 final.qxd
12/18/2006
15:08
Page 13
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
a
b
Figure 1.3 High-grade serous carcinoma. (a) Gross appearance. Cystic and solid components with extensive hemorrhage. (b) Microscopic appearance. Papillary structures interspersed with slit-like spaces. Extensive nuclear atypia and frequent mitoses present
Table 1.10 Frequency (%) of malignant epithelial histologies. Modified from reference 97 Histologic type
Malignant
LMP
Total
Serous
37.2
16.3
53.5
Mucinous
3.5
11.6
15.1
Endometrioid
15.1
3.5
18.6
Clear cell
7.0
rare
7.0
Brenner
rare
rare
rare
Mixed
2.3
2.3
Undifferentiated
3.5
3.5
Total
68.6
31.4
100
Figure 1.4 Psammocarcinoma with extensive psammoma body formation
LMP, low malignant potential
When extensive psammoma bodies are noted in conjunction with only low to moderate nuclear atypia, tumors are termed psammocarcinoma (Figure 1.4).96,99 These neoplasms demonstrate microscopic invasion, and are typically diagnosed in advanced stages. However, the clinical course may more closely resemble that of lesions with low malignant potential and favorable outcome than typical serous carcinomas.99
Mucinous
Most mucinous ovarian neoplasms are benign, and approximately 15% are of low malignant potential. Only 5% are frankly malignant. Patients present at a mean age of 52 years.97 Grossly, mucinous tumors may be very large. Although malignant tumors may be bilateral in 20% of cases, benign growths are only rarely bilateral. Microscopically, mucinous carcinomas are composed of cells resembling the lining of the
13
Ch 01 final.qxd
12/18/2006
15:08
Page 14
SURGERY FOR OVARIAN CANCER
endocervix or colon (Figure 1.5), and the possibility of metastasis from a gastrointestinal primary must be excluded. Pseudomyxoma peritonei is the presence of mucinous ascites throughout the peritoneal cavity. Most cases of pseudomyxoma peritonei are thought to be due to a primary appendiceal lesion metastatic to the ovary and peritoneum.100–102 Endometrioid
The majority of endometrioid neoplasms are malignant (Figure 1.6). The mean age at presentation is 57 years.97 On gross examination, these tumors are usu-
Figure 1.5 Mucinous carcinoma, intestinal type
a
ally 12–25 cm in size,103,104 and have cystic and solid components. Microscopically, endometrioid carcinomas resemble tumors commonly found in the uterine endometrium. Extracellular mucin may be present. Squamous differentiation is common, and may be benign or malignant. In approximately 10% of cases, endometrioid carcinoma is associated with endometriosis,105 and may arise as a result of malignant transformation. Ovarian endometrioid carcinomas may be associated with endometrial cancers of the uterus in 10–25% of cases.106–108 Differentiation between synchronous primaries and metastatic lesions from one site to another may be problematic. Most cases involving well-differentiated lesions appear to represent synchronous primaries in the uterus and ovary. However, Ulbright and Roth109 defined cases as endometrial primary tumors with ovarian metastases in the presence of either a multinodular ovarian pattern, or two or more of the following criteria: ovaries less than 5 cm in size; bilateral ovarian involvement; deep myometrial invasion; vascular invasion; and involvement of the fallopian tube lumen. Malignant mixed mesodermal (Müllerian) tumors (MMMT) of the ovary are rare, aggressive neoplasms accounting for less than 1% of all primary ovarian tumors.110 These tumors are classified with endometrioid lesions of the ovary because of similarity to
b
Figure 1.6 Endometrioid carcinoma. (a) Gross appearance. Predominantly solid with cystic spaces. (b) Microscopic appearance. Endometrioid glands infiltrating the stroma
14
Ch 01 final.qxd
12/18/2006
15:08
Page 15
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
their uterine counterpart. The average age at diagnosis is 66 years, approximately one decade older than for patients with most other epithelial subtypes.110 MMMTs are almost always diagnosed in perimenopausal or postmenopausal women. These tumors may be homologous (also called carcinosarcomas),111 or heterologous, containing elements not found in the ovary such as skeletal muscle, cartilage, or bone. Patients are usually diagnosed with advanced disease, and the prognosis is grim. DiSilvestro et al.110 reviewed 246 cases in the literature and noted a median survival of only 6–12 months, with more than 70% of patients dead 1 year from diagnosis despite treatment. Clear cell
Clear cell tumors comprise only about 7% of epithelial ovarian malignancies. The mean age at diagnosis is 53 years.112 Grossly, clear cell carcinomas may be predominantly solid or cystic, and contain white, yellow, or pale brown polypoid masses protruding into the lumen of cysts.113 Clear cell carcinomas are usually 5–20 cm in size,114 and are bilateral in about 12% of cases.115 Microscopically, the tumors are composed of clear cells and hobnail cells, though some may contain cuboidal or signet-ring cells (Figure 1.7). The typical clear cell appearance is due to the presence of copious cytoplasmic glycogen. Tumor cells may be
arranged in solid, glandular, tubular, or papillary patterns. A strong association exists between clear cell carcinoma and endometriosis, with ovarian endometriosis documented in up to 67% of cases.116 Clear cell carcinoma has also been reported to arise in extraovarian endometriosis.117 Transitional cell
Transitional cell tumors are composed of cells similar in appearance to transitional cells of the urinary tract. The term malignant Brenner tumor describes those lesions containing both invasive transitional cell groups as well as benign nests, while transitional cell carcinoma refers to those tumors lacking a benign Brenner component (see Figure 1.8).96 Brenner tumors comprise only 2% of all ovarian tumors, and over 99% are benign.118 Patients with malignant Brenner tumors present at a mean age of 64 years. Roth and Czernobilsky119 reported that those with well-differentiated lesions were usually diagnosed with stage I disease and incurred a good prognosis. Patients with poorly differentiated lesions were also noted to present with early-stage disease (80% stage IA), although 5-year survival was only 60%. Despite histologic similarities, transitional cell carcinomas display different clinical behavior. Austin and Norris120 reported that patients with transitional cell carcinoma presented with stage II–IV disease in 69% of cases,
Figure 1.7 Clear cell carcinoma. Solid pattern with cells
Figure 1.8 Transitional cell carcinoma. Irregular nests of
containing clear cytoplasm
transitional cells
15
Ch 01 final.qxd
12/18/2006
15:08
Page 16
SURGERY FOR OVARIAN CANCER
compared to only 19% of those with malignant Brenner tumors. In addition, the prognosis appeared to be worse. Among patients with stage IA transitional cell carcinoma, only 43% were alive at last contact, compared to 88% of patients with stage IA malignant Brenner tumor. Squamous
The vast majority of squamous carcinomas of the ovary arise within teratomas, or as a consequence of metastatic spread, and are not of true epithelial origin. The WHO stipulates that squamous carcinomas of the epithelial–stromal category must arise in association with either endometriosis121,122 or a Brenner tumor, or else occur in a pure form without teratomatous elements.96 Pins et al.122 reported seven cases of squamous carcinoma associated with endometriosis. Patients were diagnosed at a mean age of 49 years. Only one patient had stage I disease, and all tumors were grade 3. The authors cited a poor median survival of only 5 months. Of 11 patients with pure squamous carcinoma, the mean age at diagnosis was 56 years. Again, only one case was stage I at diagnosis, and all but one were grade 3. Grossly, the pure squamous carcinomas ranged in size from 6 to 26 cm, and were usually solid with focal areas of necrosis. Mixed epithelial types
Approximately 2–3% of epithelial ovarian cancers contain a mixture of different elements. When more than 10% of a tumor is composed of a different type of epithelium, the neoplasm qualifies for the diagnosis of a mixed epithelial tumor.96 Common mixed carcinomas include clear cell–endometrioid tumors, and serous–endometrioid tumors. Undifferentiated carcinoma
The WHO defines undifferentiated carcinoma as a malignant epithelial tumor that is too poorly differentiated to warrant classification into any of the categories previously described. Fewer than 5% of epithelial malignancies are undifferentiated. Small foci of distinguishable features such as gland formation,
16
psammoma bodies, or mucin production do not preclude the diagnosis of undifferentiated carcinoma.96 Some tumors may display neuroendocrine features, but should be differentiated from pure small cell tumors. Most tumors are solid with foci of hemorrhage and necrosis present on a cut surface. At diagnosis, about 75% are diagnosed in stages II–IV, and prognosis is generally poor with a 5-year survival rate of about 15%.123 Tumors of low malignant potential
Tumors of low malignant potential (LMP), also called borderline malignancies, were first included in the categorization of epithelial tumors of the ovary in 1971 by FIGO.124 The WHO soon followed suit in 1973.125 Approximately 15% of all ovarian malignancies are of LMP. Diagnosis of LMP tumors is made on a histologic basis. To ensure an accurate diagnosis, at least one histologic section should be examined per 1–2 cm of the greatest diameter of the ovarian cyst to ensure adequate tissue sampling. LMP tumors display epithelial budding, multilayering of the epithelium, frequent mitoses and cellular atypia.126 These neoplasms are generally non-invasive, although approximately 10% may show evidence of microinvasion, which does not appear to affect prognosis adversely.127,128 LMP tumors of all epithelial histologic types have been reported, although serous (Figure 1.9) and mucinous subtypes (Figure 1.10) are the most common. In a review of several studies comprising 352 patients with LMP lesions, 51.7% were mucinous, 41.8% serous, 3.7% endometrioid, 2.6% mixed and 0.2% Brenner cell (Table 1.11).129 LMP tumors of clear cell histology are rare, with only nine cases reported to date.130 Most patients with LMP tumors present before the age of 50 years, with a mean age of approximately 45 years, in contrast to approximately 52 years for patients with adenocarcinoma.123 The tumors occur more frequently in White women as opposed to those of African or Asian heritage.131 As with frankly invasive cancers, pregnancy, oral contraceptive use and breast feeding appear to exert a protective effect on
Ch 01 final.qxd
12/18/2006
15:08
Page 17
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
the risk for LMP tumors,132,133 although no significant correlation has been noted with age at menarche or menopause. Unlike invasive epithelial cancers, LMP tumors predominantly present in early stages, although meticulous staging may reveal occult metastases.134 Sutton135 reviewed 12 studies encompassing 946 patients with LMP tumors and noted that 80% presented with stage I disease. Other smaller studies have reported the incidence of stage II lesions to be 4–7%, and stage III lesions to be 11–14%.136,137 Stage IV
tumors are rare. Examining data from eight series with a total of 677 patients, only nine cases of stage IV disease (1.3%) were reported138–145 (Table 1.12). Therapy for LMP tumors is primarily surgical. In the usual case, total abdominal hysterectomy with bilateral salpingo-oophorectomy is performed, although patients desirous of future childbearing with disease limited to the ovary may be candidates for conservative management. Prognosis for patients with LMP tumors is generally excellent, particularly for patients with stage I disease. Barnhill et al.146 Table 1.11 Histologic types of tumors of low malignant potential from 352 patients. From reference 129 Histology
Percentage
Serous
41.8
Mucinous
51.7
Endometrioid
3.7
Mixed
2.6
Brenner cell
0.2
Clear cell
0
Figure 1.9 Serous tumor of low malignant potential. Cysts are lined by stratified cells with budding
a
b
Figure 1.10 Mucinous tumor of low malignant potential. (a) Intestinal type. Goblet cells present with nuclear stratification. (b) Endocervical type. Cells display budding and cytoplasmic mucin
17
Ch 01 final.qxd
12/18/2006
15:08
Page 18
SURGERY FOR OVARIAN CANCER
reviewed 27 studies encompassing 988 patients with stage I tumors. With follow-up ranging from 2.9 to 11.7 years, 99.3% of patients showed no evidence of disease. Only 0.7% died of disease. Trimble and Trimble126 examined 415 patients with 7 years’ median follow-up and noted 5-year survival rates of 99% for stage I, and 92% for stages II and III. There exists no definitive evidence that the use of adjuvant therapy after primary surgery improves survival for patients with LMP tumors. While survival is generally excellent regardless of stage, approximately 10% of patients will go on to develop recurrent disease. Aside from stage at presentation, attempts have been made to find risk factors for disease recurrence in order to identify a subset of patients who may benefit most from adjuvant therapy. Burks et al.147 initially defined micropapillary serous carcinoma as being characterized by a ‘filigree pattern of highly complex
Table 1.12 Stage at presentation of low-malignant-potential tumors of the ovary. From references 138–145 and 229 Stage
Percentage
I
80
II
4–7
III
11–14
IV
1.3
micropapillae arising directly from large, bulbous papillary structures’. Several authors have noted higher mortality rates among patients with micropapillary tumors, as well as those with invasive peritoneal implants.147–150 Primary peritoneal cancer
In 1959, Swerdlow first reported a tumor of the pelvic peritoneum histologically resembling a papillary serous carcinoma of the ovary.151 Primary peritoneal carcinoma (PPC) consists of a tumor with light microscopic, histochemical and immunohistochemical features indistinguishable from primary epithelial ovarian cancer.152–154 To clarify the difference between ovarian cancer and PPC, in 1993 the Gynecologic Oncology Group (GOG) specified that ‘extraovarian peritoneal serous papillary carcinoma’ should be histologically identical to epithelial ovarian cancer, with involvement of the ovary limited to less than 5 mm of cortical invasion (Table 1.13). By these criteria, approximately 10% of patients initially diagnosed with ovarian cancer may instead be reclassified as having PPC.155 Grossly, the tumor causes diffuse studding of the pelvic and abdominal peritoneum, with almost universal involvement of the omentum.153,156,157 Microscopically, PPCs most often display papillary serous differentiation (99% vs. 36% for epithelial ovarian cancer); however, other types have been reported including mucinous, endometrioid, clear cell
Table 1.13 Gynecologic Oncology Group classification of primary peritoneal carcinoma. From reference 230 1. Both ovaries must be either physiologically normal in size or enlarged by a benign process 2. Involvement in the extraovarian sites must be greater than the involvement on the surface of either ovary 3. Microscopically, the ovarian component must be one of the following: a. nonexistent b. confined to ovarian surface epithelium with no evidence of cortical invasion c. involving ovarian surface epithelium and underlying cortical stroma but with any given tumor size less than 5 × 5 mm d. tumor less than 5 × 5 mm within ovarian substance with or without surface disease 4. Histological and cytological characteristics of the tumor must be predominantly of the serous type that is similar or identical to ovarian serous papillary adenocarcinoma, any grade
18
Ch 01 final.qxd
12/18/2006
15:08
Page 19
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
and MMMT.155 As with ovarian cancer, psammoma bodies, desmoplasia and tumor necrosis are common. The grade of PPC is moderate to high grade in over 80% of cases.158 Despite the histologic similarities, differences exist between patients with epithelial ovarian cancer and PPC (Table 1.14). Patients with PPC are typically older, with mean age of approximately 61 years, compared to 56 years for epithelial ovarian cancer.153,154,156–168 Eltabbakh et al.164 reported on a series of 50 patients with PPC compared to 503 women with epithelial ovarian cancer. For the patients with PPC, the authors noted a statistically significantly higher mean age at diagnosis (63.8 vs. 55.0 years, respectively, p < 0.001), later menarche (13.3 vs. 12.8 years, p = 0.024) and less talc use (26% vs. 48.1%, p = 0.003). Molecular differences are also apparent. While epithelial ovarian cancer has been demonstrated to arise from a monoclonal proliferation of tumor cells,169–174 most investigators have reported at least some cases of PPC to be polyclonal in origin.175–178 PPC is staged and treated in an identical fashion to epithelial ovarian cancer. Although by definition there can be no stage I PPC, the vast majority of patients present in advanced stages. Chu et al.155 reviewed nine reported series of patients with PPC
Table 1.14 Comparison of ovarian and primary peritoneal cancer. Modified from reference 155 Epithelial ovarian carcinoma
Primary peritoneal carcinoma
56
61
14–92
4–92
12.8
13.3
Median parity
2
3–4
Talc exposure
48%
26%
27–30
12–24
Mean age at diagnosis (years) Age range (years) Mean age at menarche (years)
Median survival (months)
and noted that 2% presented in stage II, 73% in stage III and 25% in stage IV.
Germ cell tumors Germ cell tumors comprise approximately 20% of all ovarian tumors. Most germ cell tumors present in young women of reproductive age. In fact, for women under the age of 30, germ cell tumors are the most common ovarian neoplasm. Although some lesions are asymptomatic, most cause abdominal pain. Occasionally, torsion, rupture or intracapsular hemorrhage may lead to an acute abdomen. Fortunately, most germ cell tumors are benign, with only 2–3% composed of malignant primitive germ cell tumors. The majority of benign tumors are mature cystic teratomas. Of the malignant germ cell tumors, the most common are the dysgerminoma, endodermal sinus tumor and immature teratoma. The majority of these tumors are curable with appropriate chemotherapy and conservative surgery, which is especially important for young women desirous of future childbearing. Most germ cell tumors secrete chemical markers that may be measured in the blood and used to monitor response to therapy and potential disease recurrence. Teratomas
Teratomas are germ cell tumors composed of cells resembling products of the three embryonic layers of ectoderm, mesoderm and endoderm. The tissues present may be immature or mature, and occasionally may be monodermal with predominant representation of one particular tissue type. In general, teratomas comprised of immature elements are malignant and those composed of mature elements are benign, although any element within a benign tumor may itself undergo malignant transformation. Mature cystic teratoma The mature cystic teratoma,
or dermoid cyst, is a benign neoplasm accounting for nearly one-third of all ovarian tumors. In 10–15% of cases, these cysts may occur bilaterally. Most dermoid cysts are diagnosed in women of reproductive age, although they may be found at any age. The cyst
19
Ch 01 final.qxd
12/18/2006
15:08
Page 20
SURGERY FOR OVARIAN CANCER
lining is predominantly composed of epidermis and associated skin appendages. Grossly, the cysts are filled with sebaceous material and hair. Bone and teeth may also be apparent. Patients usually experience no symptoms, but may present with acute pain secondary to torsion of the affected ovary. Rupture of the cysts is uncommon, but is more likely to occur during pregnancy. When these tumors are diagnosed in women over the age of 40, malignant transformation of one of the cyst components is more likely, and may appear as a firm nodule on the wall of the cyst. Squamous cell carcinomas are the most common secondary tumor, occurring in about 1–2% of mature cystic teratomas. Treatment of dermoid cysts consists of either cystectomy or oophorectomy. Care should be taken to minimize spillage of cyst contents intraoperatively, as chemical peritonitis may ensue. Immature teratoma Immature teratomas are malig-
nant neoplasms composed of embryonic elements with admixed mature tissues. These tumors are bilateral in less than 5% of patients, although a benign dermoid may be found in the contralateral ovary in 10% of cases. Immature teratomas generally present before the age of 20. Grossly, the tumors may be either cystic or solid. Upon microscopic examination, the tumor is usually composed of immature neuroectoderm (Figure 1.11). Patients may also present with
Figure 1.11 Immature teratoma with neural elements
20
peritoneal implants of mature glial tissue, which does not affect prognosis. Tumors are graded from 1 to 3 based upon the amount of immature neural tissue present. Grade is correlated with prognosis and determines therapy. Initial treatment consists of removal of the affected ovary and thorough surgical staging. Only patients with stage IA grade 1 tumors may forgo adjuvant chemotherapy. Patients with stage IA disease have a 10-year survival of 70%.179 Monodermal tumors Struma ovarii is a teratoma com-
posed almost exclusively of thyroid tissue, which may be hormonally active and lead to clinical hyperthyroidism in about 30% of patients. Simple removal is usually curative, although struma may occasionally undergo malignant transformation. Metastatic disease may be treated with radioactive 131I therapy. Carcinoid tumors are rare in the ovary and histologically resemble carcinoid tumors of the gastrointestinal tract. These neoplasms are unilateral, and occur primarily in older women. Approximately 30% of patients may present with carcinoid syndrome. Dysgerminoma
The most common ovarian germ cell malignancy is the dysgerminoma, which accounts for 50% of all germ cell malignancies, but comprises only about 1% of all ovarian tumors. These lesions are grossly bilateral in 10–15% of cases, although occult disease may be present in the contralateral ovary in an additional 10% of cases. Occasionally, patients may present with an associated gonadoblastoma. Women are usually diagnosed in the first three decades of life, and sometimes during pregnancy. Grossly, the tumor appears lobulated and solid, with a pink or tan interior. Microscopically, the tumor is composed of large round clear cells, resembling primordial germ cells, which contain glycogen (Figure 1.12). Nuclei are central and contain prominent nucleoli. Tumor cells are either diffuse, or arranged in islands or cords, and are often infiltrated by lymphocytes. Up to 10% of dysgerminomas contain syncytiotrophoblast, which may secrete human chorionic gonadotropin (hCG). Lactate
Ch 01 final.qxd
12/18/2006
15:08
Page 21
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
Figure 1.12 Dysgerminoma. Cells display clear cytoplasm and
Figure 1.13 Yolk sac tumor. Communicating spaces lined by
large round nuclei with prominent nucleoli
clear cells merge with solid areas
dehydrogenase (LDH) may also be detected and used as a serum tumor marker.180 Dysgerminomas have a tendency to lymphatic spread, and a thorough surgical staging procedure is indicated. Fortunately, two-thirds of patients present with stage I disease, and may be managed with unilateral salpingo-oophorectomy. Biopsy of the contralateral ovary is not necessary if it appears grossly normal. Cytoreduction is recommended for patients with advanced disease. Patients with stage IA disease have an excellent prognosis with 10-year survival in excess of 90%, and may forgo adjuvant chemotherapy. Although up to 25% of these patients experience disease recurrence, treatment with chemotherapy at that time may still be curative. Patients with advanced disease should undergo adjuvant treatment with either chemotherapy or radiation.
termed hepatoid yolk sac tumors. On gross examination, these tumors are typically yellow solid masses with focal areas of hemorrhage and necrosis. Microscopically, the reticular pattern is most common, displaying networks of spaces lined by primitive cells that secrete α-fetoprotein (AFP). Classic Schiller–Duval bodies may be present, and are composed of single rounded or elongated papillae containing a single central blood vessel protruding into spaces. In 1976, Kurman and Norris181 reported on 71 cases of endodermal sinus tumors and noted a 3-year actuarial survival of only 13%. However, with the routine use of surgical removal followed by multi-agent chemotherapy, survival has improved dramatically. Nawa et al.182 reviewed the outcomes of 47 patients with either pure yolk sac tumors or tumors with yolk sac components and noted survival to be 95% for stage I, 75% for stage II, 30% for stage III and 25% for stage IV.
Endodermal sinus tumors
Endodermal sinus tumors, also called yolk sac tumors, are the second most common type of primitive germ cell malignancy, accounting for about 20% of cases (Figure 1.13). These tumors are infrequently bilateral (less than 5%), and present at a median of 19 years of age.181 Endodermal sinus tumors are derived either from primitive gut tissue and designated glandular yolk sac tumors, or from primitive liver tissue and
Embryonic carcinoma
Despite being a common tumor of the testis, embryonic carcinoma is extremely rare as a pure tumor of the ovary, although it may present as part of a mixed germ cell tumor. These tumors comprise only 4% of malignant germ cell tumors. Histologically, epithelial cells resembling those of the embryonic germ disc are
21
Ch 01 final.qxd
12/18/2006
15:08
Page 22
SURGERY FOR OVARIAN CANCER
noted, growing in glandular, tubular, papillary and solid patterns. Often, scattered syncytiotrophoblast cells and foci of yolk sac differentiation are present. Accordingly, serum hCG and AFP may be useful markers to follow tumor response. Kurman and Norris183 reported on a series of 15 cases in 1976 and noted that 60% of patients presented with abnormal endocrine manifestations such as precocious puberty, irregular bleeding, amenorrhea and hirsutism. Patients presented at a median age of 15 years. Actuarial survival for all patients was only 39%, although stage I patients had a slightly better survival of 50%. Improved survival has been obtained using surgery followed by multi-agent chemotherapy.
nancy; or as a metastasis from choriocarcinoma in the uterus. Most tumors are diagnosed under the age of 20. Sexual precocity and irregular bleeding are common at presentation. Treatment consists of surgery followed by multi-agent chemotherapy. Mixed germ cell tumors
Mixed tumors compose 10% of malignant germ cell tumors. Most cases are a combination of dysgerminomatous and yolk sac components. Tumors are usually unilateral, although if dysgerminoma is present as a component, 10% of cases may be bilateral. Prognosis is related to the composition of the tumor and to the volume that the most malignant component occupies.
Polyembryoma
Sex cord–stromal tumors
Also more frequently noted in the testis, polyembryoma is another extremely rare ovarian tumor composed of embryoid bodies resembling normal early embryos. In most cases, polyembryoma is associated with other malignant germ cell elements, usually immature teratoma. Chapman et al.184 reviewed 11 reported cases. Age at presentation ranged from 3 to 44 years. Patients usually presented with pain, although menstrual abnormalities were noted in four patients and precocious puberty was noted in one patient. Of the 11 patients, eight presented with stage I disease and three with stage III disease. Half of stage I patients were alive 19–132 months after diagnosis. Two patients with stage III disease died within 2 months of diagnosis, and the third was treated with surgery followed by multi-agent chemotherapy and was noted to be alive and well 20 months after diagnosis.185
Tumors derived from the sex cords and mesenchyme of the embryonic ovary compose approximately 8% of all ovarian tumors,186 and are the third most common class of ovarian neoplasms. Tumors may contain granulosa cells, theca cells, stromal cells, Sertoli cells and Leydig cells in different combinations and in various states of differentiation. Many of these tumors are hormonally active and present in children and young women. Early-stage tumors may be treated with conservative surgery, although late-stage tumors are generally treated with surgery and adjuvant multi-agent chemotherapy.
Choriocarcinoma
Choriocarcinoma is also extremely rare in the pure form and is more commonly seen as part of a mixed tumor. These malignancies are composed of both cytotrophoblast and syncytiotrophoblast, and consequently produce hCG. Ovarian choriocarcinoma may develop through one of three mechanisms: as a tumor of ovarian germ cell origin; within an ovarian preg-
22
Granulosa cell tumors
Granulosa cell tumors represent about 6% of all ovarian cancers and over half of all malignant sex cord–stromal tumors. These malignancies can be diagnosed at any age, but usually present in women after the menopause.187 Tumors are more common in women of European or American background.188 The most common presenting symptoms associated with granulosa cell tumors are abnormal uterine bleeding and abdominal pain. These tumors are the most common estrogen-producing tumors; unopposed estrogen stimulation of the uterine lining may lead to endometrial hyperplasia. A synchronous endometrial carcinoma may be present in up to 13% of patients.189–192
Ch 01 final.qxd
12/18/2006
15:08
Page 23
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
Patients may experience other symptoms of excess estrogen including breast tenderness and swelling. Occasionally, granulosa cell tumors may exert virilizing effects as well. The majority of these tumors are limited to the ovary at presentation. Granulosa cell tumors are divided into two subtypes: adult and juvenile. Adult granulosa cell tumors account for 95% of all granulosa cell tumors. Grossly, tumors may be cystic or solid and are typically large, with an average diameter of 12 cm. Cyst locules may be filled with fluid or clotted blood, and solid areas commonly display foci of hemorrhage. Cysts are prone to rupture. Tumors are bilateral in fewer than 5% of cases. Histologically, cells have light round or oval nuclei with frequent grooves, arranged in diffuse patterns (Figure 1.14). Well-differentiated tumors have follicular patterns, although a mixture of patterns may exist in a single tumor. Call–Exner bodies are a characteristic finding of the microfollicular pattern. While younger women may experience amenorrhea, postmenopausal women may have vaginal bleeding. Approximately 80–90% of patients present with stage I disease.193–195 For younger women desirous of future childbearing, stage IA tumors may be treated by removal of the affected ovary, with a wedge biopsy of the contralateral ovary to check for occult disease. Sampling of the endometrium is recommended to
Figure 1.14 Granulosa cell tumor, adult type. Diffuse pattern
exclude a synchronous primary tumor of the uterus. Stage IA disease in postmenopausal women, or those not desirous of future childbearing, may be treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy, although some have advocated adjuvant chemotherapy with bleomycin, etoposide and platinum for postmenopausal women.196 Patients with cyst rupture should receive adjuvant chemotherapy. Advanced disease is treated with surgical cytoreduction and combination chemotherapy. These tumors have an indolent course, and 5-year survival rates have been reported to be 90%.191,194,195 Unfortunately, granulosa cell tumors may present with late recurrences more than 5 years after initial diagnosis. Hines et al.197 reviewed 16 cases with recurrences ranging from 13 to 37 years after initial diagnosis. Advanced stage, tumor rupture, tumor size, mitotic activity and nuclear atypia are associated with worsened prognosis. Juvenile granulosa cell tumors are usually found in women below the age of 30. Young et al.198 reported on 125 cases and noted that 44% presented in girls under the age of 10, and that only 3% occurred in women over the age of 30. Up to 80% of tumors presenting in prepubertal females are associated with sexual precocity.113 Juvenile granulosa cell tumors have been reported in association with Potter syndrome,199 Ollier disease200,201 and Maffucci syndrome.198,202 Over 95% of patients present with stage I disease.198,202 Bilaterality occurs in less than 5% of cases. Microscopically, juvenile granulosa cell tumors are arranged in solid nodules, with follicles containing mucicarminophilic fluid. Call–Exner bodies are rare and theca cells may often be present. Nuclei are dark and lack the grooves observed in adult granulosa cell tumors. Survival for stage I and II tumors has been reported to be 92%.198,202 Unfortunately, the rare late-stage juvenile granulosa cell tumors are aggressive with short time to relapse and death. Unlike their adult counterparts, most recurrence is diagnosed within 3 years of initial diagnosis. If thorough staging reveals disease limited to the ovary, conservative surgery may be conducted to preserve future fertility.
23
Ch 01 final.qxd
12/18/2006
15:08
Page 24
SURGERY FOR OVARIAN CANCER
Adjuvant platinum-based chemotherapy is recommended for patients with stage IC or more advanced tumors. Thecoma–fibroma
The ovarian stroma gives rise to fibroblasts and theca cells. Neoplasms in this category display a variety of histologies, ranging from those composed of pure fibroblasts, to those containing a combination of cells, to those composed primarily of theca cells. Tumors in this group are generally benign neoplasms, treated by simple surgical removal. Thecoma Thecomas account for only 1% of ovarian neoplasms. Most patients present between the ages of 50 and 70.203 Abnormal bleeding occurs in 60% of patients, owing to estrogen production by the tumor. Evans et al.191 noted that endometrial hyperplasia was noted in 37% and endometrial adenocarcinomas in 27% of evaluable patients. Tumors are rarely extraovarian. Bilaterality occurs in 2% of cases. Histologically, the tumor displays two different types. The typical thecoma displays sheets or nodules of large cells containing abundant pale cytoplasm, and a variable portion of spindle cells that produce collagen. Typical thecomas almost always produce estrogen. Luteinized thecomas display clusters of steroid-type cells with abundant eosinophilic cytoplasm.
a
Estrogenic manifestations are present in only 50% of patients, and androgenic changes in 11%.204 Fibroma and fibrosarcoma Fibromas are the most
common sex cord–stromal tumor, comprising approximately 4% of all ovarian neoplasms. These benign tumors may present at any age, but are less common before the age of 30. The average age at presentation is 48 years.113 On a cut surface, fibromas are usually hard, flat and white, although areas of hemorrhage and edema may be present. Microscopically, these tumors are composed of spindle cells and abundant collagen. Because the separation between fibromas and thecomas is often vague, the term ‘fibrothecoma’ is sometimes used (Figure 1.15).113 When they are greater than 10 cm, fibromas are associated with ascites in 40% of cases.205 The presence of ovarian fibroma, ascites and hydrothorax comprise the components of Meigs’ syndrome.206 Although the syndrome is well known, only 1% of patients with fibromas will present with these findings. In 1981, Prat and Scully reported on a group of 17 fibromas with malignant behavior.207 They defined the cellular fibroma as a neoplasm characterized by densely packed nuclei and scarce collagen with 1–3 mitoses per 10 high-power fields and minimal nuclear atypia. Approximately 10% of fibromas may be classified as cellular fibromas. These tumors display low
b
Figure 1.15 Fibrothecoma. (a) Gross appearance with hard, flat cut surface. (b) Microscopic appearance
24
Ch 01 final.qxd
12/18/2006
15:08
Page 25
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
malignant potential, and are prone to recurrence, even 10 years from initial surgery. Recurrence is more likely in cases of rupture, incomplete excision, or adherent disease. In contrast, the authors defined fibrosarcomas of the ovary as neoplasms typically displaying marked nuclear atypia and more than 3 mitoses per 10 high-power fields. While extremely rare, these tumors are frankly malignant neoplasms that usually present as large, unilateral growths with areas of hemorrhage and necrosis. Prognosis is poor, and patients should be treated postoperatively with bleomycin, etoposide and cisplatin chemotherapy.196
Sertoli cell tumor Sertoli cell tumors comprise only
5% of this class of neoplasm. Young and Scully214 reviewed 23 cases and noted the mean age at presentation to be 27 years of age. Approximately two-thirds of patients may show signs of excess estrogen, resulting in postmenopausal bleeding, irregular menses and precocious puberty, depending on the age of the patient. Grossly, tumors are usually solid with a lobulated appearance. Microscopically, Sertoli cell tumors are composed of tubules, either solid or hollow, formed of Sertoli cells containing lipid. All reported cases to date have presented as unilateral, stage I tumors, with only one reported death.214
Sclerosing stromal tumors
Sclerosing stromal cell tumors were initially reported by Chalvardjian and Scully in 1973.208 Histologically, these benign tumors display pseudolobules, composed of a combination of fibroblasts and lipid-containing lutein cells. These pseudolobules may be vascular, and are separated by hypocellular fibrous tissue. Grossly, tumors are unilateral, occurring more commonly on the right side.209 Tumors may reach 20 cm in size, but ascites is uncommon. Sclerosing stromal tumors display clinical features distinct from other tumors in the thecoma–fibroma group. Unlike with many other sex cord–stromal tumors, most women are diagnosed under the age of 30. Also, while androgen and estrogen production have been reported on occasion,210–212 most tumors are not hormonally active. Sertoli–stromal cell tumors
This group of tumors is composed of neoplasms containing Sertoli cells, Leydig cells, cells resembling rete epithelial cells and cells resembling fibroblasts. These tumors may display only one cell type, or be a combination of different types. In the past, these neoplasms had been termed ‘androblastomas’ because of their tendency to cause masculinization. However, in 1958, Morris and Scully proposed the term ‘Sertoli–Leydig cell tumor’ to prevent inclusion of diverse androgenproducing tumors of different origins, and because some tumors may present with either excess estrogen or absent hormonal manifestions.213
Sertoli–Leydig cell tumor Sertoli–Leydig cell tumors account for fewer than 1% of all ovarian neoplasms. On average, patients present in their mid-twenties. Young and Scully215 reported on a series of 207 cases and noted 75% of the patients to be under the age of 30, with only 10% diagnosed over the age of 50. Presenting complaints may include menstrual irregularities and abdominal pain. Up to half of patients may present with some signs of androgen excess, including amenorrhea, hirsutism, deepening of the voice, malepattern baldness, clitorimegaly, or breast atrophy. Rarely, these tumors may secrete estrogen as well. Grossly, these tumors range in size from 5 to 15 cm, and are yellow and lobulated in appearance. Most are solid, or solid with cystic components. Microscopically, Leydig cells are present, in addition to Sertoli cells in various states of differentiation (Figure 1.16). Young and Scully215 noted that over 97% of cases were stage I at diagnosis, with 1.5% stage II and 1% stage III. Fewer than 2% of cases were bilateral. Among 164 patients for whom follow-up was available, 18% of tumors displayed malignant behavior. Prognosis was correlated with stage and degree of tumor differentiation. Stage IA disease may be treated with unilateral oophorectomy,216 resulting in a 5year survival of 92%. More advanced stages require total abdominal hysterectomy, bilateral salpingooophorectomy and surgical cytoreduction. Adjuvant chemotherapy is recommended in patients with significant residual tumor.
25
Ch 01 final.qxd
12/18/2006
15:08
Page 26
SURGERY FOR OVARIAN CANCER
(range 16–65 years). Patients presented with hyperandrogenism, hyperestrogenism, or no endocrine symptoms. The neoplasms were unilateral, and usually small. Microscopically, granulosa cells with Call–Exner bodies are present along with tubules lined by Sertoli cells. Only one case to date has been reported to display malignant behavior.220 Steroid-cell tumors
with nests of eosinophilic Leydig cells and aggregates of darker
Although these neoplasms have previously been called ‘lipid’ or ‘lipoid’ tumors, in fact 40% do not possess intracellular fat. This group of neoplasms includes tumors composed of cells that resemble Leydig, lutein and adrenal cortical cells.
Sertoli cells
Stromal luteoma Stromal luteomas account for
Figure 1.16 Sertoli–Leydig cell tumor. Edematous stroma
Sex cord tumors with annular tubules
Sex cord tumors with annular tubules possess features of both granulosa cell tumors and Sertoli–Leydig cell tumors.217,218 About 40% of patients present with signs of estrogen excess, and most patients present with abnormal vaginal bleeding. One-third of these neoplasms occur in women with Peutz–Jeghers syndrome. A strong association with adenoma malignum of the cervix also exists. When associated with Peutz–Jeghers syndrome, sex cord tumors with annular tubules tend to be bilateral and multi-focal, with the primary ovarian lesion measuring less than 3 cm in size. Disease in this circumstance is benign. When no association with Peutz–Jeghers syndrome is apparent, tumors are usually large and unilateral, but approximately 20% are malignant. Microscopically, simple and complex ring-shaped tubules are present. Management of these tumors parallels that of granulosa cell tumors. Gynandroblastoma
Gynandroblastomas are extremely rare ovarian tumors. Martin-Jimenez et al.219 presented a review of 17 cases gleaned from the literature. The authors reported the mean age of presentation as 29.5 years
26
approximately 20% of tumors in this category. Hayes and Scully221 reported 25 cases and noted the mean age at presentation to be 58. Sixty per cent of their patients presented with symptoms of excess estrogen production, and 12% with signs of hyperandrogenism. Grossly, the authors described the tumors to be well circumscribed, less than 3 cm in size, and completely confined to the ovarian stroma. Microscopically these tumors are composed of steroid cells without crystals completely surrounded by a rim of ovarian stroma. Stromal hyperthecosis is usually present. These tumors are benign and treated with surgical excision. Leydig cell tumors Leydig cell tumors also account for
approximately 20% of steroid-cell tumors. Like stromal luteomas, the mean age at presentation is in the late fifties. Grossly, these tumors are unilateral and usually under 3 cm in size. Roth and Sternberg222 noted two different types – hilar, and the extremely rare non-hilar variety. Histologically, Leydig cell tumors are composed of lutein or adrenocortical cells, and display Reinke crystals (Figure 1.17). Most patients present with signs of virilization, although irregular bleeding and postmenopausal bleeding may occur in some patients. These lesions are benign and treated with simple surgical removal. Signs of hyperandrogenism usually regress, but half of patients may be left with residual symptoms.
Ch 01 final.qxd
12/18/2006
15:08
Page 27
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
Gonadoblastoma
Figure 1.17 Leydig cell tumor with occasional eosinophilic crystals
Steroid cell tumor, not otherwise specified Approx-
imately 60% of steroid cell tumors lack the characteristics of Leydig cell tumors or stromal luteomas, and are termed steroid cell tumors not otherwise specified. Hayes and Scully223 examined 63 cases and noted a mean age at presentation of 43 years, although reported ages ranged from 2 to 80 years. About 40% of patients presented with virilization, and 6% with hyperestrogenism. Another 6% presented with Cushing’s syndrome. At the time of diagnosis, only four tumors were bilateral. Grossly, these tumors appeared solid and yellow, ranging in size from 1 to 45 cm (mean 8.5 cm). In the series by Hayes and Scully, 81% of patients had stage I disease, 6% had stage II and 13% had stage III or IV. About 25% of these lesions display malignant behavior. Poor prognosis is correlated with Cushing’s syndrome, tumors larger than 7 cm, the presence of more than two mitoses per 10 high-power fields, nuclear atypia and the presence of necrosis or hemorrhage. No clinically malignant cases have been reported to date in patients less than 20 years of age. After surgical removal, adjuvant chemotherapy may be considered for advanced stage patients or those with risk factors for malignant behavior.
Gonadoblastoma is a rare tumor first defined by Scully in 1953.224 These tumors occur in young patients, usually in those with dysgenetic gonads. Most patients are phenotypic females who may display virilization, and the remainder are phenotypic males with female internal secondary sexual organs. Occasionally, these neoplasms may occur in normal females. Over 80% of patients have sex-chromatin-negative nuclei, and the most common karyotypes are 46,XX and 45,XO/46,XY (mosaic).225 Scully reviewed 74 cases225 and described the tumors as yellow-brown or gray and calcified, ranging from microscopic to several centimeters in size. Microscopically, the tumor is composed of large germ cells and small cells resembling immature Sertoli cells. The cells grow in solid nodules that often contain areas of calcification. About 50% of patients with gonadoblastoma may have a synchronous dysgerminoma.
Metastatic tumors to the ovary Several different malignancies may metastasize to the ovaries, including gynecologic primaries and those from more distant sites. In fact, at the time of surgical exploration for an adnexal mass, about 5–10% of ovarian tumors are found to be of metastatic origin. Common gynecologic sources of metastases include endometrial carcinoma and fallopian tube carcinoma. The most common sources of non-gynecologic metastases include the gastrointestinal tract and the breast. Krukenberg tumors are metastatic ovarian lesions composed of mucin-filled signet-ring cells contained within cellular ovarian stroma (Figure 1.18). These tumors typically spread from a primary gastric carcinoma, but may also originate from other mucinous primaries such as breast or colon cancers. In some cases, difficulty may arise in distinguishing an ovarian metastasis from a synchronous mucinous primary tumor in cases of intestinal cancer. Grossly, intestinal metastases generally result in bilateral ovarian involvement. When characteristic histologic features cannot differentiate, immunohistochemical
27
Ch 01 final.qxd
12/18/2006
15:08
Page 28
SURGERY FOR OVARIAN CANCER
a
b
Figure 1.18 Krukenberg tumor (gastric metastasis). (a) Gross appearance. (b) Microscopic appearance with signet-ring cells
staining may be helpful. Cytokeratin-7 is usually positive in primary ovarian cancers, and cytokeratin-20 is usually positive in intestinal metastases.
6.
McGowan L, Parent L, Lednar W, et al. The woman at risk for developing ovarian cancer. Gynecol Oncol 1979; 7: 325–44
7.
Parazzini F, La Vecchia C, Negri E, et al. Menstrual factors and the risk of epithelial ovarian cancer. J Clin Epidemiol 1989; 42: 443–8
8.
Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case–control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1212–20
9.
Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331: 771–6
10.
Casagrande JT, Louie EW, Pike MC, et al. Incessant ovulation and ovarian cancer. Lancet 1979; 2: 170–3
11.
Keal EE. Asbestosis and abdominal neoplasms. Lancet 1960; 2: 1211–16
12.
Newhouse ML, Pearson RM, Fullerton JM, et al. A case control study of carcinoma of the ovary. Br J Prev Soc Med 1977; 31: 148–53
13.
Graham J, Graham R. Ovarian cancer and asbestos. Environ Res 1967; 1: 115–28
14.
Henderson WJ, Hamilton TC, Griffiths K. Talc in normal and malignant ovarian tissue. Lancet 1979; 1: 499
15.
Longo DL, Young RC. Cosmetic talc and ovarian cancer. Lancet 1979; 2: 1011–12
ACKNOWLEDGMENTS We would like to thank Dr Geza Acs for providing gross and histologic photographs for this manuscript.
REFERENCES 1.
Tortolero-Luna G, Mitchell MF, Rhodes-Morris HE. Epidemiology and screening of ovarian cancer. Obstet Gynecol Clin North Am 1994; 21: 1–23
2.
Baker TR, Piver MS. Etiology, biology, and epidemiology of ovarian cancer. Semin Surg Oncol 1994; 10: 242–8
3.
Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26
4.
Yancik R, Ries LG, Yates JW. Ovarian cancer in the elderly: an analysis of surveillance, epidemiology, and end results program data. Am J Obstet Gynecol 1986; 154: 639–47
5.
28
Ries LAG, Kosary CL, Hankey BF, et al., eds. Cancer Statistics Review 1973–1994. National Institutes of Health Publication No. 97-2789. Bethesda, MD: National Cancer Institute, 1997
Ch 01 final.qxd
12/18/2006
15:08
Page 29
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
16.
Venter PF. Ovarian epithelial cancer and chemical carcinogenesis. Gynecol Oncol 1981; 12: 281–5
17.
Hartge P, Hoover R, Lesher LP, et al. Talc and ovarian cancer. J Am Med Assoc 1983; 250: 1844
18.
Roe FJ. Controversy: cosmetic talc and ovarian cancer. Lancet 1979; 2: 744
19.
Whittemore AS, Wu ML, Paffenbarger RS Jr, et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol 1988; 128: 1228–40
31.
Piver MS, Baker TR, Jishi MF, et al. Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981–1991. Cancer 1993; 71: 582–8
32.
Menczer J, Modan M, Ranon L, et al. Possible role of mumps virus in the etiology of ovarian cancer. Cancer 1979; 43: 1375–9
33.
Cramer DW, Welch WR, Cassells S, et al. Mumps, menarche, menopause, and ovarian cancer. Am J Obstet Gynecol 1983; 147: 1–6
34.
Rose DP, Boyar AP, Wynder EL. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer 1986; 58: 2363–71
20.
Cramer DW, Welch WR, Scully RE, et al. Ovarian cancer and talc: a case-control study. Cancer 1982; 50: 372–6
21.
Cook LS, Kamb ML, Weiss NS. Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol 1997; 145: 459–65
35.
Cramer DW, Harlow BL, Willett WC, et al. Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet 1989; 2: 66–71
22.
Lingeman CH. Environmental factors in the etiology of carcinoma of the human ovary: a review. Am J Ind Med 1983; 4: 365–79
36.
Stocks P. Cancer mortality in relation to national consumption of cigarettes, solid fuel, tea and coffee. Br J Cancer 1970; 24: 215–25
23.
Beral V, Fraser P, Chilvers C. Does pregnancy protect against ovarian cancer? Lancet 1978; 1: 1083–7
37.
24.
dos Santos Silva I, Swerdlow AJ. Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use. Br J Cancer 1995; 72: 485–92
Trichopoulos D, Papapostolou M, Polychronopoulou A. Coffee and ovarian cancer. Int J Cancer 1981; 28: 691–3
38.
Byers T, Marshall J, Graham S, et al. A case–control study of dietary and nondietary factors in ovarian cancer. J Natl Cancer Inst 1983; 71: 681–6
25.
Roush GC, Holford TR, Schymura MJ, et al. Cancer Risk and Incidence Trends: the Connecticut Perspective. New York: Hemisphere, 1987
39.
Cramer DW, Welch WR, Hutchison GB, et al. Dietary animal fat in relation to ovarian cancer risk. Obstet Gynecol 1984; 63: 833–8
26.
Buell P, Dunn JE. Cancer mortality among the Japanese Issei and Nisei of California. Cancer 1965; 18: 656–64
40.
Slattery ML, Schuman KL, West DW, et al. Nutrient intake and ovarian cancer. Am J Epidemiol 1989; 130: 497–502
27.
Parker SL, Davis KJ, Wingo PA, et al. Cancer statistics by race and ethnicity. CA Cancer J Clin 1998; 48: 31–48
41.
28.
Annegers JF, Strom H, Decker DG, et al. Ovarian cancer: incidence and case–control study. Cancer 1979; 43: 723–9
Fairfield KM, Hankinson SE, Rosner BA, et al. Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis. Cancer 2001; 92: 2318–26
42.
Koch M, Gaedke H, Jenkins H. Family history of ovarian cancer patients: a case–control study. Int J Epidemiol 1989; 18: 782–5
43.
Hartge P, Schiffman MH, Hoover R, et al. A case–control study of epithelial ovarian cancer. Am J Obstet Gynecol 1989; 161: 10–16
29.
West RO. Epidemiologic study of malignancies of the ovaries. Cancer 1966; 19: 1001–7
30.
Greene MH, Clark JW, Blayney DW. The epidemiology of ovarian cancer. Semin Oncol 1984; 11: 209–26
29
Ch 01 final.qxd
12/18/2006
15:08
Page 30
SURGERY FOR OVARIAN CANCER
57.
Monteiro AN, August A, Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 1996; 93: 13595–9
58.
Milner J, Ponder B, Hughes-Davies L, et al. Transcriptional activation functions in BRCA2. Nature 1997; 386: 772–3
59.
Houlston RS, Collins A, Slack J, et al. Genetic epidemiology of ovarian cancer: segregation analysis. Ann Hum Genet 1991; 55: 291–9
Scully R, Anderson SF, Chao DM, et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA 1997; 94: 5605–10
60.
Bewtra C, Watson P, Conway T, et al. Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol 1992; 11: 180–7
Gowen LC, Avrutskaya AV, Latour AM, et al. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998; 281: 1009–12
61.
Narod SA, Madlensky L, Bradley L, et al. Hereditary and familial ovarian cancer in southern Ontario. Cancer 1994; 74: 2341–6
Takahashi H, Behbakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995; 55: 2998–3002
62.
Schildkraut JM, Thompson WD. Familial ovarian cancer: a population-based case–control study. Am J Epidemiol 1988; 128: 456–66
63.
Couch FJ, Hartmann LC. BRCA1 testing – advances and retreats. J Am Med Assoc 1998; 279: 955–7
64.
Malone KE, Daling JR, Thompson JD, et al. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. J Am Med Assoc 1998; 279: 922–9
65.
Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993; 52: 678–701
66.
Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676–89
67.
Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401–8
68.
Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335: 1413–16
69.
Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and
44.
Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 1992; 80: 700–7
45.
Schildkraut JM, Risch N, Thompson WD. Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. Am J Hum Genet 1989; 45: 521–9
46.
47.
48.
49.
Lynch HT, Lynch JF, Conway TA. Hereditary ovarian cancer. In: Rubin SC, Sutton GP, eds. Ovarian Cancer. New York: McGraw-Hill, 1993: 189–217
50.
Lynch HT, Harris RE, Guirgis HA, et al. Familial association of breast/ovarian carcinoma. Cancer 1978; 41: 1543–9
51.
Berchuck A, Cirisano F, Lancaster JM, et al. Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol 1996; 175: 738–46
52.
Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71
53.
Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789–92
54.
Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. Nat Med 1997; 3: 721–2
55.
Zhang H, Tombline G, Weber BL. BRCA1, BRCA2, and DNA damage response: collision or collusion? Cell 1998; 92: 433–6
56.
Chapman MS, Verma IM. Transcriptional activation by BRCA1. Nature 1996; 382: 678–9
30
Ch 01 final.qxd
12/18/2006
15:08
Page 31
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
sporadic ovarian cancer. J Am Med Assoc 2000; 283: 2260–5 70.
Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260: 812–16
71.
Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75: 1215–25
Genetics Studies Consortium. J Am Med Assoc 1997; 277: 915–19 82.
Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339: 424–8
83.
Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 235–40
84.
Ness RB, Grisso JA, Vergona R, et al. Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 2001; 12: 307–12
85.
Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case–control study. Lancet 2001; 357: 1467–70
86.
Streuwing JP, Watson P, Easton EF, et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 1995: 33–5
87.
Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 1996; 14: 1730–6, discussion 7–40
Tobacman JK, Greene MH, Tucker MA, et al. Intraabdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982; 2: 795–7
88.
Mangan CE, Rubin SC, Rabin DS, et al. Lymph node nomenclature in gynecologic oncology. Gynecol Oncol 1986; 23: 222–6
77.
Mackey SE, Creasman WT. Ovarian cancer screening. J Clin Oncol 1995; 13: 783–93
89.
Keettel WC, Pixley EE. Diagnostic value of peritoneal washings. Clin Obstet Gynecol 1958; 1: 592
78.
NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. J Am Med Assoc 1995; 273: 491–7
90.
79.
van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000; 77: 350–6
Feldman GB, Knapp RC, Order SE, et al. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 1972; 32: 1663–6
91.
Holm-Nielsen P. Pathogenesis of ascites in peritoneal carcinomatosis. Acta Pathol Microbiol Scand 1953; 33: 10–21
92.
Bergman F. Carcinoma of the ovary: a clinical–pathological study of 86 autopsied cases with special reference to mode of spread. Acta Obstet Gynecol Scand 1966; 45: 211
93.
Abrams LA, Spiro R, Goldstein N. Metastases in carcinoma. Cancer 1950; 3: 74
72.
73.
Bellacosa A, Genuardi M, Anti M, et al. Hereditary nonpolyposis colorectal cancer: review of clinical, molecular genetics, and counseling aspects. Am J Med Genet 1996; 62: 353–4 Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36: 801–18
74.
Aarnio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64: 430–3
75.
Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. J Am Med Assoc 1997; 277: 997–1003
76.
80.
van Nagell JR Jr, Gallion HH, Pavlik EJ, et al. Ovarian cancer screening. Cancer 1995; 76: 2086–91
81.
Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer
31
Ch 01 final.qxd
12/18/2006
15:08
Page 32
SURGERY FOR OVARIAN CANCER
94.
Burghardt E, Girardi F, Lahousen M, et al. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991; 40: 103–6
106. Kline RC, Wharton JT, Atkinson EN, et al. Endometrioid carcinoma of the ovary: retrospective review of 145 cases. Gynecol Oncol 1990; 39: 337–46
95.
Moore DH. Primary surgical management of early epithelial ovarian carcinoma. In Rubin SC, Sutton GP, eds. Ovarian Cancer, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2001: 201–18
107. Czernobilsky B, Silverman BB, Mikuta JJ. Endometrioid carcinoma of the ovary. A clinicopathologic study of 75 cases. Cancer 1970; 26: 1141–52
96.
Scully RE. Histological Typing of Ovarian Tumors, 2nd edn. New York: Springer-Verlag, 1999
108. Tidy J, Mason WP. Endometrioid carcinoma of the ovary: a retrospective study. Br J Obstet Gynaecol 1988; 95: 1165–9
97.
Robboy SJ, Duggan M, Kurman RJ. The female reproductive system. In Rubin E, Farber J, eds. Pathology, 2nd edn. Philadelphia: LB Lippincott, 1988
98.
Aure JC, Hoeg K, Kolstad P. Psammoma bodies in serous carcinoma of the ovary. A prognostic study. Am J Obstet Gynecol 1971; 109: 113–18
99.
Gilks CB, Bell DA, Scully RE. Serous psammocarcinoma of the ovary and peritoneum. Int J Gynecol Pathol 1990; 9: 110–21
100. Ronnett BM, Kurman RJ, Shmookler BM, et al. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. Am J Surg Pathol 1997; 21: 1144–5 101. Cuatrecasas M, Matias-Guiu X, Prat J. Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations. Am J Surg Pathol 1996; 20: 739–46 102. Chuaqui RF, Zhuang Z, Emmert-Buck MR, et al. Genetic analysis of synchronous mucinous tumors of the ovary and appendix. Hum Pathol 1996; 27: 165–71 103. Long ME, Taylor HCJ. Endometrioid carcinoma of the ovary. Am J Obstet Gynecol 1964; 90: 936–50 104. Schueller EF, Kirol PM. Prognosis in endometrioid carcinoma of the ovary. Obstet Gynecol 1966; 27: 850–8 105. Stern RC, Dash R, Bentley RC, et al. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 2001; 20: 133–9
32
109. Ulbright TM, Roth LM. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Hum Pathol 1985; 16: 28–34 110. DiSilvestro PA, Gajewski WH, Ludwig ME, et al. Malignant mixed mesodermal tumors of the ovary. Obstet Gynecol 1995; 86: 780–2 111. Dehner LP, Norris HJ, Taylor HB. Carcinosarcomas and mixed mesodermal tumors of the ovary. Cancer 1971; 27: 207–6 112. Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998; 70: 255–8 113. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, Fallopian tube, and broad ligament. In Atlas of Tumor Pathology, Third Series, Fascicle 23. Washington, DC: Armed Forces Institute of Pathology, 1999 114. Ohkawa K, Amasaki H, Terashima Y, et al. Clear cell carcinoma of the ovary: light and electron microscopic studies. Cancer 1977; 40: 3019–29 115. Eastwood J. Mesonephroid (clear cell) carcinoma of the ovary and endometrium: a comparative prospective clinico-pathological study and review of literature. Cancer 1978; 41: 1911–28 116. Brescia RJ, Dubin N, Demopoulos RI. Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival. Int J Gynecol Pathol 1989; 8: 132–8 117. Hitti IF, Glasberg SS, Lubicz S. Clear cell carcinoma arising in extraovarian endometriosis: report of three cases and review of the literature. Gynecol Oncol 1990; 39: 314–20 118. Wheeler JE. Pathology of malignant ovarian epithelial tumors and miscellaneous and rare ovarian and paraovarian neoplasms. In Rubin SC, Sutton GP, eds.
Ch 01 final.qxd
12/18/2006
15:08
Page 33
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
Ovarian Cancer, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2001: 99–134 119. Roth LM, Czernobilsky B. Ovarian Brenner tumors. II. Malignant. Cancer 1985; 56: 592–601
132. Trimble EL, Trimble CL. Epithelial ovarian tumors of low malignant potential. In Markman M, Hoskins WJ, eds. Cancer of the Ovary. New York: Raven Press, 1993:
120. Austin RM, Norris HJ. Malignant Brenner tumor and transitional cell carcinoma of the ovary: a comparison. Int J Gynecol Pathol 1987; 6: 29–39
133. Harlow BL, Weiss NS, Roth GJ, et al. Case–control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 1988; 48: 5849–2
121. Lele SB, Piver MS, Barlow JJ, et al. Squamous cell carcinoma arising in ovarian endometriosis. Gynecol Oncol 1978; 6: 290–3
134. Yazigi R, Sandstad J, Munoz AK. Primary staging in ovarian tumors of low malignant potential. Gynecol Oncol 1988; 31: 402–8
122. Pins MR, Young RH, Daly WJ, et al. Primary squamous cell carcinoma of the ovary. Report of 37 cases. Am J Surg Pathol 1996; 20: 823–33
135. Sutton GP. Ovarian tumors of low malignant potential. In Rubin SC, Sutton GP, eds. Ovarian Cancer, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2001: 399–417
123. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971; 37: 1–9 124. Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 1971; 50: 1–7 125. Serov SF, Scully RE, Sobin LH. International histological classification and staging of tumors. No. 9 Histologic typing of ovarian tumors. Geneva: World Health Organization, 1973 126. Trimble CL, Trimble EL. Management of epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1994; 55: S52–61 127. Nayar R, Siriaunkgul S, Robbins KM, et al. Microinvasion in low malignant potential tumors of the ovary. Hum Pathol 1996; 27: 521–7
136. Buttini M, Nicklin JL, Crandon A. Low malignant potential ovarian tumours: a review of 175 consecutive cases. Aust NZ J Obstet Gynaecol 1997; 37: 100–3 137. Nakashima N, Nagasaka T, Oiwa N, et al. Ovarian epithelial tumors of borderline malignancy in Japan. Gynecol Oncol 1990; 38: 90–8 138. Chambers JT, Merino MJ, Kohorn EI, et al. Borderline ovarian tumors. Am J Obstet Gynecol 1988; 159: 1088–94 139. Julian CG, Woodruff JD. The biologic behavior of low-grade papillary serous carcinoma of the ovary. Obstet Gynecol 1972; 40: 860–7 140. Nikrui N. Survey of clinical behavior of patients with borderline epithelial tumors of the ovary. Gynecol Oncol 1981; 12: 107–19
128. Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Hum Pathol 1990; 21: 397–403
141. Nation JG, Krepart GV. Ovarian carcinoma of low malignant potential: staging and treatment. Am J Obstet Gynecol 1986; 154: 290–3
129. Chu CS, Randall TC, Mikuta JJ. Low malignant Potential Tumors Of The Ovary. Baltimore, MD: Post Graduate Obstetrics & Gynecology, 1998; 18: 1–6
142. Kliman L, Rome RM, Fortune DW. Low malignant potential tumors of the ovary: a study of 76 cases. Obstet Gynecol 1986; 68: 338–44
130. Norris HJ, Mount PM. Pathology of ovarian tumors of low malignant potential. In Rutledge F, Wharton T, Gershenson D, eds. Gynecologic Cancer: Diagnosis and Treatment Strategies. Austin: University of Texas Press, 1987: 171–92
143. Bostwick DG, Tazelaar HD, Ballon SC, et al. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 1986; 58: 2052–65
131. Harlow BL, Weiss NS, Lofton S. Epidemiology of borderline ovarian tumors. J Natl Cancer Inst 1987; 78: 71–4
144. Fort MG, Pierce VK, Saigo PE, et al. Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1989; 32: 269–72
33
Ch 01 final.qxd
12/18/2006
15:08
Page 34
SURGERY FOR OVARIAN CANCER
145. Barnhill D, Heller P, Brzozowski P, et al. Epithelial ovarian carcinoma of low malignant potential. Obstet Gynecol 1985; 65: 53–9 146. Barnhill DR, Kurman RJ, Brady MF, et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13: 2752–6 147. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive lowgrade carcinoma related to serous borderline tumors. Am J Surg Pathol 1996; 20: 1319–30 148. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996; 20: 1331–45 149. Eichhorn JH, Bell DA, Young RH, et al. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol 1999; 23: 397–409 150. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000; 31: 539–57 151. Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary. Am J Obstet Gynecol 1959; 77: 197 152. Raju U, Fine G, Greenawald KA, et al. Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases. Hum Pathol 1989; 20: 426–36 153. Truong LD, Maccato ML, Awalt H, et al. Serous surface carcinoma of the peritoneum: a clinicopathologic study of 22 cases. Hum Pathol 1990; 21: 99–110 154. Lele SB, Piver MS, Matharu J, et al. Peritoneal papillary carcinoma. Gynecol Oncol 1988; 31: 315–20 155. Chu CS, Menzin AW, Leonard DG, et al. Primary peritoneal carcinoma: a review of the literature. Obstet Gynecol Surv 1999; 54: 323–35 156. Fromm GL, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990; 75: 89–95 157. Killackey MA, Davis AR. Papillary serous carcinoma of the peritoneal surface: matched-case comparison
34
with papillary serous ovarian carcinoma. Gynecol Oncol 1993; 51: 171–4 158. Dalrymple JC, Bannatyne P, Russell P, et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 1989; 64: 110–15 159. Altaras MM, Aviram R, Cohen I, et al. Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects. Gynecol Oncol 1991; 40: 230–6 160. Zhou J, Iwasa Y, Konishi I, et al. Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study. Cancer 1995; 76: 429–36 161. Kannerstein M, Churg J, McCaughey WT, et al. Papillary tumors of the peritoneum in women: mesothelioma or papillary carcinoma. Am J Obstet Gynecol 1977; 127: 306–14 162. Ransom DT, Patel SR, Keeney GL, et al. Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer 1990; 66: 1091–4 163. August CZ, Murad TM, Newton M. Multiple focal extraovarian serous carcinoma. Int J Gynecol Pathol 1985; 4: 11–23 164. Eltabbakh GH, Piver MS, Natarajan N, et al. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol 1998; 91: 254–9 165. Ben-Baruch G, Sivan E, Moran O, et al. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III–IV ovarian papillary serous carcinoma. Gynecol Oncol 1996; 60: 393–6 166. Dvoretsky PM, Richards KA, Angel C, et al. Distribution of disease at autopsy in 100 women with ovarian cancer. Hum Pathol 1988; 19: 57–63 167. Gooneratne S, Sassone M, Blaustein A, et al. Serous surface papillary carcinoma of the ovary: a clinicopathologic study of 16 cases. Int J Gynecol Pathol 1982; 1: 258–69 168. White PF, Merino MJ, Barwick KW. Serous surface papillary carcinoma of the ovary: a clinical, pathologic, ultrastructural, and immunohistochemical study of 11 cases. Pathol Annu 1985; 20: 403–18
Ch 01 final.qxd
12/18/2006
15:08
Page 35
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
169. Kupryjanczyk J, Thor AD, Beauchamp R, et al. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Mod Pathol 1996; 9: 166–73
182. Nawa A, Obata N, Kikkawa F, et al. Prognostic factors of patients with yolk sac tumors of the ovary. Am J Obstet Gynecol 2001; 184: 1182–8
170. Pejovic T, Heim S, Mandahl N, et al. Bilateral ovarian carcinoma: cytogenetic evidence of unicentric origin. Int J Cancer 1991; 47: 358–61
183. Kurman RJ, Norris HJ. Embryonal carcinoma of the ovary: a clinicopathologic entity distinct from endodermal sinus tumor resembling embryonal carcinoma of the adult testis. Cancer 1976; 38: 2420–33
171. Mok CH, Tsao SW, Knapp RC, et al. Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 1992; 52: 5119–22
184. Chapman DC, Grover R, Schwartz PE. Conservative management of an ovarian polyembryoma. Obstet Gynecol 1994; 83: 879–82
172. Jacobs IJ, Kohler MF, Wiseman RW, et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992; 84: 1793–8
185. Tsukahara Y, Fukuta T, Yamada T, et al. Retroperitoneal giant tumor formed by migrating polyembryoma with numerous embryoid bodies from an ovarian mixed germ cell tumor. Gynecol Obstet Invest 1991; 31: 58–60
173. Li S, Han H, Resnik E, et al. Advanced ovarian carcinoma: molecular evidence of unifocal origin. Gynecol Oncol 1993; 51: 21–5 174. Tsao SW, Mok CH, Knapp RC, et al. Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. Gynecol Oncol 1993; 48: 5–10 175. Muto MG, Welch WR, Mok SC, et al. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res 1995; 55: 490–2 176. Schorge JO, Muto MG, Welch WR, et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998; 90: 841–5 177. Bandera CA, Muto MG, Welch WR, et al. Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum. Oncogene 1998; 16: 3455–9 178. Moll UM, Valea F, Chumas J. Role of p53 alteration in primary peritoneal carcinoma. Int J Gynecol Pathol 1997; 16: 156–62
186. Young RH, Scully RE. Ovarian sex cord-stromal tumours: recent advances and current status. Clin Obstet Gynaecol 1984; 11: 93–134 187. Schwartz PE, Smith JP. Treatment of ovarian stromal tumors. Am J Obstet Gynecol 1976; 125: 402–11 188. Ohel G, Kaneti H, Schenker JG. Granulosa cell tumors in Israel: a study of 172 cases. Gynecol Oncol 1983; 15: 278–86 189. Bennington JL, Ferguson BR, Haber SL. Incidence and relative frequency of benign and malignant ovarian neoplasms. Obstet Gynecol 1968; 32: 627–32 190. Fox H, Agrawal K, Langley FA. A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis. Cancer 1975; 35: 231–41 191. Evans AT 3rd, Gaffey TA, Malkasian GD Jr, et al. Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol 1980; 55: 231–8
179. Kurman RJ, Norris HJ. Malignant germ cell tumors of the ovary. Hum Pathol 1977; 8: 551–64
192. Nakashima N, Young RH, Scully RE. Androgenic granulosa cell tumors of the ovary. A clinicopathologic analysis of 17 cases and review of the literature. Arch Pathol Lab Med 1984; 108: 786–91
180. Schwartz PE, Morris JM. Serum lactic dehydrogenase: a tumor marker for dysgerminoma. Obstet Gynecol 1988; 72: 511–15
193. Bjorkholm E, Silfversward C. Prognostic factors in granulosa-cell tumors. Gynecol Oncol 1981; 11: 261–74
181. Kurman RJ, Norris HJ. Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases. Cancer 1976; 38: 2404–19
194. Malmstrom H, Hogberg T, Risberg B, et al. Granulosa cell tumors of the ovary: prognostic factors and outcome. Gynecol Oncol 1994; 52: 50–5
35
Ch 01 final.qxd
12/18/2006
15:08
Page 36
SURGERY FOR OVARIAN CANCER
195. Piura B, Nemet D, Yanai-Inbar I, et al. Granulosa cell tumor of the ovary: a study of 18 cases. J Surg Oncol 1994; 55: 71–7
207. Prat J, Scully RE. Cellular fibromas and fibrosarcomas of the ovary: a comparative clinicopathologic analysis of seventeen cases. Cancer 1981; 47: 2663–70
196. Schwartz PE, Price FV, Snyder MK. Management of ovarian stromal tumors. In Rubin SC, Sutton GP, eds. Ovarian Cancer, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2001: 383–98
208. Chalvardjian A, Scully RE. Sclerosing stromal tumors of the ovary. Cancer 1973; 31: 664–70
197. Hines JF, Khalifa MA, Moore JL, et al. Recurrent granulosa cell tumor of the ovary 37 years after initial diagnosis: a case report and review of the literature. Gynecol Oncol 1996; 60: 484–8 198. Young RH, Dickersin GR, Scully RE. Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am J Surg Pathol 1984; 8: 575–96 199. Roth LM, Nicholas TR, Ehrlich CE. Juvenile granulosa cell tumor: a clinicopathologic study of three cases with ultrastructural observations. Cancer 1979; 44: 2194–205 200. Tamimi HK, Bolen JW. Enchondromatosis (Ollier’s disease) and ovarian juvenile granulosa cell tumor. Cancer 1984; 53: 1605–8 201. Velasco-Oses A, Alonso-Alvaro A, Blanco-Pozo A, et al. Ollier’s disease associated with ovarian juvenile granulosa cell tumor. Cancer 1988; 62: 222–5 202. Lewis RJ, Ketcham AS. Maffucci’s syndrome: functional and neoplastic significance. Case report and review of the literature. J Bone Joint Surg Am 1973; 55: 1465–79 203. Bjorkholm E, Silfversward C. Theca-cell tumors. Clinical features and prognosis. Acta Radiol Oncol 1980; 19: 241–4
209. Marelli G, Carinelli S, Mariani A, et al. Sclerosing stromal tumor of the ovary. Report of eight cases and review of the literature. Eur J Obstet Gynecol Reprod Biol 1998; 76: 85–9 210. Ho Yuen B, Robertson DI, Clement PB, et al. Sclerosing stromal tumor of the ovary. Obstet Gynecol 1982; 60: 252–6 211. Quinn MA, Oster AO, Fortune D, et al. Sclerosing stromal tumour of the ovary case report with endocrine studies. Br J Obstet Gynaecol 1981; 88: 555–8 212. Damajanov I, Drobnjak P, Grizelj V, et al. Sclerosing stromal tumor of the ovary: a hormonal and ultrastructural analysis. Obstet Gynecol 1975; 45: 675–9 213. Morris JM, Scully RE. Endocrine Pathology of the Ovary. St Louis: Mosby, 1958 214. Young RH, Scully RE. Ovarian Sertoli cell tumors: a report of 10 cases. Int J Gynecol Pathol 1984; 2: 349–63 215. Young RH, Scully RE. Ovarian Sertoli–Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985; 9: 543–69 216. Zaloudek C, Norris HJ. Sertoli–Leydig tumors of the ovary. A clinicopathologic study of 64 intermediate and poorly differentiated neoplasms. Am J Surg Pathol 1984; 8: 405–18 217. Hart WR, Kumar N, Crissman JD. Ovarian neoplasms resembling sex cord tumors with annular tubules. Cancer 1980; 45: 2352–63
204. Zhang J, Young RH, Arseneau J, et al. Ovarian stromal tumors containing lutein or Leydig cells (luteinized thecomas and stromal Leydig cell tumors) – a clinicopathological analysis of fifty cases. Int J Gynecol Pathol 1982; 1: 270–85
218. Tavassoli FA, Norris HJ. Sertoli tumors of the ovary. A clinicopathologic study of 28 cases with ultrastructural observations. Cancer 1980; 46: 2281–97
205. Samanth KK, Black WC 3rd. Benign ovarian stromal tumors associated with free peritoneal fluid. Am J Obstet Gynecol 1970; 107: 538–45
219. Martin-Jimenez A, Condom-Munro E, Valls-Porcel M, et al. Gynandroblastoma of the ovary. Review of the literature. J Gynecol Obstet Biol Reprod (Paris) 1994; 23: 391–4
206. Meigs JV, Cass JW. Fibroma of the ovary with ascites and hydrothorax with a report of seven cases. Am J Obstet Gynecol 1937; 107: 538
220. Novak ER. Gynandroblastoma of the ovary: review of 8 cases from the ovarian tumor registry. Obstet Gynecol 1967; 30: 709–15
36
Ch 01 final.qxd
12/18/2006
15:08
Page 37
EPIDEMIOLOGY, STAGING AND CLINICAL CHARACTERISTICS
221. Hayes MC, Scully RE. Stromal luteoma of the ovary: a clinicopathological analysis of 25 cases. Int J Gynecol Pathol 1987; 6: 313–21
International Federation Obstetrics, 1994; 22
of
Gynecology
and
222. Roth LM, Sternberg WH. Ovarian stromal tumors containing Leydig cells. II. Pure Leydig cell tumor, non-hilar type. Cancer 1973; 32: 952–60
227. Herbst AL. Neoplastic Diseases of the Ovary. In Mishell DR Jr, Stenchever MA, Droegemueller W, et al., eds. Comprehensive Gynecology, 3rd edn. St Louis: Mosby-Year Book, 1997: 901–44
223. Hayes MC, Scully RE. Ovarian steroid cell tumors (not otherwise specified). A clinicopathological analysis of 63 cases. Am J Surg Pathol 1987; 11: 835–45
228. Fine G, Clarke HD, Horn RC Jr. Mesonephroma of the ovary. A clinical, morphological, and histogenetic appraisal. Cancer 1973; 31: 398–410
224. Scully RE. Gonadoblastoma: a gonadal tumor related to dysgerminoma (seminoma) and capable of sex hormone production. Cancer 1953; 6: 455–63
229. Katzenstein AL, Mazur MT, Morgan TE, et al. Proliferative serous tumors of the ovary. Histologic features and prognosis. Am J Surg Pathol 1978; 2: 339–55
225. Scully RE. Gonadoblastoma. A review of 74 cases. Cancer 1970; 25: 1340–56 226. Pettersson F. Annual Report on the Results of Treatment in Gynecological Cancer. Stockholm:
230. Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case–control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993; 50: 347–51
37
Ch 02 final.qxd
12/18/2006
15:11
Page 39
CHAPTER 2
Preoperative preparation and surgical instrumentation Marcela G del Carmen, Robert E Bristow, Linda R Duska
INTRODUCTION While surgery is the cornerstone of ovarian cancer diagnosis and initial treatment, it is in fact a detailed process that begins well before the patient ever reaches the operating room. It is therefore incumbent upon the surgeon to lay the foundation for a safe and successful operation and recovery through appropriate diagnostic evaluation, optimization of co-morbid medical conditions, and having a working understanding of the contemporary surgical instrumentation utilized during ovarian cancer surgery.
PREOPERATIVE EVALUATION Risk assessment In preparation for surgery for a suspected ovarian cancer all patients should undergo a comprehensive his-
tory and physical examination with a bimanual rectovaginal pelvic examination. The review of symptoms and examination should focus specifically on those areas that may indicate a reduced capacity to tolerate major surgery or place the patient at elevated risk for postoperative complications. The five-tiered classification system of the American Society of Anesthesiologists (ASA) can provide a global assessment of the risk for adverse perioperative outcomes (Table 2.1). In a prospective study of 6301 general surgical patients, Wolters et al. found that increasing ASA classification (I–IV) was significantly associated with longer operative time, increased intraoperative blood loss, a higher likelihood of postoperative mechanical ventilation requirement, longer hospital stay and time in the intensive care unit, a higher incidence of bronchopulmonary infection and other pulmonary complications, cardiac complications (arrhythmia, myocardial infarction), more frequent
Table 2.1 American Society of Anesthesiologists (ASA) classification system ASA class
Description
1
Healthy patient
2
Mild systemic disease – no functional limitation
3
Severe systemic disease – definite functional limitation
4
Severe life-threatening systemic disease that is a constant threat to life
5
Moribund, unlikely to survive 24 h with or without operation
39
Ch 02 final.qxd
12/18/2006
15:11
Page 40
SURGERY FOR OVARIAN CANCER
wound infection, a higher risk of bowel anastomosis dehiscence and a higher mortality rate.1 After controlling for confounding factors (type and extent of operation, age, medical co-morbidities), ASA classification was an independent and significant predictor of the overall risk of postoperative complications, with ASA classes II–IV being associated with 1.6-fold, 2.2-fold and 4.3-fold increased risk, respectively, relative to ASA class I patients.1 The validity of the ASA classification system as a predictor of postoperative complications specifically in gynecologic oncology patients was examined by Giannice et al. in a case–control study of 323 patients aged 70 years and older undergoing either minor or major surgical procedures.2 Compared to patients classified as ASA I–II, those patients who were ASA III–V were significantly more likely to experience any postoperative complication (48% vs. 28%), two or more postoperative complications (13% vs. 9%), or severe (grade 3 or 4) postoperative complications (17% vs. 5%). In this study, there were no significant differences in operative time, median blood loss, or transfusion rate according to the ASA classification.
Laboratory and routine testing The recommended routine preoperative laboratory testing program prior to surgery for suspected ovarian cancer should include a minimum of a complete blood count (CBC), serum electrolytes, age-appropriate health screening studies, a chest radiograph, and electrocardiogram for women aged 50 years and above (Table 2.2). The CBC may reveal anemia, which may be acute (e.g. due to gastrointestinal losses from secondary tumor involvement) or chronic (due to chronic disease or underlying hemoglobinopathy) and require further evaluation (e.g. peripheral smear, reticulocyte count, serum iron studies, or hemoglobin electrophoresis) or blood product replacement prior to surgery. Derangements of the platelet count may also be seen with ovarian cancer. Thrombocytosis (platelet count > 400 000/ml) may be present in as many as 22% of patients undergoing primary surgery for epithelial ovarian cancer and has been associated
40
with advanced-stage disease, higher tumor grade, more frequent lymph node metastasis, a larger volume of ascites and a hypercoagulable state predisposing to pulmonary embolism compared to patients with normal platelet counts.3,4 Among patients with advanced-stage disease, thrombocytosis has also been implicated as a predictor of worse overall survival outcome.3,5 Rarely, thrombocytopenia in the setting of newly diagnosed ovarian cancer may indicate the presence of a chronic disseminated intravascular coagulopathy. Routine examination of serum electrolytes is recommended to identify abnormalities in fluid balance and renal function that may be present as co-morbid conditions or caused by advancedstage ovarian cancer. Significant hyponatremia (Na < 120 mEq/l), hyperkalemia (K > 5.0 mEq/l), hypokalemia (K < 3.3 mEq/l) and renal insufficiency (creatinine > 2.5 mg/ml) require further evaluation
Table 2.2 Preoperative testing program prior to ovarian cancer surgery Routine All patients Complete blood count Serum electrolytes Chest radiograph Pap smear* Age 50 and above Electrocardiogram Screening sigmoidoscopy/colonoscopy* Mammography† Indicated for specific personal history, symptoms, or physical findings Serum chemistries Coagulation studies Echocardiogram Exercise stress test Pulmonary function tests Sigmoidoscopy/colonoscopy/barium enema/upper gastrointestinal series Urinalysis *As per recommended screening guidelines; †baseline mammography at age 40; subsequent screening studies every 1–2 years between ages 40 and 50 years
Ch 02 final.qxd
12/18/2006
15:11
Page 41
PREOPERATIVE PREPARATION AND SURGICAL INSTRUMENTATION
and correction prior to surgery. In selected patients, a serum chemistry panel may identify significant disturbances in synthetic liver function (infectious or alcoholic hepatitis) or calcium balance (hypercalcemia of malignancy). A history of poorly controlled endocrinopathies (diabetes, hyper- or hypothyroidism, adrenal insufficiency) should also be specifically elicited in the preoperative evaluation, with additional testing and medical specialist consultation obtained as necessary to optimize the patient’s overall fitness for surgery. Coagulation studies (prothrombin time, activated partial thromboplastin time) are unnecessary as routine preoperative tests and should be obtained only if indicated by symptoms (easy bruisability or bleeding) or history (family member with bleeding diathesis). Similarly, a preoperative urinalysis is unlikely to yield clinically significant results unless the patient is symptomatic. A chest radiograph is indicated for all women with suspected ovarian cancer, irrespective of age, to look for the presence of a pleural effusion or pulmonary metastases, which may impair postoperative respiratory function. Selected patients may benefit from preoperative thoracentesis or chest tube placement to optimize ventilation during and after surgery. Although severe underlying pulmonary disease is uncommon in ovarian cancer patients, those with a history of longstanding smoking, chronic obstructive pulmonary disease, or severe asthma may benefit from preoperative pulmonary function testing. Routine electrocardiography should be performed in women aged 50 years and older and in patients with a significant cardiac history. Unrecognized cardiac conditions can have devastating consequences in the perioperative period. The preoperative evaluation should therefore detail any symptoms suggestive of ischemic heart disease, impaired cardiac reserve (reduced exercise tolerance, dyspnea, chest pain, orthopnea, or unexplained syncopal episodes) or peripheral vascular disease. Positive findings may require further evaluation with an echocardiogram, exercise stress test, or angiography prior to proceeding with major surgery. In these instances, a cardiologist
should be consulted for optimization of cardiac function and preoperative clearance. Screening sigmoidoscopy or colonoscopy should be obtained in women aged 50 years and older if not done within the previous 5 years. Directed evaluation of the colon (colonoscopy, barium enema) is indicated for patients with occult blood in the stool or evidence of large-bowel obstruction to exclude the presence of a primary colorectal malignancy. An upper gastrointestinal series or upper endoscopy may be necessary to investigate symptoms of a more proximal disturbance in the gastrointestinal tract (hematemesis, bilious emesis) on an individualized basis.
Tumor markers Serum tumor markers, although frequently obtained, are not a prerequisite to undertaking surgery for suspected ovarian cancer. Nevertheless, specific abnormalities can reaffirm the clinical suspicion in many cases and may occasionally suggest another site of primary malignancy in patients with an ovarian mass. CA-125 is an antigenic determinant on a high molecular weight glycoprotein recognized by the murine monoclonal antibody OC125.6 An arbitrary cut-off value of 35 U/ml has been set as the upper limit of normal for CA-125 in clinical practice; however, levels tend to be somewhat lower in postmenopausal women and in women who have undergone hysterectomy, such that lower cut-off levels (20–26 U/ml) have been proposed for these patients.7–9 The CA125 is not specific to ovarian cancer, however, as elevated levels may be seen with non-ovarian malignancies (e.g. endometrial cancer, pancreatic cancer) or benign conditions (endometriosis, leiomyomas, pelvic inflammatory disease, congestive heart failure).7,10,11 Nevertheless, approximately 80% of all patients with non-mucinous epithelial ovarian cancer will have an elevated CA-125 level (> 35 U/ml).7 This observation is stage-dependent, with only 50% of patients with stage I disease having levels of > 35 U/ml compared to approximately 90% of patients with advanced-stage epithelial ovarian cancer.12
41
Ch 02 final.qxd
12/18/2006
15:11
Page 42
SURGERY FOR OVARIAN CANCER
In general, a preoperative serum CA-125 level is recommended in patients undergoing surgery for suspected ovarian cancer, not so much for its diagnostic value, but rather to serve as a baseline level in the event that an ovarian cancer diagnosis is confirmed pathologically.13 Whether or not a preoperative CA-125 level can be used to predict the outcome of primary cytoreductive surgery for advanced-stage disease is controversial. Using a threshold level of 500 U/ml, Chi et al. reported a positive predictive value of 78% and a negative predictive value of 73% for optimal residual disease in 100 patients with stage III epithelial tumors.14 In contrast, Memarzadeh et al. reviewed 99 patients from UCLA Medical Center with advanced-stage disease and found that, while the ideal threshold level of 912 U/ml yielded a positive predictive value of 78% for optimal cytoreduction, the negative predictive value was just 31%.15 These mixed results suggest that an isolated serum CA-125 value is not sufficiently accurate to justify deferring an attempt at primary cytoreduction when advancedstage ovarian cancer is suspected. In addition to CA-125, ovarian cancer may be associated with abnormal elevations of other tumor markers that may have clinical utility in certain circumstances. Carcinoembryonic antigen (CEA), an oncofetal antigen found in small amounts in the adult colon, is elevated in 25–50% of ovarian cancer patients and may be a useful marker for tumors of mucinous histology. Elevated CEA values are associated with cancers of the colon and pancreas, as well as benign conditions of the liver, gastrointestinal tract and lung, and in smokers. CA19-9, part of the Lewis blood group antigens, is elevated in endometrial, gastrointestinal and lung cancers in addition to ovarian cancer, but is most useful in monitoring patients with pancreatic cancer. Mucinous ovarian cancers express CA19-9 more frequently than other histologic subtypes. CA27.29 is a tumor-associated antigen in the human milk fat globule membrane that is most commonly used to follow response to therapy in patients with metastatic breast cancer, but may be elevated in approximately 60% of ovarian cancers. In patients
42
≤ 30 years of age undergoing surgery for a solid ovarian mass, it is appropriate to obtain baseline serum tumor markers for ovarian germ cell tumors, specifically lactate dehydrogenase (dysgerminoma), α-fetoprotein (endodermal sinus tumor, embryonic carcinoma) and human chorionic gonadotropin (choriocarcinoma).
Advanced radiographic imaging techniques There are two primary diagnostic objectives in radiographic imaging of the patient with suspected ovarian cancer: the determination of the presence of malignancy in an ovarian mass and the evaluation of tumor extent. Contemporary imaging techniques for the evaluation of ovarian cancer include ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET). Transabdominal and transvaginal ultrasound imaging are frequently used to characterize an ovarian mass, with findings of solid components, thick (≥ 3 mm) septations, papillary projections or excrescences and size ≥ 9 cm suggestive of malignancy. These features can also be appreciated on CT and MRI, and are likewise predictive of ovarian cancer. Kurtz et al. reporting for the Radiology Diagnostic Oncology Group, described results of a prospective study evaluating the accuracy of Doppler ultrasound, CT and MRI in 280 patients undergoing surgery for suspected ovarian cancer.16 The accuracy of all three imaging modalities for the overall detection of ovarian cancer was similar (91%); however, for diagnosis of malignancy in the ovary, the performance of MRI was statistically significantly better (91%) compared to Doppler ultrasound (78%), but not statistically different from that of CT (85%). For diagnosis of malignancy in the extraovarian pelvis and in the abdomen, MRI yielded higher accuracy (91% and 95%, respectively) compared to both ultrasound (88% and 90%, respectively) and CT (87% and 93%, respectively); however, these differences were not statistically significant. Both CT and MRI were found to have greater sensitivity than ultrasound for detecting abdominal
Ch 02 final.qxd
12/18/2006
15:11
Page 43
PREOPERATIVE PREPARATION AND SURGICAL INSTRUMENTATION
metastasis. Because of its cost-effectiveness, ultrasound imaging remains the procedure of choice for the initial evaluation of an ovarian mass. If further characterization of suspected abdominal disease is required to plan the operative approach, either CT or MRI is appropriate. CT is widely available, relatively easy to interpret and frequently the only imaging study obtained prior to ovarian cancer surgery. Recently, attention has focused on attempts to utilize preoperative CT imaging to predict the outcome of primary cytoreductive surgery for patients with advanced-stage disease. In 1993, Nelson et al. identified CT criteria of omental attachment to the spleen, large-volume tumor (> 2 cm) on the diaphragm, liver parenchyma, pleura, bowel mesentery, involvement of the gall bladder fossa, or suprarenal para-aortic adenopathy that predicted optimal cytoreduction with a sensitivity of 92%.17 In this study, however, the positive predictive value was just 67%, indicating that one out of every three patients predicted to be unresectable would, in fact, be optimally debulked if submitted to surgical exploration. Subsequent studies have examined various combinations of similar ‘resectability’ criteria with only modest improvements in predictive accuracy.18–20 Although continued advances in CT technology provide for increasingly better image resolution, the inability to exclude patients reliably from an attempt at cytoreductive surgery is troublesome. Based on the currently available data it seems reasonable to conclude that the operability of advanced ovarian cancer should be determined on an individual basis, with perhaps the greatest consideration being given to the skill and preparedness of the surgeon to put forth a maximum effort. PET uses radiopharmaceuticals labeled with positron-emitting isotopes such as 11C, 13N, 15O and 18F. 2-[18F]fluoro-2-deoxy-D-glucose (2-[18F] FDG), a glucose analog, is commonly used in oncologic imaging and takes advantage of the high glycolytic rate characteristic of malignant tissue compared with corresponding normal tissue. A variety of clinical applications of PET imaging of ovarian cancer have been
studied in recent years. While PET imaging has shown reliable accuracy for identifying primary or recurrent ovarian cancer metastases of 1 cm or larger, the utility of PET for evaluating an adnexal mass is less clear.21–23 Rieber et al. evaluated the ability of PET to characterize suspicious adnexal masses detected by ultrasonography in 103 patients, 12 of whom ultimately had pathologically confirmed ovarian malignancies.24 While PET imaging demonstrated an overall accuracy of 76% for detecting ovarian malignancy, the sensitivity was just 58% compared to 92% sensitivity for ultrasonography. Fenchel et al. studied PET performance in 99 patients with an incidentally detected adnexal mass and reported that the falsenegative rate for stage I ovarian cancers or borderline tumors was 71%.25 Taken together, these data indicate that PET imaging has insufficient sensitivity for detecting early-stage ovarian cancer. On the other hand, PET appears to be a sensitive technique for detecting recurrent ovarian cancer, particularly when combined with CT in patients with clinically occult suspected recurrence.26
PREOPERATIVE PREPARATION Preoperative nutritional supplementation The majority of ovarian cancer patients will not have a significant component of malnutrition at the time of initial diagnosis. Nevertheless, selected patients with advanced-stage disease involving the intestinal tract or producing massive ascites will present with either a functional or a mechanical bowel obstruction and associated nutritional compromise. A thorough inquiry regarding normal body weight, oral intake and gastrointestinal symptoms (e.g. nausea, vomiting, hematochezia, change in stool caliber) should be conducted. A 5% or more weight loss in a period of a month, a 10% weight loss in 6 months, or a current weight < 85% of the ideal body weight may be indicative of significant malnutrition.20 A targeted approach to laboratory evaluation can also provide important information suggestive of malnutrition. This includes
43
Ch 02 final.qxd
12/18/2006
15:11
Page 44
SURGERY FOR OVARIAN CANCER
a serum albumin level of < 3.0 g/dl, anergy to skin testing (e.g. Candida), a serum transferrin level of < 200 mg/dl and a total lymphocyte count of < 1200 cells/µl.27 Establishing the diagnosis of malnutrition is not difficult. In contrast, determining whether or not preoperative optimization of the patient’s nutritional status will significantly reduce the likelihood of postoperative morbidity has been more problematic. The most definitive study on the subject was published in 1991 by the Veteran Affairs Total Parenteral Nutrition Cooperative Study Group, who reported on perioperative total parenteral nutrition in 395 malnourished patients undergoing laparotomy or noncardiac thoracotomy.28 In this study, patients were randomized to receive either parenteral nutrition for 7–15 days preoperatively and 3 days postoperatively or no parenteral nutritional supplementation whatsoever (control group). Overall, both groups experienced similar rates of complications and postoperative mortality; however, patients receiving parenteral nutrition had significantly more infectious complications (14.1%) compared to control patients (6.4%). In a subset analysis, it was determined that severely malnourished patients who received parenteral nutrition had fewer non-infectious complications (5%) than controls (43%), without a concomitant increase of infectious morbidity. The authors concluded that the use of preoperative parenteral nutrition should be confined to patients who are severely malnourished. More recently, Heyland et al. reported results of a meta-analysis of 26 randomized clinical trials of parenteral nutrition in 2211 patients who were either critically ill or undergoing surgery.29 Analysis of those studies reporting surgical patients revealed that perioperative parenteral nutrition was associated with significantly lower rates of complications (relative risk 0.76, 95% confidence interval 0.48–1.00) but no difference in mortality rates (relative risk 0.91, 95% confidence interval 0.68–1.21). Contemporary indications for perioperative parenteral nutritional supplementation have been sum-
44
marized by Buzby as follows: first, preoperative parenteral nutrition should be considered in the most severely malnourished surgical candidates if an operative delay is not contraindicated and is not indicated for patients with only mild to moderate malnutrition; second, postoperative parenteral nutrition should be considered for malnourished surgical patients when oral or enteral feeding is not anticipated for 7–10 days postoperatively in previously well-nourished patients or 5–7 days in previously malnourished or critically ill patients.30 It has also been suggested that, if parenteral nutrition is administered perioperatively, it should be continued for a minimum of 7 days, as the risk of complications (e.g. electrolyte abnormalities, infection) outweigh any potential benefit if administered for shorter time intervals.31
Antibiotic prophylaxis As with most patients undergoing any major gynecologic operation, surgical site infection is a leading cause of postoperative morbidity in ovarian cancer surgical patients as well.32 Risk factors associated with an increased likelihood of developing a postoperative surgical site infection include obesity, diabetes, other sites of concomitant infection, a prolonged surgical time, excessive blood loss and prolonged hospitalization. Even in the absence of risk factors, however, prophylactic antibiotics are indicated for patients with a suspected diagnosis of ovarian cancer, as the procedure is likely to include abdominal hysterectomy and possible surgery on the intestinal tract. Although the use of prophylactic antibiotics has not been studied specifically in ovarian cancer patients, analogous data were presented by Mittendorf et al. in a meta-analysis of 25 randomized studies comparing the use of prophylactic antibiotic use versus no antibiotic prophylaxis in patients undergoing an abdominal hysterectomy.33 This large study documented a significant decrease in the incidence of surgical site infections in those patients who received antibiotics prior to undergoing hysterectomy. For maximum reduction of the risk of postoperative infection, antibiotics should
Ch 02 final.qxd
12/18/2006
15:11
Page 45
PREOPERATIVE PREPARATION AND SURGICAL INSTRUMENTATION
be administered approximately 30 min prior to incision but no earlier than 2 h prior to incision.34 Acceptable antibiotic choices include: cephazolin 1 g, cefotetan 1 g to 2 g, clindamycin 800 mg, and doxycycline 100 mg. Patients at risk of developing bacterial endocarditis require extended prophylactic antibiotic coverage (Table 2.3). These patients include women with prosthetic cardiac valves, a history of bacterial endocarditis in the past, complex cyanotic congenital cardiac disease, acquired valvular dysfunction, mitral valve prolapse with regurgitation and hypertrophic cardiomyopathy.
Bowel preparation Because ovarian cancer surgery carries the possibility of bowel resection or injury, preoperative bowel preparation is generally recommended in all such cases. The potential benefits of bowel preparation for ovarian cancer patients are largely extrapolated from data in the colorectal surgical literature. It is commonly accepted that surgical breach in the integrity of the intestinal tract, and particularly the colon, is associated with an increase in the risk of complications such as wound infection and intra-abdominal abscess. In an effort to reduce infection-related complications from intestinal surgery, both mechanical and antibiotic methods of bowel preparation have been recommended. Mechanical bowel preparation is thought to reduce fecal load, and thereby the risk of bacterial contamination, and generally includes the
use of oral cathartic agents and colonic irrigation (i.e. enema). Recently, the clinical value of a mechanical bowel preparation has been called into question by several prospective randomized trials. Brownson et al. reported that, among 179 patients undergoing bowel resection and anastomosis randomized to either mechanical preparation or no preparation, mechanical bowel preparation was associated with higher rates of anastomotic leak and intra-abdominal infection.35 Several other randomized trials have found no significant difference in the incidence of anastomotic leak between patients who have undergone mechanical bowel preparation and those who have not.36,37 In addition, Zmora et al. prospectively randomized 380 patients undergoing elective colon and rectal resections to undergo a mechanical bowel preparation or not prior to surgery.38 All patients received preoperative oral and intravenous antibiotics, and the two groups were well matched with respect to demographics, surgical procedures and duration of antibiotic therapy. The results of this study showed no significant difference between the two groups in terms of the incidence of wound infection, clinically apparent anastomotic leak, or intra-abdominal abscess. The authors concluded that elective colon and rectal surgery could be safely performed without mechanical bowel preparation. Although mechanical bowel preparation may reduce the amount of feces in the colon, the problem of persistent colonic bacteria provides the rationale
Table 2.3 Preoperative antibiotic prophylaxis for patients at risk for bacterial endocarditis
Antibiotic Ampicillin plus gentamicin
Regimen Ampicillin, 2 g IM/IV plus gentamicin, 1.5 mg/kg IM/IV(not to exceed 120 mg) give within 30 min of starting procedure Ampicillin, 1 g IM/IV, or amoxicillin, 1 g orally, 6 h later
Penicillin-allergic patients: vancomycin plus gentamicin
Vancomycin, 1 g IV over 1–2 h, plus gentamicin, 1.5 mg/kg IM/IV (not to exceed 120 mg) complete injection/infusion within 30 min of starting the procedure
45
Ch 02 final.qxd
12/18/2006
15:11
Page 46
SURGERY FOR OVARIAN CANCER
for using either non-absorbable or minimally absorbable oral antibiotics, in addition to routine intravenous antibiotics, to reduce the bacterial load. Theoretically, if the bowel is entered intraoperatively, there will be less chance of contamination. Multiple studies have been conducted, with conflicting results. In a randomized trial of 350 patients undergoing colon and rectal resections, Coppa and Eng demonstrated that the wound infection rate was significantly reduced when oral neomycin and erythromycin were added to mechanical bowel preparation and intravenous antibiotics, especially for prolonged procedures (> 215 min) and rectal resections.39 Such findings have been supported by additional randomized studies in the surgical literature.40 Interestingly, others have demonstrated no difference between oral antibiotics, intravenous antibiotics and a combination of the two in preventing septic complications or wound infections in patients undergoing elective colorectal surgery.41 Amidst these conflicting data, a large survey of North American colorectal surgeons was conducted by Nichols et al., who showed that most surgeons (86.5%) add oral and parenteral antibiotics to a mechanical preparation regimen of either oral polyethylene glycol solution or sodium phosphate solution with or without bisacodyl.42 Oral neomycin and erythromycin or metronidazole were the antibiotics most commonly used. This regimen seems reasonable for patients undergoing ovarian cancer surgery as well. Prophylactic parenteral antibiotics should be given at the time of anesthesia induction and repeated if the procedure exceeds two half-lives of the antibiotic used, fecal contamination occurs, or rectal surgery is performed. For single-agent parenteral antibiotic prophylaxis, second-generation cephalosporins are recommended (e.g. cefotetan, 2 g).
Thromboembolic prophylaxis The incidence of deep vein thrombosis (DVT) in women undergoing a pelvic surgical procedure lasting
46
longer than 30 min is 30%.43 Virtually all patients undergoing a surgical procedure for suspected ovarian cancer should be considered to be at moderate or high risk of developing a postoperative DVT. Consequently, some form of thromboembolic prophylaxis is warranted for the majority of cases, as DVT prophylaxis has been documented to prevent the occurrence of a fatal pulmonary embolism. Either pharmacologic or mechanical methods of prophylaxis can be used with comparable efficacy. Low-dose unfractionated heparin (5000 units) given subcutaneously 1–2 h before surgery and every 8 h thereafter has been shown to be effective in preventing DVT formation in a randomized trial of patients undergoing gynecologic oncology surgery.44 Low-molecular-weight heparin (LMWH) (enoxaparin, 40 mg once a day) has been documented to be as efficacious in DVT prophylaxis as low-dose unfractionated heparin and may have a lower incidence of bleeding complications.45 Dalteparin, another LMWH agent, can also be given once a day at a dose of 2500 units. Mechanical methods of DVT prophylaxis include graduated compression stockings and intermittent pneumatic compression devices, which have been shown to decrease the risk of DVT in moderate-risk patients. However, the use of graduated compression stockings alone has not been sufficiently studied in high-risk patients to support their use for DVT prophylaxis in this setting. Pneumatic compression devices must be in place at induction of anesthesia and continued until the patient is fully ambulatory. When used in this fashion, pneumatic compression appears to be effective in reducing DVT risk among medium- and high-risk patients.44 For patients undergoing surgery for suspected ovarian cancer, either pharmacologic or mechanical DVT prophylaxis is appropriate. Considering the risk of postoperative bleeding complications associated with heparin therapy, however, pneumatic compression devices, with or without graduated compression stockings, would seem to have a superior risk–benefit
Ch 02 final.qxd
12/18/2006
15:11
Page 47
PREOPERATIVE PREPARATION AND SURGICAL INSTRUMENTATION
profile. In patients at extremely high risk for postoperative DVT (e.g. history of a postoperative thromboembolic event), combined therapy with both methods may be considered, although there are currently no data that support an additive benefit over either method alone.
SURGICAL INSTRUMENTATION Retractors Usually, surgery for ovarian cancer is performed through a midline abdominal incision and requires access to both pelvic and abdominal structures, often simultaneously. A self-retaining retractor is essential to optimizing exposure, maximizing patient safety and reducing surgeon fatigue. Of the available models of self-retaining retractors, those with a fixed arm attaching the retractor ring to the operating table are best suited to ovarian cancer surgery. The Bookwalter retractor is the standard self-retaining fixed-ring retractor and is versatile enough to be adapted to a
variety of operative requirements (Figure 2.1). The retractor clips that attach the blades to the ring allow for two-dimensional adjustments of the blade position in relation to the surgical field. The oval ring of the Bookwalter is most commonly used for ovarian cancer surgery, but circular and hinged rings are also available, depending on the exposure needed. For example, the hinged ring can be used to surgical advantage when operating in the upper abdomen (e.g. diaphragm, liver, spleen) by increasing the angulation of the retractor blade to provide more pronounced ventral displacement of the costal margin, improving exposure. The Omni retractor has two adjustable ‘boomerang’ shaped arms, rather than a ring, that are attached to a fixed post. Each arm can be moved in three dimensions, and finer modifications in exposure can be achieved with the adjustable retractor blades. The Omni retractor is especially helpful when operating on obese patients, since the extent of lateral retraction is not limited by the width of a retractor ring (e.g. Bookwalter). Non-fixed self-retaining retractors, such as the Balfour and O’Connnor– O’Sullivan, can also be used, but are more limited in their field of exposure and are less steady than the fixed models, since they are stabilized only by creating pressure on the opposing sides of the abdominal wall incision. With any self-retaining retractor, the surgeon must exercise particular attention when placing the blades along the lateral abdominal wall so as not to compress the psoas muscle and traumatize the underlying femoral nerve.
ELECTROSURGERY The electrosurgical unit
Figure 2.1 Bookwalter self-retaining retractor. The fixed arm attaches to the operating room bed. The retractor blades can be adjusted in two dimensions in relation to the surgical field, or rotated around the oval ring to optimize exposure. Photograph courtesy of Aesculap Incorporated, Center Vallay, PA
The electrosurgical unit (ESU), electrocautery, or Bovie (Valleylab, Boulder, CO) consists of a generator and electrodes and is probably the most commonly used instrument in ovarian cancer surgery. The ESU can be configured as either a unipolar or a bipolar device that generates an alternating current of variable frequency. The unipolar device is versatile and
47
Ch 02 final.qxd
12/18/2006
15:11
Page 48
SURGERY FOR OVARIAN CANCER
can be used for both cutting and cauterizing tissue. With cutting current, a continuous high-frequency flow leads to a rapid buildup of heat and vaporization of intracellular water, resulting in local tissue disintegration without a significant coagulative effect but with minimal lateral heat transfer. In contrast, coagulation mode employs an interrupted current of lower energy, which leads to a slower heating of intracellular water, increasing the resistance to flow and producing a more pronounced coagulative effect on small blood vessels. Often a combination (or blended) current produces the most satisfactory tissue effect. Most gynecologic oncology surgeons utilize the unipolar ESU. Generally, the lowest effective generator settings should be used in order to avoid excessive thermal damage to surrounding tissues. Customary settings for a blended current range from 30 to 40 W for coagulation and from 30 to 50 W for cutting. The bipolar ESU employs a dual paddle design that conducts current to produce a tissue coagulating effect. Recently, a group of surgical instruments referred to as ‘vessel sealers’ have demonstrated clinical utility by simultaneously cauterizing a tissue pedicle and cutting it with a self-contained surgical knife (e.g. Ligasure®, Valleylab, Boulder, CO, Figure 2.2). The bipolar current generated reforms the collagen in vessel walls and connective tissue, producing a permanent seal that can effectively cauterize vessels up to 7 mm in diameter. Vessel sealers can be adapted for both laparoscopic and open applications and are par-
ticularly useful for controlling vascular pedicles in areas that are difficult to reach.
Argon beam coagulator As compared to the standard ESU, which conducts current through air, the argon beam coagulator (ABC) (Conmed Corp, Utica, NY), conducts radiofrequency current to the target tissue through a coaxial stream of inert argon gas that is automatically regulated. ABC power settings range from 70 to 150 W and are selected according to the type of tissue being treated (e.g. 70–80 W for cauterizing small-caliber vessels, 110–120 W for treating the surface of the liver or spleen). The ABC does not come into direct contact with the tissue; rather, as the current contacts the tissue via the stream of argon gas, individual ‘arc tunnels’ are formed within the target tissue. It is the formation of these arc tunnels that is thought to account for a more uniform distribution of current within the tissue and therefore a more uniform coagulative effect with less thermal injury. The ABC can effectively cauterize vessels of up to 3 mm in diameter. The flow of argon gas serves to improve visualization of the operative field by displacing blood and debris. In addition to its utility in achieving hemostasis, the underlying coagulative necrosis generated by application of the ABC is an efficient means of destroying small-volume implants of metastatic ovarian cancer and may facilitate optimal cytoreduction of disease in sites inaccessible to conventional resection. Tumor destruction has been documented in areas such as bowel mesentery, the diaphragm, ureters, vagina, presacral space and the iliac vessels.46,47 When used for ovarian cancer tumor implant ablation, the depth of tissue destruction is dependent on both the power setting and tissue interaction time.48
Cavitron ultrasonic surgical aspirator
Figure 2.2 The Ligasure® vessel sealer. Photograph courtesy of Valleylab, Boulder, CO
48
The cavitron ultrasonic surgical aspirator (CUSA) (Valleylab, Boulder, CO) is another surgical adjunct that may be used during cytoreduction of advancedstage ovarian cancer. The CUSA handpiece encloses
Ch 02 final.qxd
12/18/2006
15:11
Page 49
PREOPERATIVE PREPARATION AND SURGICAL INSTRUMENTATION
a hollow titanium tube that vibrates at high frequency in a longitudinal axis. The variable amplitude of longitudinal vibration determines the depth of tissue disruption when the handpiece is placed in contact with tissue. The handpiece also contains an irrigation and aspiration system to remove tissue fragments and reduce heat buildup. The extent of tissue disruption is also dependent on the water content of the target tissue, the CUSA causing relatively greater damage to tissues with a high water content (visceral parenchyma, nodal tissue, tumor implants) compared to tissue composed of predominantly connective tissue (muscle, ureter, vessel wall adventitia). The CUSA can be used to resect ovarian cancer metastases on the diaphragm, bowel serosa, liver and splenic capsules, and the peritoneum. Several reports have cited the efficacy and safety of the CUSA as an adjunctive procedure in achieving optimal cytoreduction in areas inaccessible by more standard surgical techniques.49,50 In one prospective trial, the CUSA was associated with a lower perioperative blood loss, shorter hospital stay and less overall morbidity when compared to the findings in patients in whom the CUSA was not used during the cytoreductive effort.51
Automated stapling devices Advanced-stage ovarian cancer commonly involves the intestinal tract by contiguous extension or distant peritoneal metastasis. Consequently, the surgeon must be familiar with a variety of techniques of bowel resection and anastomosis. Traditionally, these procedures were performed using hand-sewn suture techniques. The introduction of automated surgical stapling devices permits the same procedures to be performed with comparable efficacy, greater simplicity and perhaps increased speed. There are multiple brands of commercially available automated stapling devices; however, all utilize the same basic principle of compressing an inverted ‘U-shaped’ staple into a ‘sideways-B’ in the closed position (Figure 2.3). The closed staple position secures the tissue contained within but does not constrict the vascular supply to
the resulting staple line, with the exception of the vascular load staplers (see below). There are three basic categories of automated stapling devices used for bowel surgery as well as other purposes. All contemporary stapling devices are single-use and disposable. The first category is the thoracoabdominal (TA) stapler, which lays down a double row of titanium staples staggered in an overlapping fashion (Figure 2.4). The TA stapler does not have a cutting component and therefore is used to close a segment of the intestinal tract distal to the point of division, or to close an enterotomy or colostomy created during one of the anastomotic techniques described in Chapter 7. The TA stapler is available in three different sizes (30 mm, 60 mm and 90 mm), depending on the width of tissue to be secured. There are two standard staple sizes for the TA stapler, the choice being dependent upon the compression thickness of the stapled tissue. The 3.5-mm staple (open position) compresses to a thickness of approximately 1.5-mm in the closed position, while the 4.8-mm staple (open position) should be used for tissue that will compress to approximately 2.0 mm in the closed position. The Roticulator stapling device is a variation of the standard TA stapler that incorporates a rotating shaft and hinged cartridge head to allow greater flexibility of application. It is particularly useful when dividing a segment of colon or rectum deep in the pelvis. The Roticulator lays down a double row of 4.8-mm titanium staples 55 mm in length.
Figure 2.3 Automated stapling device. Titanium staple in the compressed (closed) position. Photograph courtesy of United States Surgical Corporation, Norwalk, CT
49
Ch 02 final.qxd
12/18/2006
15:11
Page 50
SURGERY FOR OVARIAN CANCER
The second category of automated stapling devices is the gastrointestinal anastomosis (GIA) stapler, which lays down two double rows of staggered titanium staples and has a self-contained cutting blade that divides the tissue between (Figure 2.5).
The GIA stapler is used simultaneously to secure and divide a segment of bowel or other tissue and is available in two lengths – 60 mm and 80 mm – depending on the width of tissue. The basic staple sizes adapted for use in the GIA staplers are 3.8 mm, which
Figure 2.4 Thoracoabdominal (TA) stapling device. Photograph courtesy of United States Surgical Corporation, Norwalk, CT
Figure 2.5 Gastrointestinal anastomosis (GIA) stapling device. Photograph courtesy of United States Surgical Corporation, Norwalk, CT
50
Ch 02 final.qxd
12/18/2006
15:11
Page 51
PREOPERATIVE PREPARATION AND SURGICAL INSTRUMENTATION
Figure 2.6 Circular end-to-end anastomosis (CEEA) stapling device. Photograph courtesy of United States Surgical Corporation, Norwalk, CT
compresses to 1.5 mm in the closed position; and 4.8 mm, which compresses to 2.0 mm in the closed position. Vascular load staple cartridges are also now in use with the GIA-type staplers that have a staple size of 2.5 mm, which compresses to 1.0 mm in the closed position. The staple line thus created is hemostatic for most small-caliber vascular pedicles. The third category of automated stapling devices is the circular end-to-end anastomosis (CEEA) stapler (Figure 2.6). The CEEA stapler lays down a double row of circular staples and has a self-contained circular cutting blade that simultaneously excises the inverted internal tissue. The 4.8-mm staples compress to a tissue thickness of approximately 2 mm. The CEEA stapler is most commonly used to create endto-end anastomoses of the colon but is also applicable to small bowel–small bowel and small bowel–colon anastomoses. Both straight and curved shafts are available with the CEEA stapler, although when performing a low colorectal anastomosis, navigation of the pelvic curvature is usually easier with the curved model. A low-profile detachable anvil (Figure 2.6) is also available for the CEEA stapler, which is easier to place within the bowel lumen in some circumstances (e.g. stapled end-to-side anastomosis, see Chapters 5 and 7). The standard CEEA stapler comes in four sizes that reflect the outer diameter of the circular staple cartridge: 21 mm, 25 mm, 28 mm and 31 mm. In general, the functional lumenal diameter is approxi-
mately 10 mm smaller than the size of the stapler used to create the anastomosis. A 33-mm cartridge, yielding a 23-mm lumenal diameter, is also available from selected manufacturers (Ethicon Endosurgery, Cincinnati, OH). Successful outcomes using automated surgical staplers to perform bowel anastomoses, including colorectal anastomoses below the levator muscles, have been reported in the gynecologic literature since the late 1970s.52,53 The rate of enteric anastomoticrelated complications following trauma-related intestinal surgery has been confirmed to be similar regardless of whether an automatic stapler or handsewn technique is used.54 In one of the largest case series documenting the use of end-to-end anastomosis stapling devices in the setting of radical gynecologic surgery, the two anastomotic breakdowns reported were noted in patients who had previously undergone radiation therapy.55 Some authors have argued that the favorable outcomes associated with the use of automated stapling devices in patients with gynecologic malignancies are due, at least in part, to improved blood flow to the anastomosis, a contention that has been confirmed in an animal model.53,55,56 It must be stressed that, in all instances, the method of anastomosis elected should reflect the technique with which the surgeon is the most comfortable. The specifications of the three types of automated stapling devices are depicted in Figure 2.7.
51
Ch 02 final.qxd
12/18/2006
15:11
Page 52
SURGERY FOR OVARIAN CANCER
Stapler type
Staple line
Open
Thoracoabdominal (TA)
Staple size Compressed
3.5 mm 4.8 mm
1.5 mm 2.0 mm
2.5 mm 3.8 mm 4.8 mm
1.0 mm 1.5 mm 2.0 mm
cutting blade Gastrointestinal anastomosis (GIA)
Cartridge diameter
Lumenal diameter*
21 mm 25 mm 28 mm 31 mm 33 mm
11 mm 15 mm 18 mm 21 mm 23 mm
cutting blade
Circular end-to-end anastomosis (CEEA)
4.8 mm
2.0 mm
* approximate
Figure 2.7 Specifications of the three types of automated stapling devices
patients with ovarian carcinoma. Aust NZ J Obstet Gynaecol 1978; 18: 209–12
REFERENCES 1.
Wolters U, Wolf T, Stützer H, Schröeder T. ASA classification and perioperative variables as predictors of postoperative outcome. Br J Anaesth 1996; 77: 217–22
2.
Giannice R, Foti E, Poerio A, et al. Perioperative morbidity and mortality in elderly gynecological oncological patients (>/= 70 years) by the American Society of Anesthesiologists physical status classes. Ann Surg Oncol 2004; 11: 219–25
3.
Li AJ, Madden AC, Cass I, et al. The prognostic significance of thrombocytosis in epithelial ovarian cancer. Gynecol Oncol 2004; 92: 211–14
4.
Planner RS, O’Sullivan EF, Campbell JJ, Ball DL. The hypercoaguable state and pulmonary embolism in
52
5.
Menczer J, Schejter E, Geva D, et al. Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Oncol 1998; 19: 82–4
6.
Bast RC, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331–7
7.
Bast RC, Klug TL, St John E. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883–7
8.
Alagoz T, Buller RE, Berman M, et al. What is a normal CA125 level? Gynecol Oncol 1994; 53: 93–7
Ch 02 final.qxd
12/18/2006
15:11
Page 53
PREOPERATIVE PREPARATION AND SURGICAL INSTRUMENTATION
9.
Bon GG, Kenemans P, Verstraeten R, et al. Serum tumour marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol 1996; 174: 107–14
10.
Ozols RF, Steele GD, Phillips TL, Chabner BA. Atlas of Clinical Oncology: Ovarian Cancer. Hamilton: BC Decker, 2003: 107–12
11.
Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med 1994; 121: 124
12.
Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4: 1–12
13.
Brooks SE. Preoperative evaluation of patients with suspected ovarian cancer. Gynecol Oncol 1994; 55: S80
14.
Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000; 77: 227–31
15.
Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2003; 13: 120–4
16.
Kurtz AB, Tsimikas JV, Tempany CMC, et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgey and histopathologic analysis – report of the Radiology Diagnostic Oncology Group. Radiology 1999; 212: 19–27
ty of ovarian carcinoma at primary laparotomy? Br J Obstet Gynaecol 2003; 109: 369–75 21.
Karlan BY, Hawkins R, Hoh C, et al. Whole-body positron emission tomography with 2-[18F]fluoro-2deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993; 51: 175–81
22.
Hubner KF, McDonald TW, Niethammer JG, et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-18Fdeoxy-D-glucose (2-18F-FDG). Gynecol Oncol 1993; 51: 197–204
23.
Bristow RE, Simpkins F, Pannu HK, et al. Positron emission tomography for detecting clinically occult surgically respectable metastatic ovarian cancer. Gynecol Oncol 2002; 85: 196–200
24.
Rieber A, Nüssle K, Stöhr H, et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. Am J Roentgenol 2001; 177: 123–9
25.
Fenchel S, Grab D, Nuessle K, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002; 223: 780–8
26.
Bristow RE, del Carmen MG, Pannu HK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003; 90: 519–28
27.
Barakat KK, Bevers MW, Gershenson DM. Hoskins WJ. Handbook of Gynecologic Oncology. London: Martin Dunitz, 2000: 111–30
17.
Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993; 11: 166–72
28.
Perioperative total parenteral nutrition in surgical patients. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. N Engl J Med 1991; 325: 525–32
18.
Meyer JI, Kennedy AW, Friedman R, et al. Ovarian carcinoma: value of CT in predicting success of debulking surgery. Am J Roentgenol 1995; 165: 875–8
29.
Heyland DK, MacDonald S, Keefe L, Drover JW. Total preanteral nutrition in the critically ill patient. A meta-analysis. J Am Med Assoc 1998; 280: 2013–19
19.
Bristow RE, Duska LR, Lambrou NC, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000; 89: 1532–40
30.
Buzby GP. Overview of randomized clinical trials of total parenteral nutrition for malnourished surgical patients. World J Surg 1993; 17: 173–7
31.
20.
Byrom J, Widjaja E, Redman CW, et al. Can preoperative computed tomography predict respectabili-
Waitzberg DL, Plopper C, Terra RM. Postoperative total parenteral nutrition. World J Surg 1999; 23: 560–4
53
Ch 02 final.qxd
12/18/2006
15:11
Page 54
SURGERY FOR OVARIAN CANCER
32.
Hemsell DL. Prophylactic antibiotics in gynecologic and obstetric surgery. Rev Infect Dis 1991; 13: S821–41
33.
Mittendorf R, Aronson MP, Berry RE. Avoiding serious infections associated with abdominal hysterectomy: a meta-analysis of antibiotic prophylaxis. Am J Obstet Gynecol 1993; 169: 1119–24
44.
Clarke-Pearson DL, DeLong E, Synan IS, et al. A controlled trial of two low-dose heparin regimens for the prevention of post-operative deep vein thrombosis. Obstet Gynecol 1990; 75: 684–9
45.
Enoxacan Study Group. Efficacy and safety of enoxaperin versus unfractionated heparin for the prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84: 1099–103
46.
Brand E, Pearlman N. Electrosurgical debulking of ovarian cancer: a new technique using the argon beam coagulator. Gynecol Oncol 1990; 39: 115–18
47.
Burke P, Mealy K, Gillen P, et al. Requirement for bowel preparation in colorectal surgery. Br J Surg 1994; 81: 907–10
Eisenkop SM, Nalick RH, Wang H, Nelson T. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 1993; 51: 224–9
48.
37.
Santos JC Jr, Batista J, Sirimarco MT, et al. Prospective randomized trial of mechanical bowel preparation in patients undergoing elective colorectal surgery. Br J Surg 1994; 81:1673–6
Bristow RE, Smith Sehdev AE, Kaufman HS, Montz FJ. Ablation of metastatic ovarian carcinoma with the argon beam coagulator: pathological analysis of tumor destruction. Gynecol Oncol 2001; 83: 49–55
49.
38.
Zmora O, Mahajna A, Bar-Zakai B, et al. Colon and rectal surgery without mechanical bowel preparation: a randomized prospective trial. Ann Surg 2003; 237: 363–7
Deppe G, Malviya VK, Malone JM. Debulking surgery for ovarian cancer with the Cavitron Ultrasonic Surgical Aspirator (CUSA) – a preliminary report. Gynecol Oncol 1988; 31: 223–6
50.
39.
Coppa GF, Eng K. Factors involved in antibiotic selection in elective colon and rectal surgery. Surgery 1988; 104: 853–8
Adelson MD, Baggish MS, Seifer DB, et al. Cytoreduction of ovarian cancer with the Cavitron ultrasonic surgical aspirator. Obstet Gynecol 1988; 72: 140–3
40.
Clarke JS, Condon RE, Bartlett JG, et al. Preoperative oral antibiotics reduce septic complications of colon operations: results of prospective, randomized, double-blind clinical study. Ann Surg 1977; 186: 251–9
51.
van Dam PA, Tjalma W, Weyler J, et al. Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomized trial. Am J Obstet Gynecol 1996; 174: 943–50
41.
Stellato TA, Danziger LH, Gordon N, et al. Antibiotics in elective colon surgery. A randomized trial of oral, systemic, and oral/systemic antibiotics for prophylaxis. Am Surg 1990; 56: 251–4
52.
Wheeless CR. Avoidance of permanent colostomy in pelvic malignancy using the surgical stapler. Obstet Gynecol 1979; 54: 501–5
53.
42.
Nichols RL, Smith JW, Garcia RY, et al. Current practices of preoperative bowel preparation among North American colorectal surgeons. Clin Infect Dis 1997; 24: 609–19
Wheeless CR, Dorsey JH. Use of the automatic surgical stapler for intestinal anastomosis associated with gynecologic malignancies: review of 283 procedures. Gynecol Oncol 1981; 11: 1–7
54.
43.
Clarke-Pearson DL, Olt G. Thromboembolism in patients with gyn tumors: risk factors, natural history, and prophylaxis. Oncology 1989; 3: 39–45
Kirkpatrick AW, Baxter KA, Simons RK, et al. Intraabdominal complications after surgical repair of small bowel injuries: an international review. J Trauma 2003; 55: 399–406
34.
35.
36.
54
Classen DC, Evans RS, Pestotnik SL, et al. The timing of prophylactic administration of antibiotics and the risk of surgical wound infection. N Engl J Med 1992; 326: 281–6 Brownson P, Jenkins S, Nott D, et al. Mechanical bowel preparation before colorectal surgery: results of a prospective randomized trial [abstract]. Br J Surg 1994; 79: 461–2
Ch 02 final.qxd
12/18/2006
15:11
Page 55
PREOPERATIVE PREPARATION AND SURGICAL INSTRUMENTATION
55.
Harris WJ, Wheeless CR. Use of the end-to-end anastomosis stapling device in low colorectal anastomosis associated with radical gynecologic surgery. Gynecol Oncol 1986; 23: 350–7
56.
Wheeless CR, Smith JJ. A comparison of the flow of iodine 125 through three different intestinal anastomoses: standard, Gambee, and stapler. Obstet Gynecol 1983; 62: 513–18
55
Ch 03 final.qxd
12/18/2006
15:12
Page 57
CHAPTER 3
Management of early-stage ovarian cancer Anil K Sood, David M Gershenson
INTRODUCTION A minority of patients with epithelial ovarian cancer will have disease confined to the ovary or extraovarian pelvis, and can be expected to have a favorable longterm survival outcome. A comprehensive surgical staging procedure is critical not only for identifying this select subset of patients but also for determining the prescription for adjuvant therapy. While most patients with borderline tumors, ovarian germ cell tumors and sex cord stromal tumors will have earlystage disease, the information gleaned from surgical staging is no less relevant. This chapter will define the rationale for and techniques of the ovarian cancer staging operation for women with apparent early-stage disease.
EPITHELIAL OVARIAN CANCER Rationale for surgical staging The large number of deaths from ovarian cancer is largely due to the fact that most women go undiagnosed until extensive tumor spread has occurred, leading to poor survival. Survival of women with ovarian cancer is determined largely by stage – women with stage I or II cancer have 5-year survival rates between 50 and 90%,1 whereas survival of women with advanced-stage disease decreases to around 30%.2 Because of the lack of an acceptable screening test for ovarian cancer, early detection becomes crucial to improving survival. Historically, it was thought that
most patients with ovarian cancer did not have symptoms until advanced stages, and as a result ovarian cancer was often called the ‘silent killer’. However, recent studies suggest that most patients, even those with early-stage carcinoma, do have symptoms.3,4 Goff et al. reported that only 11% of stage I/II patients reported no symptoms before their diagnosis.3 Eltabbakh et al. performed a retrospective analysis of 72 women with stage I or II borderline or invasive ovarian cancers and found that most (78%) of the patients had presenting symptoms of either abdominal or pelvic pain, bloatedness or vaginal bleeding.4 Collectively, these studies emphasize that even women with early-stage ovarian cancer have symptoms, and individuals with non-specific symptoms should be carefully evaluated for possible ovarian pathology. The detection of a pelvic mass is relatively easy; however, the preoperative characterization of that mass as benign versus malignant has remained a challenge despite the use of numerous modalities including ultrasound and serum markers. Although surgery alone is curative in only a small number of patients, it remains the most important modality of treatment in an individual with a suspicious pelvic mass found to be ovarian cancer. The stage of disease is determined by the extent of tumor at the time of initial diagnosis. The staging classification for ovarian cancer is based on surgical and pathologic findings, and was last modified by the International Federation of Gynecology and Obstetrics (FIGO) in 1985 (Table 3.1). Earlystage epithelial ovarian carcinoma is defined pathologically as tumor limited to one or both ovaries or tumor extension confined to the pelvis. This diagnosis can be
57
Ch 03 final.qxd
12/18/2006
15:12
Page 58
SURGERY FOR OVARIAN CANCER
Table 3.1 FIGO staging for primary carcinoma of the ovary Stage
Description
I
Growth limited to the ovaries
IA
Growth limited to one ovary; no ascites present containing malignant cells; no tumor on the external surfaces; capsule intact
IB
Growth limited to both ovaries; no ascites present containing malignant cells; no tumor on the external surfaces; capsules intact
IC
Tumor either stage IA or IB, but with tumor on the surface of one or both ovaries; or with capsule ruptured; or with ascites present containing malignant cells, or with positive peritoneal washings
II
Growth involving one or both ovaries with pelvic extension
IIA
Extension and/or metastases to the uterus and/or tubes
IIB
Extension to other pelvic tissues
IIC
Tumor either stage IIA or IIB but with tumor on the surface of one or both ovaries; or with capsule(s) ruptured; or with ascites present containing malignant cells, or with positive peritoneal washings
III
Tumor involving one or both ovaries with peritoneal implants outside the pelvis and/or positive retroperitoneal or inguinal nodes; superficial liver metastasis equals stage III; tumor is limited to the true pelvis but with histologically verified malignant extension to small bowel or omentum
IIIA
Tumor grossly limited to the true pelvis with negative nodes with histologically confirmed microscopic seeding or abdominal peritoneal surfaces
IIIB
Tumor of one or both ovaries; histologically confirmed implants of abdominal peritoneal surfaces, none exceeding 2 cm in diameter; nodes negative
IIIC
Abdominal implants greater than 2 cm in diameter and/or positive retroperitoneal or inguinal nodes
IV
Growth involving one or both ovaries with distant metastases; if pleural effusion is present, there must be positive cytology to allot a case to stage IV; parenchymal liver metastasis equals stage IV
obtained only after an exhaustive surgical staging procedure.5 This chapter will focus on the implications of and technique for surgical staging of early-stage ovarian cancer. For the purpose of this chapter, we will define early-stage disease as FIGO stages I and II. A gynecologic surgeon embarking upon exploratory surgery on a patient with a pelvic mass should be prepared to perform full staging and, if needed, cytoreduction for ovarian cancer. Approximately 15–30% of patients with epithelial ovarian cancers present with disease confined to the ovaries.6 Although a high proportion of patients with stage I ovarian cancer are cured by the surgical removal of tumor, the curative value of postoperative treatment has not been proved. Thus, accurate predictors of
58
relapse might allow clinicians to separate those patients with an extremely small risk from those with an appreciable risk of relapse who might benefit from adjuvant therapy. The importance of surgical staging was further highlighted by Bagley et al. who showed a 30% discrepancy between staging by non-oncologists and reoperation by gynecologic oncologists.7 Since then, others have also demonstrated that there can be up to 30% discrepancy between reported surgical findings by non-oncologic surgeons and the definitive stage demonstrated in re-operation by a gynecologic oncologist.8–10 Piver et al. identified the metastatic sites most frequently overlooked by the non-oncologist as the diaphragm, omentum and retroperitoneal lymph
Ch 03 final.qxd
12/18/2006
15:13
Page 59
MANAGEMENT OF EARLY-STAGE OVARIAN CANCER
nodes.8,9 Young et al. systematically restaged 100 patients referred to them with apparent early-stage ovarian cancer.6 Thirty-one per cent were found to have a more advanced stage and most of these patients had stage III disease. McGowan et al. found that, among 291 patients with ovarian cancer, only 54% received proper staging.11 The most commonly missed sites included the diaphragm, biopsy of the pelvic peritoneum, peritoneal fluid sampling and omental biopsy. The likelihood of complete staging varied depending on the specialty of the operating surgeon: gynecologic oncologists, 97%; obstetrician– gynecologists, 53%; and general surgeons, 35%. Mayer et al. found a higher survival rate in patients with stage I and II disease who were comprehensively staged by a gynecologic oncologist, compared with those women who underwent more limited surgical procedures by a non-oncologic gynecologist or a general surgeon.10 Le et al. evaluated 80 patients with apparent stage I ovarian cancer with a comprehensive surgical staging procedure and 30 (38%) were upstaged after the surgical staging, most to stage III.12 Furthermore, they found that endometrioid, mucinous and clear cell carcinoma had better correlation with a true surgical stage I (76–88%) than other histologic subtypes. Serous and anaplastic tumors had about a 70% chance of being upstaged by the careful surgical procedure. In a subsequent study, Le et al. evaluated 138 patients with tumor grossly confined to the ovary at the time of laparotomy.13 Ninety-four (68%) patients had a complete surgical staging procedure and 36% of these patients were found to have extraovarian metastases. Forty-three per cent of those not having staging laparotomy were offered chemotherapy based on high-risk factors only. Among surgically proven stage I patients treated expectantly, only 10% developed a recurrence compared to 28% in the unstaged group who were treated expectantly because of lack of risk factors (p = 0.036).13 This study supports the concept that absence of surgical pathologic high-risk factors is inferior to comprehensive staging laparotomy findings with regard to guiding adjuvant therapy. Not surprisingly, patients who
were not properly staged had a high risk of developing recurrent disease despite receiving chemotherapy. Collectively, these studies suggest that there is a substantial likelihood of finding metastatic disease if a formal staging surgery is performed in women with disease apparently confined to the ovary or ovaries. Furthermore, a gynecologic oncologist should be involved in performing the staging procedure for ovarian cancer. If the operative risks are not too high, a restaging procedure must be routinely considered before the decision is made concerning an adjuvant treatment.
Incision selection and management Abdominal wall anatomy
A detailed knowledge of the abdominal and pelvic anatomy is crucial to the success of a gynecologic surgeon. The layers of the abdominal wall include the skin, superficial fascia, external oblique, internal oblique, transversus abdominis muscles and aponeuroses, the transversalis fascia, the preperitoneal fat and the parietal peritoneum (Figure 3.1). The combination of aponeuroses and muscles cross each other in such a way to strengthen the anterolateral abdominal wall. The three flat muscles of the abdominal wall originate from the lower six ribs, thoracolumbar fascia, the iliac crest and the lateral two-thirds of the inguinal ligament. The insertion of these muscles is onto the linea alba through their aponeuroses. These muscles are innervated by the inferior five intercostal nerves as well as the subcostal, iliohypogastric and ilioinguinal nerves. These muscles increase the intraabdominal pressure, which can play a role in normal processes such as defecation and micturition. They also play a role in flexion and rotation of the trunk. The rectus abdominis is a long strap muscle – the two inferior parts lie together, whereas superiorly the muscles broaden out where they are separated by the linea alba. The upper attachment of the rectus abdominis muscle is up to three times as broad as the pubic insertion. The rectus abdominis muscle is largely enclosed in the rectus sheath, formed by the aponeuroses of the
59
Ch 03 final.qxd
12/18/2006
15:13
Page 60
SURGERY FOR OVARIAN CANCER
External oblique muscle Internal oblique muscle Posterior sheath
Transversus abdominis muscle
Arcuate line
Rectus muscle
Rectus muscle
Figure 3.1 Anatomy of the anterior abdominal wall
three flat abdominal muscles. The rectus abdominis muscle originates from the symphysis pubis and the pubic crest and inserts onto the xiphoid process and fifth through seventh costal cartilages. The pyramidalis is a small muscle that originates from the body of pubis and inserts onto the linea alba. It is innervated by the subcostal nerve, but does not have much functional significance. The fibers of the rectus abdominis and pyramidalis muscles run in a vertical fashion. The rectus sheath forms by the fusion and separation of the aponeuroses of the flat abdominal muscles (Figure 3.2). At its lateral margin, the internal oblique aponeurosis splits into two layers – one passing anterior to the rectus muscle and one passing posterior to it. The anterior layer joins with the aponeurosis of the external oblique to form the anterior wall of the rectus sheath, and the posterior layer joins with the aponeurosis of the transversus abdominis muscle to form the posterior wall of the rectus sheath. The anterior and posterior walls of the rectus sheath fuse in the anterior midline to form the linea alba. The inferior portion of the rectus sheath is deficient in its posterior wall, because the internal oblique aponeurosis does not split here to enclose the rectus muscle. The infe-
60
a
1 2 3
b 1 2 3
Figure 3.2 Anatomy of the rectus sheath in cross-section. (a) Above the arcuate line; (b) below the arcuate line. 1, external oblique; 2, internal oblique; 3, transversus abdominis muscles
rior limit of the posterior wall of the rectus sheath is marked by a crescentic border called the arcuate line. The position of the arcuate line is usually midway between the umbilicus and the pubic crest. Inferior to the arcuate line, the aponeuroses of the three flat abdominal muscles pass anterior to the rectus muscle to form the anterior layer of the rectus sheath. The posterior wall of the rectus sheath is also deficient superior to the costal margin, because the transversus
Ch 03 final.qxd
12/18/2006
15:13
Page 61
MANAGEMENT OF EARLY-STAGE OVARIAN CANCER
abdominis muscle passes internal to the costal cartilages, and the internal oblique muscle is attached to the costal margin. The fibers of the external oblique, the internal oblique and the transversus abdominis muscles run transversely or diagonally. Superior to the costal margin, the rectus abdominis muscle lies directly on the thoracic wall. In addition to the rectus abdominis muscle, the rectus sheath contains the superior and inferior epigastric vessels, and the terminal parts of the inferior five intercostals and subcostal vessels and nerves. The distribution and course of the nerves and blood vessels of the abdominal wall bear directly on the postoperative healing and function of the abdominal wall. The implications of various types of abdominal incisions on postoperative healing are discussed later in this chapter. The transversalis fascia is the internal investing layer, which lines the entire abdominal wall. It is continuous from side to side, deep to the linea alba. Internal to the transversalis fascia is the peritoneum, and these two layers are separated by a variable amount of extraperitoneal fat. The blood supply to the abdominal wall comes from several sources. The main blood supply of the rectus muscles and midabdomen comes from the superior epigastric arteries and the inferior epigastric arteries. The superior epigastric artery is a continuation of the internal thoracic artery and it enters the rectus sheath from behind the seventh costal cartilage and descends posterior to the rectus. It has multiple branches in the substance of the rectus muscle and anastomosis to the inferior epigastric artery. The inferior epigastric artery arises from the external iliac artery and continues in a cephalad course along the posterolateral portion of the rectus muscle. It has anastomoses with the superior epigastric artery. The lateral abdominal wall is supplied by the lower intercostal and lumbar arteries and the superficial and deep circumflex arteries. The deep circumflex artery runs on the deep aspect of the anterior abdominal wall, parallel to the inguinal ligament, and along the iliac crest between the transversus abdominis and internal oblique muscles. The veins lie in close proximity to these arteries. The medial abdominal wall
receives blood from the epigastric arteries. Overall, the anterior abdominal wall is well vascularized except for the linea alba. The innervation of the anterior abdominal wall (skin and muscles) is derived almost entirely from the thoracoabdominal (seventh to eleventh intercostals) nerves. The inferior part of the anterolateral abdominal wall is supplied by the iliohypogastric and ilioinguinal nerves. The thoracoabdominal nerves supply the internal and external obliques, rectus abdominis and the transversus abdominis muscles. The main trunks of the thoracoabdominal nerves pass anteriorly from the intercostal spaces and then run between the internal oblique and transversus abdominis muscles. The iliohypogastric and ilioinguinal nerves are sensory in function. Both nerves supply the lower part of the internal oblique and transversus muscles. The anterior cutaneous nerves penetrate the rectus sheath a short distance from the median plane. The anterior cutaneous branches of T7 to T9 supply the skin superior to the umbilicus, T10 innervates the skin at the level of the umbilicus; and T11, T12 and L1 supply the skin inferior to the umbilicus. The nerve supply to the anterior abdominal wall can be damaged by some incisions. A transverse incision is least likely to cause injury to nerves. Similarly, a vertical incision in the midline has a low likelihood of nerve damage. However, a vertical incision that passes lateral to the rectus muscle or through the muscle will denervate the medial tissues, depending on the length of the incision. Type of incision
This chapter will focus on open surgical techniques – details regarding laparoscopic approaches are discussed in Chapter 12. It is the responsibility of the surgeon to select one of the several abdominal incisions available that is most suited to the successful performance of the planned procedure (Figure 3.3). The main considerations in selecting an incision for any operation are exposure, ability to extend the incision and minimize risk for complications. The incision can influence the relative ease with which abdominal and
61
Ch 03 final.qxd
12/18/2006
15:13
Page 62
SURGERY FOR OVARIAN CANCER
Midline
Low Maylard Cherney Pfannenstiel
Figure 3.3 Incision selection for ovarian cancer surgery; the low vertical midline incision is the most versatile when ovarian malignancy is suspected
pelvic dissection can be accomplished. Limited exposure through an inadequate incision is dangerous and can result in a poor cosmetic and therapeutic outcome. Although several types of abdominal surgical incisions are available to the gynecologic surgeon, the most common surgical approach for women with suspected ovarian cancer is by the midline vertical incision. It provides easy access to both the deep pelvis and the upper abdomen. A low vertical incision is a highly versatile incision, which can be easily extended superiorly if disease is discovered in the upper abdomen. It is a relatively simple incision that can provide rapid access to the abdomen and pelvis in emergency cases. A vertical incision has minimal associated blood loss because there are no significant blood vessels encountered during this incision. The disadvantages of a vertical incision include less cosmesis, less strength due to greater tension and higher rates of wound breakdown. The appearance of the surgical incision will be noticed by the patient and family members. Most patients are concerned about the length and final appearance of the surgical incision. It is helpful to mark the entire distance between the pubic symphysis and the xiphoid process; this allows for a straight inci-
62
sion should the need arise for extending a limited incision. If a previous scar is present, depending on its appearance, it can be either excised or incised. Entry into the peritoneal cavity is at times easier above the superior extent of the previous scar in order to avoid entry into dense adhesions, also avoiding inadvertent damage to the abdominal organs. Making a midline incision alongside a previous paramedian incision should be avoided in order to prevent devascularization of the intervening tissues. Transverse incisions have the advantage of being more cosmetic and less painful, and tend to have less effect on pulmonary function, and may be stronger than a vertical incision. Transverse incisions are appropriate for small, benign pathology or when dissection is primarily limited to the pelvis. The disadvantages of a transverse incision include more technical difficulty, greater blood loss and limited access to the upper abdomen. Thus, for ovarian cancer staging and cytoreduction, transverse incisions have a limited role. If a surgeon makes a transverse incision and needs access to the upper abdomen, either a separate vertical incision (T-incision) must be made or the transverse incision can be extended upward laterally (J-incision). Pfannenstiel incision is probably the most limiting, because the rectus muscles are retracted and it provides less access to the pelvis than other transverse incisions. The Cherney incision is made closer to the pubic symphysis to divide the tendon of the rectus abdominis at the pubic crest. Its disadvantages include the need for lower placement of the incision and difficulty in retracting the abdominal wall in an obese patient. The Maylard incision is most commonly made in the infraumbilical region. If a Pfannenstiel incision has been performed and the pelvic exposure is inadequate, the incision should not be converted to a Maylard incision, because the ends of the rectus muscle will retract beneath the previously dissected rectus fascia and will not be easily reapproximated. The Pfannenstiel incision can be converted to a Cherney incision for greater exposure. Surgical incisions are closed most commonly by primary intention (approximation of the surgical wound
Ch 03 final.qxd
12/18/2006
15:13
Page 63
MANAGEMENT OF EARLY-STAGE OVARIAN CANCER
to allow healing), and less commonly by secondary intention (the skin and subcutaneous tissues are allowed to heal spontaneously) and delayed primary closure (tissues are approximated after allowing time for granulation). There are multiple factors that can affect postoperative wound healing including tissue oxygenation, the patient’s age and other co-morbid conditions, nutritional status and other therapeutic and pharmacologic agents. The midline abdominal incision should be closed with an internal mass closure technique using monofilament delayed absorbable or permanent suture. In comparison to the rapidly absorbable suture, the delayed absorbable suture is associated with a lower incidence of incisional hernia.14 However, there are no significant differences in risk of incisional hernia between delayed absorbable and non-absorbable sutures.14 The continuous mass closure (Figure 3.4) appears to be similar to the interrupted mass closure with regard to short- and longterm wound security, but the continuous method is more cost-efficient and faster.15,16 We prefer to use the running Smead–Jones closure, with each bite 1.5–2 cm lateral to the edge of the fascial incision.
The transverse incisions are closed with a running delayed-absorbable suture in the fascia. There are limited data regarding the use of subcutaneous retention sutures; however, Soisson et al. have found that their use in obese women (subcutaneous tissue of 5 cm or greater) was associated with a lower risk of superficial wound separation in univariate and multivariate analyses.17
Surgical staging technique The standards for staging were established more than 20 years ago by the Gynecologic Oncology Group.18 Buchsbaum et al. performed a prospective study of 187 patients with malignant ovarian cancer through the Gynecologic Oncology Group to develop a standard surgical procedure for ovarian cancer patients.18 The stage was elevated in almost 13% of patients based on full surgical staging. Several steps exploring both the intra- and the retroperitoneal spaces are performed at the time of surgical management for complete staging evaluation (summarized in Table 3.2). If a perioperative diagnosis of invasive ovarian malignancy is not
1 cm
Rectus sheath Muscle Posterior rectus sheath
2 cm
a
b
Figure 3.4 (a) Continuous mass closure of vertical midline incision; (b) the closure incorporates all fascial and muscular layers of the anterior abdominal wall, with each bite taken 2 cm back from the midline incision edge
63
Ch 03 final.qxd
12/18/2006
15:13
Page 64
SURGERY FOR OVARIAN CANCER
possible, then a secondary staging procedure should be considered as soon as possible. Exploration
The type of incision is discussed above in detail. Our standard approach is to perform a midline vertical incision in cases where an ovarian malignancy is suspected. The initial incision is made from the umbilicus to the pubic bone. The incision is then extended superiorly, as needed, to complete the staging operation in the upper abdomen or perform cytoreductive surgery. Sampling of the peritoneal fluid is obtained for cytologic examination. When no ascites is present, a peritoneal washing with 100–150 ml of saline solution must be performed. Washings are obtained from the pelvis, the paracolic spaces and the level of each hemidiaphragm. Careful and thorough exploration of the entire peritoneal cavity is performed in a systematic fashion by inspection and palpation for tumor implants. The exploration is started by palpating the right paracolic space, and advancing the hand to the right kidney, suprahepatic space, the right diaphragm, right hepatic lobe, gallbladder, Morison’s pouch, left hemi-diaphragm, left hepatic lobe, spleen, stomach,
Table 3.2 Systematic surgical staging for epithelial ovarian cancer Peritoneal cytology Careful and systematic abdominal exploration – inspect and palpate all peritoneal surfaces Omentectomy Total abdominal hysterectomy and bilateral salpingooophorectomy Pelvic and para-aortic lymphadenectomy Random and directed peritoneal biopsies – posterior cul-desac, bladder reflection, both pelvic sidewalls and both paracolic spaces Biopsy or scrapings from the undersurface of both diaphragms Appendectomy in selected cases (for example, mucinous histology)
64
transverse colon, left kidney and left paracolic space. Decompression of the stomach may facilitate access to these structures. The lesser sac is entered on the left side of the gastrocolic ligament to evaluate the stomach and pancreas. The entire small bowel and colon including the mesentery are carefully examined. Both surfaces of the small bowel mesentery are inspected from the jejunum to the cecum. The retroperitoneal areas are palpated along the vascular structures. The pancreas and duodenum can be palpated transperitoneally. The results from this exploration are carefully noted with regard to tumor size, extent and location. Any other abnormalities are also recorded. Management of the primary tumor
The primary ovarian tumor and pelvis should be carefully examined. Both ovaries should be evaluated for size, presence of gross tumor, capsule rupture, external excrescences and adherence to surrounding structures. If surgical findings are suggestive of a benign mass in a young patient, then ovarian cystectomy may be indicated. Otherwise, a unilateral salpingooophorectomy should be performed and submitted for frozen section evaluation. If bilateral ovarian masses are present, the more suspicious side should be removed initially. If frozen section analysis reveals a malignant epithelial tumor, then standard surgical therapy consists of hysterectomy and bilateral salpingo-oophorectomy. In patients for whom fertility is not a concern, removal of the contralateral ovary is justified even if it appears normal. Specifically, the contralateral ovary may harbor occult metastatic disease or even a primary lesion. Hysterectomy is also recommended in most cases, as the uterus may be involved by microscopic lymphatic or serosal metastasis and is a potential site for a synchronous primary tumor of the endometrium. The possibility of conservative surgery is discussed later in this chapter. Although the issue of whether intraoperative rupture of malignant ovarian tumors influences the prognosis of patients with stage I ovarian cancer is controversial, ideally an adnexal mass should be removed
Ch 03 final.qxd
12/18/2006
15:13
Page 65
MANAGEMENT OF EARLY-STAGE OVARIAN CANCER
intact. Sainz de la Cuesta et al. evaluated 79 patients with stage I invasive epithelial ovarian cancer and found that, compared to women with stage IA disease, individuals with intraoperative rupture had a higher risk of recurrence and decreased overall survival.19 However, other studies have failed to show an adverse effect of tumor rupture or ascites on survival in patients with stage I disease.20–22 The findings of at least some of these studies are probably confounded by inadequate staging information and the effect of histologic grade. Staging biopsies
As a part of staging, surgical biopsies are taken to evaluate microscopic metastases in high-risk areas, which grossly appear normal. Adhesions and any other abnormal-appearing areas on the peritoneum should be biopsied. If no abnormalities on peritoneal surfaces are noted, then directed biopsies of the peritoneum are taken from the posterior cul-de-sac, bladder peritoneum, bilateral pelvic sidewalls, both paracolic gutters and the undersurface of the diaphragm on both sides. Some surgeons prefer to take peritoneal scrapings from the diaphragms rather than biopsies, and put the specimen on a slide, fixed immediately with a preservative.23 Omentectomy
An omentectomy should be performed as a part of the staging procedure. The vascular supply of the omentum comes from the right and left gastroepiploic arteries, which arise from the gastroduodenal artery and the splenic artery, respectively. In the absence of gross omental disease, an infracolic omentectomy appears to be adequate.18 The value of omentectomy is illustrated by the finding that clinical impression is reported to be inaccurate in 45% of cases with metastases to the omentum.18 In patients with apparent early-stage ovarian cancer, omental disease is detected in about 5% (0–10%).6,18 The omentum is elevated and the posterior reflection onto the transverse colon incised to enter the lesser sac (Figure 3.5). The lesser sac is further developed by dissecting between the posterior
layer of the gastrocolic ligament and the anterior layer of the transverse mesocolon. During this dissection, the middle colic artery must be protected from injury. The dissection is then continued bilaterally toward the hepatic and splenic flexures. On the left, hard traction should be avoided, so that the splenic capsule is not torn. After the omentum has been fully mobilized from the transverse colon, a series of clamps are placed across the omental arteries and veins, avoiding the gastroepiploic vascular arcade along the greater curvature of the stomach (Figure 3.6). The infracolic omentum is removed and the pedicles are sequentially suture ligated. Retroperitoneal lymph node dissection
In 1985, FIGO modified the staging for ovarian carcinoma to reflect the prognostic significance of metastatic spread to the pelvic or para-aortic lymph nodes.24 Assessment of the retroperitoneal nodes is an important part of the initial staging for ovarian cancer. Ovarian cancer drains preferentially to the high aortic nodes in the vicinity of the junction of the ovarian veins and the vena cava on the right side and the renal vein on the left side (Figure 3.7).25–28 Therefore, the diagnostic aortic lymph node sampling should include the high aortic nodes as well as the lower aortic and common iliac regions. Lymphatic drainage of the ovary is known to follow the gonadal blood supply. The para-aortic lymph nodes are part of the lumbar lymph node groups, which comprise three subgroups: preaortic, retroaortic and lateral aortic. The lateral group receives lymphatic drainage from the iliac lymph nodes, ovaries and other pelvic organs. The dominant lymph channels coalesce in the infundibulopelvic ligament, where they travel with the pampiniform plexus of the ovarian veins, and then drain toward the inferior pole of the kidney and move medially into the para-aortic and precaval lymph nodes. An additional pathway from the hilus of the ovary traverses the broad ligament draining into the obturator, external and common iliac lymph nodes.29–31
65
Ch 03 final.qxd
12/18/2006
15:13
Page 66
SURGERY FOR OVARIAN CANCER
Operator
Second assistant
Omentum
First assistant
Stomach
Omentum
Colon
Line of incision Posterior taenia Mesocolon Transverse colon
Mesocolon
Posterior taenia
Figure 3.5 Infracolic omentectomy. The omentum is elevated into the incision and the posterior reflection onto the transverse colon incised to provide access to the lesser sac
Operator
Anterior taenia
Figure 3.6 Infracolic omentectomy. After developing the lesser sac, the omental vascular pedicles are skeletonized, clamped, divided and ligated
66
Ch 03 final.qxd
12/18/2006
15:13
Page 67
MANAGEMENT OF EARLY-STAGE OVARIAN CANCER
The frequency of lymphatic spread in patients with apparent stage I ovarian cancer ranges from 5 to 20% (Table 3.3). Cass et al. evaluated 96 consecutive patients treated at two institutions, with disease visibly confined to one ovary.32 Forty-two patients had lymph node sampling only on the side ipsilateral to
the neoplastic ovary, four (10%) of whom had lymph node metastases. Fifty-four patients had bilateral sampling performed and ten (19%) of these patients were found to have lymph node involvement. Among the ten patients with bilateral sampling, 50% had only ipsilateral involvement. However, the remaining 50%
Para-aortic nodes
Common iliac nodes Internal iliac nodes External iliac nodes
Figure 3.7 Lymphatic drainage of the ovary. The principal drainage routes are: (1) cephalad, along the course of the ovarian vessels, to the high para-aortic nodes, and (2) through the broad ligament to the obturator, external and common iliac nodes
Table 3.3 Positive lymph nodes in ovarian cancer visibly confined to the ovary(ies) Author
Number of cases
Positive pelvic (%)
Positive para-aortic (%)
Both (%)
35
8.6
5.7
2.9
Burghardt31 – stage I/II
27
11.1
3.7
14.8
Cass32
96
7.3
5.2
2.1
Petru33 – stage I
40
17.5
2.5
2.5
Chen26
11
9.1
18.2
Benedetti–Panici25
– stage I
– stage I
– stage I
67
Ch 03 final.qxd
12/18/2006
15:13
Page 68
SURGERY FOR OVARIAN CANCER
had either contralateral (30%) alone or bilateral (20%) lymph node involvement.32 All patients with positive lymph nodes in this study had high-grade disease. This study emphasizes the importance of performing bilateral pelvic and para-aortic lymph node dissection in patients with apparent local disease. Petru et al. evaluated 40 patients with disease grossly confined to the ovary who underwent comprehensive surgical staging.33 Nine (23%) were found to have lymph node metastases. Although most patients with nodal metastases had high-grade (2 or 3) disease, none of the other clinical–morphologic factors such as ascites, adherence or extracystic excrescences were predictive of nodal metastasis. One of six patients with unilateral ovarian involvement had isolated contralateral pelvic nodal metastasis. The results of this study do not support limiting lymphadenectomy to any subset of patients with stage I ovarian cancer. Some of the variation in the nodal positivity rates may be explained by the differences in the type of lymphadenectomy performed, which can range from cursory sampling to systematic removal of all the lymphatic tissue surrounding the retroperitoneal vessels. Technique for pelvic lymph node dissection
The peritoneum overlying the pelvic wall is opened, extending from the round ligament to above the aortic bifurcation. The ureter, psoas muscle, genitofemoral nerve and iliac vessels are identified. The paravesical and pararectal spaces are developed. The paravesical space is lined medially by the bladder and vagina, laterally by the external iliac vessels and the obturator fossa, posteriorly by the cardinal ligament and anteriorly by the pubic ramus. The floor of the paravesical space is formed by the endopelvic fascia. The anterior paravesical space is opened by dissecting between the umbilical artery at the lateral border of the bladder and the external iliac vein. The umbilical artery is identified by retracting up on the lateral bladder peritoneum. The pararectal space is lined laterally by the hypogastric artery, medially by the rectum, posteriorly and superiorly by the sacrum, and inferiorly by the cardinal ligament. This space is developed, using
68
blunt dissection between the ureter and the hypogastric artery. This dissection should be performed with care to avoid dissecting lateral to the hypogastric artery, because of the risk of bleeding from the internal iliac venous system. Exposure of the operative field is maintained by using a fixed retractor – we prefer to use the Bookwalter retractor. Bleeding up to this point is usually minimal. An incision is made through the fatty tissue overlying the external iliac artery. The external and common iliac vessels are mobilized from the pelvic wall, first with scissors then digitally. A small branch to the psoas muscle is usually encountered and is clipped and divided. The obturator space is entered lateral to the vessels, and the obturator nerve is identified. Lymph node samples are removed from the external iliac, internal iliac and obturator regions (Figure 3.8). If bleeding occurs in the obturator space, it usually can be controlled by tamponade with a moist pack. Technique for para-aortic lymph node dissection
The peritoneal incision on the right begins at the infundibulopelvic ligament and crosses the vena cava and aorta and ends at the duodenum at the ligament of Treitz (Figure 3.9). The cecum and ascending colon are then mobilized from the loose underlying connective tissue. The lymph node dissection is then started on the vena cava from the mid-common iliac region extending superiorly. The nodal bundle is elevated and small vascular branches from the great vessels are clipped and divided. The next step is removal of the para-aortic lymph nodes to the left of the aorta. The left ureter is identified and retracted out of harm’s way. The sheath of the common iliac artery is incised and a plane between the lymph node-containing fat pad and the common iliac artery is developed. The dissection is carried superiorly to the level of the left renal vein. The origin of the left ovarian vein at the left renal vein is isolated, clamped and divided. The fat pad is clipped sequentially, medially and superiorly, and transected. The nodal bundle is elevated and posterior attachments are clipped and divided. The
Ch 03 final.qxd
12/18/2006
15:13
Page 69
MANAGEMENT OF EARLY-STAGE OVARIAN CANCER
Round ligament
Genitofemoral nerve Obturator fossa Psoas muscle
Ureter
External iliac artery and nerve
a
Obturator nerve
Hypogastric artery
b
Figure 3.8 Pelvic lymph node dissection. (a) The retroperitoneum has been opened, the ureter retracted medially and the para-vesicle and para-rectal spaces developed; lymph node-bearing tissue is sharply dissected from the underlying external iliac artery and vein. (b) The external iliac vessels are retracted laterally, exposing the obturator space; the lymph node-bearing tissue anterior to the obturator nerve is sharply dissected and removed
Duodenum
Superior mesenteric artery Duodenum
Pre-caval lymph nodes Right ureter
Para-aortic lymph nodes
Right renal vein Aorta
a
b
c
Inferior mesenteric artery
Figure 3.9 Para-aortic lymph node dissection. (a) The cecum and terminal ileum are mobilized by incising the peritoneum of the base of the small bowel mesentery up to the ligament of Treitz. (b) The ureter is retracted laterally and the lymph node-bearing tissue in the para-aortic and pre-caval fat pad is carefully dissected from the underlying vessels. (c) The duodenum is mobilized cephalad, exposing the high para-aortic nodes for removal
69
Ch 03 final.qxd
12/18/2006
15:13
Page 70
SURGERY FOR OVARIAN CANCER
operative field is irrigated to evaluate the level of hemostasis.
cauterized. Some gynecologic surgeons invert the appendiceal stump, while others do not.
Appendectomy
Adjuvant therapy
The appendix is a potential site for metastasis from ovarian malignancies.34 Nevertheless, routine appendectomy during primary surgical treatment for ovarian carcinoma is controversial. Malfetano identified no metastasis to the appendix in early-stage ovarian carcinomas, while it was noted in 70% of stage III and IV ovarian carcinomas.35 The high likelihood of appendiceal involvement has been reported by others as well.36,37 Bese et al. evaluated 90 patients with malignant ovarian carcinoma and found that none of the early-stage patients had metastases to the appendix.37 However, metastases to the appendix were detected in 21% of stage III and 50% of stage IV ovarian cancer patients. Others have reported metastases to the appendix in up to 70% of patients with advanced (stage III or IV) ovarian cancer. Some physicians have recommended routine appendectomy in women with mucinous cystadenocarcinomas, as these tumors can be metastatic from the gastrointestinal tract, and the appendix may harbor the primary lesion.35 Overall, the risk associated with an appendectomy during staging surgery for ovarian cancer appears to be low.34,37,38 Westermann et al. performed 233 appendectomies during extensive gynecologic procedures and reported no procedure-related morbidity.34 Therefore, appendectomy strictly for determining the extent of disease does not appear to be beneficial. However, appendectomy may have a role in patients with mucinous cancers or in those with advanced disease for cytoreduction.38 The technique for appendectomy depends on the location of the appendix. For a retrocecal appendix, the cecum may need to be mobilized by incising the peritoneum laterally. The mesoappendix and the appendiceal artery are sequentially clamped, cut and suture ligated (Figure 3.10). The base of the appendix is crushed and ligated with non-absorbable suture. The appendix is removed and the exposed mucosa is
As discussed above, patients with localized tumor have good overall survival.1 However, the specific subsets of patients likely to benefit from adjuvant chemotherapy are not clearly known. It is generally accepted that patients with stage IA or IB, grade 1 ovarian cancer comprise a ‘good prognosis’ group and can be safely treated with surgery only, and do not require adjuvant chemotherapy.5,39 Patients with
70
a
Appendiceal artery
b
Figure 3.10 Appendectomy. (a) The appendiceal artery is identified running in the base of the mesoappendix and clamped. (b) The mesoappendix is divided and ligated; the base of the appendix is ligated, divided, ligated and cauterized
Ch 03 final.qxd
12/18/2006
15:13
Page 71
MANAGEMENT OF EARLY-STAGE OVARIAN CANCER
stage IC or grade 3, and stage II ovarian cancer are generally considered to need adjuvant therapy because of the 30–40% risk of recurrence within 5 years. However, the role of adjuvant therapy in women with stage IA or IB, grade 2 ovarian cancer is unresolved, because of the small number of patients studied.1 The Gynecologic Oncology Group randomized 81 patients with stage IA or IB, grade 1 or 2 ovarian cancer to receive either no chemotherapy or melphalan.39 There were no differences in either disease-free survival or overall survival and both groups of patients had 5-year overall survival exceeding 90%.39 In a second trial, 141 patients with stage I, grade 3 or stage II patients were randomized to treatment with either melphalan or 32P.39 Again, there were no differences in the disease-free or overall survival. Bolis et al. evaluated 271 consecutive patients with stage I ovarian cancer in two randomized trials.40 Trial I compared six cycles of cisplatin chemotherapy to no further therapy in stage IA, IB, grades 2 and 3 ovarian cancer. Cisplatin significantly reduced the relapse rate by 65%, but the survival was not significantly different. In trial II, patients with stage IA (grade 2), IB and IC were randomized to receive cisplatin chemotherapy or 32P. Again, the relapse rate was decreased by 61%, but the overall survival was similar.40 Young et al. performed another randomized study through the Gynecologic Oncology Group (protocol no. 95), which compared intraperitoneal 32P versus intravenous cyclophosphamide (1 g/m2) and cisplatin (100 mg/m2) in ‘poor prognosis’ patients (stages IA and IB, grade 3 and IC, II).41 There was a better progression-free interval, and better treatment compliance with a lower complication rate in the chemotherapy arm. However, there was no difference in overall survival. In a subsequent Gynecologic Oncology Group study (protocol no. 157, patients with stage IA and IB (grade 3), IC and II epithelial ovarian cancer were randomized to receive either three or six cycles of paclitaxel (175 mg/m2) and carboplatin (AUC 7.5).42 Recurrence rates were not sig-
nificantly different between the two arms, but there was greater toxicity with six cycles of chemotherapy. Recently, two additional prospective randomized trials on early-stage ovarian cancer have been completed and published.43–45 The International Collaborative Ovarian Neoplasm (ICON1) and the Adjuvant ChemoTherapy in Ovarian Neoplasm (ACTION) trials were both designed to include a large number of patients. However, owing to slow accrual, the trials were stopped prematurely. The ICON1 trial (n = 477) enrolled all patients with early stages, grades, histologic cell types and those for whom the responsible physician was ‘uncertain whether the patients would benefit from immediate adjuvant chemotherapy’. The ACTION trial (n = 448) included patients with stage IA and IB, grades 2–3, all IC and IIA, and all I–IIA clear cell carcinomas of the ovary. Both studies recommended platinum-based chemotherapy, but the type of chemotherapy was not further specified. The results of the combined trials showed better overall survival with adjuvant chemotherapy compared to the observation arm (82% vs. 74%, p = 0.008).43,44 Recurrence-free survival was also better with adjuvant chemotherapy (76% vs. 65%, p = 0.001).43,44 However, when the trials were analyzed separately, differences in outcomes emerged. In the ACTION trial, there was improvement in recurrence-free survival with adjuvant chemotherapy, but the difference in overall survival was not significantly different.43,44 Further subset analyses revealed that stage I patients with complete staging did not benefit from chemotherapy, whereas those with incomplete staging (more likely to have higher stage disease) did have an improvement in both overall and recurrence-free survival. In the ICON1 trial, platinum-based adjuvant chemotherapy improved both overall and recurrencefree survival.45 The ICON1 trial probably included many patients with more advanced disease, since about 25% of patients were incompletely staged. Although the findings from these two trials suggest that platinum-based adjuvant chemotherapy probably has the greatest impact on incompletely staged
71
Ch 03 final.qxd
12/18/2006
15:13
Page 72
SURGERY FOR OVARIAN CANCER
patients, identification of the truly ‘high-risk’ earlystage patients is still needed. Collectively, the published data suggest that wellstaged patients with stage IA or IB, grade 1 ovarian cancer have a good prognosis and do not benefit from adjuvant chemotherapy. The role of adjuvant chemotherapy in grade 2 patients is not clearly known at present. All other early-stage and incompletely staged patients should be treated with platinum-based chemotherapy. Until further studies are completed, our practice is to treat these ‘high-risk’ early-stage patients with six cycles of paclitaxel and carboplatin chemotherapy.
SPECIAL CIRCUMSTANCES Low malignant potential (borderline) ovarian tumors Epithelial ovarian tumors of low malignant potential (LMP) were first described by Taylor in 1929 as a group of tumors with histologic features and biological behavior between benign and frankly malignant epithelial ovarian neoplasms.46 In 1971, FIGO included these tumors as a separate entity in its classification and staging system of gynecologic malignancies.47 About 3000 women are diagnosed with borderline ovarian tumors annually in the USA. Histological criteria for the diagnosis of borderline ovarian tumors include nuclear atypia, stratification of the epithelium, formation of microscopic papillary projections and the absence of stromal invasion. It is widely accepted that LMP tumors have a much better prognosis than invasive epithelial ovarian cancers. In a large retrospective study, Kaern et al. treated 370 patients with LMP ovarian tumors and reported a total mortality rate of 7.8% and total recurrence rate of 7.3% for all stages.48 Up to 90% of ovarian borderline tumors present with stage I disease and these patients have an excellent 5-year survival approaching 100%.49 Staging is of paramount importance, because it has consistently been shown to be a significant prognostic
72
factor.48,50–53 Some authors have reported that 18–20% of apparent stage I tumors are upstaged on final pathologic examination.53–55 There are many patients who are operated upon at local hospitals where a gynecologic oncologist may not be available to perform surgical staging. Lin et al. evaluated the adequacy of surgical staging of cases of serous borderline tumors referred for a second opinion.56 Most patients (78%) were treated primarily by general obstetrician–gynecologists. Only 12% had comprehensive surgical staging, as defined by biopsy samples taken from pelvic and abdominal peritoneum, omentum and retroperitoneal lymph nodes. There were substantial differences in the likelihood of staging based on the physician’s training: general surgeons performed complete staging in 0% of patients, obstetrician–gynecologists in 9% and gynecologic oncologists in 50%. Approximately 47% of patients who underwent biopsies were upstaged as a result of positive biopsies. However, surgical staging of patients with borderline ovarian tumors remains controversial. Unless there is gross residual disease, some authors feel that a restaging laparotomy is probably not needed.57 The most common histologic subtype of borderline ovarian tumors is serous. Serous LMP tumors have an overall risk of recurrence of approximately 10–15%.58–60 Patients with stage I ovarian LMP tumors have an excellent prognosis with a recurrence risk of less than 5%, and patients with stage II–IV have a risk of relapse of about 20%.57 Zanetta et al. followed 339 women with stage I–III LMP tumors prospectively and reported a 99.6% disease-free survival for stage I patients and 95.8% for stage II and III patients.57 A number of risk factors for recurrence have been identified including stage and residual disease.61–65 Intraoperative management of LMP tumors is similar to that for invasive ovarian carcinoma and should include systematic staging and upper abdominal exploration. These tumors can be large and a definitive diagnosis based on frozen section evaluation can be difficult. Under these circumstances, a frozen section diagnosis of ‘at least low malignant
Ch 03 final.qxd
12/18/2006
15:13
Page 73
MANAGEMENT OF EARLY-STAGE OVARIAN CANCER
potential’ should be adequate to proceed with surgical staging. Most studies have reported a high incidence of finding invasive foci in these tumors on final pathology.66,67 Menzin et al. studied 48 patients with a frozen section diagnosis of borderline malignancy and found that 27% had invasive carcinoma on final pathology.68 Houck et al. evaluated 140 women with borderline tumors of the ovary.67 Frozen section interpreted a benign lesion as borderline or borderline lesions as malignant when compared with permanent pathologic diagnoses in about 11%. Furthermore, malignant lesions were interpreted as borderline or borderline lesions read as benign by frozen section in 29%.67 Management of the adnexa is discussed in more detail below. The staging operation should include omentectomy, multiple peritoneal biopsies, and pelvic and para-aortic lymphadenectomy. Women with LMP tumors tend to present at younger ages and are more likely to have early-stage disease. Consequently, preservation of fertility is highly desirable by many women with LMP tumors. Several studies have examined the role of fertility preservation in these patients. Lim-Tan et al. followed 35 women with LMP tumors who underwent a unilateral or bilateral cystectomy.69 The overall recurrence rate was 12% and was mostly associated with positive margins and extent of disease. However, all patients were alive with an average follow-up of 7.5 years.69 In addition, several patients in this study had subsequent successful full-term pregnancies.69 Gotlieb et al. treated 39 patients with borderline ovarian tumors with conservative management.70 Fifteen women had 22 pregnancies after conservative treatment in this study. Morris et al. evaluated 43 patients with LMP tumors who underwent a cystectomy or oophorectomy with or without surgical staging.71 Overall recurrence was more frequent in patients with ovarian cystectomy (58%) than in those with unilateral oophorectomy (23%, p < 0.04). However, when patients with only stage I tumors are considered, the risk of recurrence was similar between the two groups. After treatment, 81% of the patients retained normal menstrual cycles
and 12 of 24 patients attempting pregnancy conceived 25 pregnancies. Collectively, these studies suggest that patients with ovarian borderline tumors have a high likelihood of achieving a successful pregnancy. The decision regarding conservative surgery in a young patient with an adnexal mass is based on several characteristics. If the mass is unilateral with surrounding normal ovarian tissue, then an ovarian cystectomy may be performed. The ovarian capsule should be inspected for any evidence of rupture, adherence, or excrescences. If no normal ovarian tissue is evident, then an oophorectomy or salpingooophorectomy is appropriate. The specimen should be submitted for frozen section analysis and the contralateral ovary is carefully inspected. Although some authors have recommended routine biopsy of a normal-appearing contralateral ovary, we prefer to leave it undisturbed, because of low yield and potential for peritoneal adhesions or inducement of ovarian failure. If bilateral adnexal masses are present, then intraoperative decision-making may be more difficult. In such cases, we recommend removing the more suspicious lesion first by conservative means (ovarian cystectomy, if possible) and sent for frozen section analysis. If an LMP tumor is diagnosed, then either ovarian cystectomy or oophorectomy should be performed on the contralateral side. As discussed above, systematic surgical staging should be performed in these patients. Ideally, the various intraoperative scenarios and possible treatment options should be discussed with the patient and her family preoperatively. Even for patients with stage II–IV LMP tumors who have not completed childbearing, conservative surgery may be appropriate. Treatment of the ovaries should be considered separately from treatment of extraovarian disease. Metastatic disease in ovarian LMP tumors tends to be of small volume and fully resectable in most patients.62 The outcome of patients with peritoneal implants remains quite good with surgical resection. In young patients for whom bilateral salpingo-
73
Ch 03 final.qxd
12/18/2006
15:13
Page 74
SURGERY FOR OVARIAN CANCER
oophorectomy cannot be avoided, uterine preservation should be considered because in vitro fertilization with donor oocytes may be an option in the future. Some authors have raised a question as to whether the uterus and the remaining ovary(ies) should be removed after childbearing has been completed for women treated conservatively for ovarian LMP tumors. There is no scientific basis for such a recommendation. For women with early-stage LMP tumors or more extensive disease, who have undergone surgical staging and resection of all gross disease, there is no known benefit for subsequent surgery. For women without full surgical staging at primary surgery, there may be potential prognostic and/or therapeutic benefits. The pros and cons of each approach should be carefully discussed with patients focusing on the risk–benefit ratio. There are limited data regarding retroperitoneal lymph node involvement in borderline tumors. Leake et al. evaluated 171 patients with borderline ovarian tumors and performed a full surgical staging on 34.55 The incidence of retroperitoneal lymphatic involvement was 21%.55 The occurrence of positive pelvic and para-aortic lymph nodes was 17% and 18%, respectively. Although the nodal status of patients did not significantly affect survival, those with positive lymph nodes did have a higher incidence of recurrence.55 However, some authors have questioned whether an observed focus of lymph node disease may be due to in situ transformation within the node, since no focus of invasion was found in the ovaries.72 Therefore, retroperitoneal lymph node sampling may provide some prognostic information regarding recurrence in patients with borderline ovarian tumors, but its impact on therapeutic intervention or survival has not been confirmed. However, because of the inaccuracy of intraoperative frozen section in predicting borderline pathology on the final pathologic diagnosis, as discussed above, it would be prudent to perform a full systematic staging including a retroperitoneal lymph node dissection.
74
Fertility preservation in patients with epithelial ovarian cancer Although most women with invasive ovarian cancer are postmenopausal, and in these women bilateral salpingo-oophorectomy and hysterectomy are standard treatment, a conservative treatment approach must be considered in young patients with stage I ovarian cancer. Conservative treatment approach is used here to denote surgery that preserves the reproductive potential without compromising the likelihood of cure. It has been estimated that 3–17% of all epithelial ovarian cancers occur in women < 40 years of age.73–77 Nevertheless, a staging procedure is necessary to confirm the early stage and to guide chemotherapy decisions. As discussed above, standard management of epithelial ovarian cancer involves abdominal hysterectomy, bilateral salpingooophorectomy and staging biopsies. However, many women with early-stage ovarian cancer wish to maintain reproductive capability. Although this has been considered by some physicians, there are limited data with regard to the safety of this approach.78–81 Schilder et al. evaluated 52 patients with stage I invasive epithelial ovarian cancer (42 with stage IA and ten with stage IC cancer), who underwent fertilitysparing surgery (conservation of the uterus, one ovary and fallopian tube).81 All patients underwent staging biopsies and 20 patients received adjuvant chemotherapy. Five patients developed tumor recurrence, but the estimated survival was 98% at 5 years and 93% at 10 years. Twenty-four patients attempted pregnancy and 17 (71%) conceived. These 17 patients had 26 term deliveries and five spontaneous abortions. Zanetta et al. performed 53 fertility-sparing procedures (unilateral salpingo-oophorectomy) and 46 hysterectomies with bilateral salpingo-oophorectomy.82 With a median follow-up of 7 years, recurrence was suffered by 9% of the conservatively managed patients and 11% of the radically managed patients. Despite the potential risk, several studies have shown no survival difference in stage IA ovarian cancer patients treated with unilateral versus bilateral salpingo-oophorectomy.81,83 Although these data are
Ch 03 final.qxd
12/18/2006
15:13
Page 75
MANAGEMENT OF EARLY-STAGE OVARIAN CANCER
encouraging, these are relatively small studies and it is difficult to draw definitive conclusions. Some authors have proposed specific criteria including young age, stage IA tumor, low grade and possibility of close follow-up78 to select low-risk patients for a conservative operation. Systematic secondary hysterectomy and adnexectomy after completion of childbearing is classically advocated when pregnancy is no longer a concern. As shown above, the risk of relapse after a conservative approach is low, especially in welldifferentiated tumors. The benefits of a secondary systematic radical operation in this setting are not clearly known. General criteria for conservative surgical treatment are listed in Table 3.4. Although strict criteria usually exclude patients with bilateral, adherent, or ruptured tumors, and individuals with ascites or positive cytologic washings, some studies suggest that such criteria can be liberalized, especially if adjuvant chemotherapy is used. The role of conservative management in patients with non-epithelial ovarian cancers is discussed later in this chapter. Emerging reproductive technologies are now allowing for pregnancies for patients who historically have not been able to maintain reproductive potential. For example, donor oocyte transfer and hormonal support allows a woman without ovaries to sustain a normal intrauterine pregnancy. Therefore, traditional guidelines for surgical management of ovarian
cancer patients may have to be modified for selected young individuals.
Germ cell tumors Malignant germ cell tumors represent about 10% of all ovarian tumors. Dysgerminoma is the most common malignant germ cell tumor. The median age of patients with ovarian germ cell tumors (OGCT) falls in the teenage years. Germ cell tumors are classified on the basis of the World Health Organization (WHO) classification introduced in 1973.84 The different types of OGCT are listed in Table 3.5. Bilateral ovarian involvement with tumor is uncommon except in pure dysgerminoma, in which 10–15% of tumors are bilateral. Bilateral ovarian involvement may also occur in cases of advanced-stage OGCT and in cases of mixed germ cell tumors that have a dysgerminoma component. Before the advent of effective chemotherapy, the prognosis of patients with these tumors was dismal, particularly for individuals with non-dysgerminoma and advanced cases.85,86 After the introduction of cisplatin-based chemotherapy, survival has improved dramatically and a reassessment of the extent of surgery has been required.
Table 3.5 World Health Organization classification of germ cell tumors Dysgerminoma
Table 3.4 Criteria for conservative surgical management of ovarian cancer patients Young patient desirous of future childbearing Patient and family consent and agreement to close follow-up No evidence of dysgenetic gonads Specific situations: any unilateral malignant germ cell tumor any unilateral stromal tumor any unilateral borderline tumor stage IA invasive epithelial tumor
Endodermal sinus tumor Embryonal carcinoma Polyembryoma Choriocarcinoma Teratomas immature mature (dermoid cyst) monodermal (struma ovarii, carcinoid) Mixed forms Gonadoblastoma
75
Ch 03 final.qxd
12/18/2006
15:13
Page 76
SURGERY FOR OVARIAN CANCER
Owing to the propensity of germ cell tumors to occur in young women, this diagnosis should be considered in women of reproductive age presenting with a pelvic mass. An algorithm for management of young patients with an ovarian mass is presented in Figure 3.11. Preoperative evaluation should include evaluation of serum tumor markers including β-human chorionic gonadotropin, α-fetoprotein, lactate dehydrogenase (LDH1 and LDH2 fractions), placental alkaline phosphatase and CA125. A chest X-ray is indicated, as germ cell tumors can metastasize to the lungs or mediastinum. Owing to the association of germ cell tumors with dysgenetic gonads (5% of all cases), a karyotype analysis should be considered for premenarchal girls with a pelvic mass of > 2 cm.87 The initial treatment of patients with germ cell tumors is surgical, which establishes the diagnosis and initiates therapy. A suggested algorithm for management of patients with an OGCT is presented in Figure 3.12. In patients suspected of having an OGCT, a laparotomy through a vertical incision should be per-
formed. The role of laparoscopy in the management of OGCT is undefined. If ascites is present, then the fluid should be evacuated and submitted for cytologic analysis. In the absence of ascites, a peritoneal washing from the abdomen and pelvis using saline should be performed and submitted for cytologic analysis. For most patients with germ cell tumors, unilateral salpingo-oophorectomy with preservation of the normal contralateral ovary, fallopian tube and uterus are appropriate, preserving the potential for fertility. Several studies have supported the principle of using conservative surgery for the vast majority of young patients with OGCT.85,88 In patients with limited disease, the role of fertility-sparing surgery is now well established.89 Peccatori et al. treated 100 patients with OGCT with fertility-sparing surgery.90 The overall survival was 96% with a mean follow-up of 55 months. Kurman and Norris evaluated 218 patients with OGCT and noted no worsening of outcome associated with conservative surgery in 182 patients
Tumor markers: AFP hCG LDH PLAP Premenarchal
Mass > 2 cm
Postmenarchal
Cystic > 8 cm Negative tumor markers
Cystic > 8 cm Solid, suspicious Positive tumor markers
Observation for 6–8 weeks
Karyotype
Decreasing size
Increasing size
Surgery
Clinical follow-up
Surgery
Figure 3.11 Algorithm for the management of the young patient with an ovarian mass. AFP, α-fetoprotein; hCG, human chorionic gonadotropin; LDH, lactate dehydrogenase; PLAP, placenta alkaline phosphatase
76
Ch 03 final.qxd
12/18/2006
15:13
Page 77
MANAGEMENT OF EARLY-STAGE OVARIAN CANCER
If the tumor appears confined to one or both ovaries, it is imperative to perform proper staging. Surgical staging is important to determine the extent of disease for prognostic reasons and for guiding postoperative adjuvant therapy. Without a careful staging operation, about 25% of women with stage IA dysgerminoma can relapse after conservative surgery.91 All areas of the abdomen and pelvis should be carefully inspected and palpated. Any suspicious areas should be resected if possible or biopsied. Peritoneal washings should be obtained for cytologic evaluation. Systematic staging biopsies including multiple peritoneal biopsies, omentum, bilateral pelvic and paraaortic lymph nodes should be performed. Systematic staging during primary surgical management is advocated by most gynecologic oncologists.89,92–94 However, it is controversial whether an individual should be restaged after inadequate first surgery. Some would argue that restaging is not necessary because OGCT are highly responsive to chemotherapy even at recurrence, and sensitive tumor markers are available for most patients.
who had tumors grossly confined to one ovary.85 These studies reveal at least equivalent sustained remission rates between conservative surgery and bilateral salpingo-oophorectomy with or without hysterectomy. If a unilateral mass suspected of being malignant is encountered at primary surgery in a young patient, a unilateral salpingo-oophorectomy with frozen section analysis should be performed. If the frozen section reveals a germ cell tumor, then the other ovary and uterus can be left in situ. Routine biopsy of the remaining ovary should be avoided, because this could lead to adhesion formation, ovarian failure and/or infertility. If bilateral ovarian masses are present, the more suspicious one should be removed for frozen section analysis. If there is a malignancy, then a bilateral salpingo-oophorectomy is indicated. Ovarian cystectomy of one or both ovaries may be considered in selected patients, although this surgical approach has not been extensively tested. Owing to the high cure rates with chemotherapy, this approach may be appealing for patients who desire to preserve fertility.
Germ cell tumor Grossly confined to ovary/ovaries
Metastatic disease
USO, inspect contralateral ovary
USO, remove readily resectable metastasis
Remove contralateral ovary if replaced by tumor or dysgenetic
BEP × 3 to 6 cycles
Surgical staging performed
? SLL if macroscopic residual with immature teratoma
Surgical staging not performed
No metastatic disease
All others
Observation
Adjuvant treatment
Stage 1A dysgerminoma or stage 1A, grade 1 immature teratoma
BEP × 3 cycles
CT or ultrasound scan of abdomen/pelvis q 3 mo × 12 mo q 6 mo × 12 mo
BEP × 3 cycles
Observation
If relapse BEP × 4 to 6 cycles
Figure 3.12 Algorithm for management of ovarian germ cell tumors. USO, unilateral salpingo-oophorectomy; BEP, bleomycin, etoposide, cisplatin chemotherapy, SLL, second-look laparotomy
77
Ch 03 final.qxd
12/18/2006
15:13
Page 78
SURGERY FOR OVARIAN CANCER
Despite the importance of complete surgical staging, inadequate staging at initial surgery remains relatively common.89 This presents a dilemma to the treating physician regarding postoperative treatment. Imaging with computed tomography should be performed. Most germ cell tumors are very chemosensitive; therefore, if chemotherapy is planned and there is no evidence of bulky residual disease, surgical exploration is probably unnecessary. Because of the increasing frequency of long-term survivors after combination treatment for OGCT, the implications of such treatment on ovarian function and reproductive potential have been addressed. Gershenson evaluated the menstrual and reproductive function of 40 patients who had been treated with conservative surgery followed by combination chemotherapy for malignant OGCT.95 Prior to treatment 83% reported regular menstrual cycles, and after treatment 68% had regular menstruation. Of the 16 patients who attempted pregnancy after completing chemotherapy, 11 delivered 22 healthy infants.95 Tangir et al. evaluated 64 patients treated with fertility-preserving surgery for OGCT.96 Thirty-eight attempted conception and 29 (76%) achieved at least one pregnancy. Among these patients, 25 had been treated with adjuvant combination chemotherapy. Thus, most women with OGCT will retain normal menstrual function and a reasonable probability of having normal offspring.
cyclophosphamide (VAC), or cisplatin, vinblastine and bleomycin (PVB) were used in the 1970s and 1980s with improved outcome. Subsequently, the combination of bleomycin, etoposide and cisplatin (BEP) was found to be more active.97,98 Gershenson et al. reported that 96% of OGCT patients treated with BEP remained in sustained remission.97 Similarly, Williams et al. reported a Gynecologic Oncology Group study in which 89 of 93 patients (96%) remained continuously disease free.98 Patients with dysgerminoma were historically treated with radiation; although dysgerminoma is very radiosensitive, fertility could not be preserved with such treatment. However, several studies over the past 12–15 years have demonstrated that BEP is a highly effective regimen in treatment of ovarian dysgerminoma.97,99,100 Based on these studies, chemotherapy has essentially replaced radiation therapy for treatment of ovarian dysgerminoma patients and 3–4 cycles of BEP appear to be adequate.
Sex cord–stromal tumors Ovarian sex cord–stromal tumors (OSCST) are diverse and relatively uncommon, and their classification is based on the WHO system (Table 3.6). A hallmark of their biologic behavior is the production of
Table 3.6 World Health Organization classification of sex cord–stromal tumors
Postoperative therapy
Prior to combination chemotherapy, the prognosis of patients with an OGCT was dismal. However, starting around 1970, combination chemotherapy was found to improve the outcome of OGCT patients. Currently, the only patients with an OGCT who should be considered for treatment with surgery alone are those with well-documented stage IA, grade 1 pure immature teratoma or stage I pure dysgerminoma. For all other patients with non-dysgerminoma tumors, postoperative chemotherapy is currently the standard treatment. Combination chemotherapy regimens including vincristine, dactinomycin and
78
A.
Granulosa stromal cell 1. Granulosa cell 2. Thecoma–fibroma
B.
Androblastomas; Sertoli–Leydig cell tumors 1. Well-differentiated (Pick’s adenoma, Sertoli cell tumor 2. Intermediate differentiation 3. Poorly differentiated 4. With heterologous elements
C.
Lipid cell tumors
D.
Gynandroblastoma
E.
Unclassified
Ch 03 final.qxd
12/18/2006
15:13
Page 79
MANAGEMENT OF EARLY-STAGE OVARIAN CANCER
steroid hormones including estrogens, androgens, progestins and cortisol. This hormonal production can result in clinical changes. Over one-third of patients with Sertoli–Leydig cell tumors will present with definite evidence of androgen excess in the form of virilization.101 Similarly, a high proportion of young patients with juvenile granulosa cell tumor of the ovary will present with isosexual pseudo-precocity manifested by various combinations of uterine bleeding, vaginal discharge, enlargement of breasts or labia, or the appearance of pubic hair, axillary hair, or both.102 Preoperative evaluation of patients with suspected sex cord–stromal tumors should include evaluation of potential serum tumor markers such as androstenedione, testosterone and inhibin levels. Granulosa cell tumor of the ovary is the most common type of sex cord–stromal tumor and accounts for 70% of the tumors in this category. This neoplasm is divided into adult and juvenile types based on different clinical and histopathologic features. Juvenile granulosa cell tumors (JGCTs) represent only about 5% in prepubertal girls and women younger than 30 years.103 JGCT patients typically present at an early stage and have a favorable prognosis, although those with more advanced disease may experience an aggressive clinical course.104 Most patients with adult granulosa cell tumors also present with early-stage disease, but relapses tend to occur in a more indolent
fashion. Surgery is the mainstay of initial management for patients with a suspected sex cord–stromal tumor of the ovary. A suggested algorithm for management of patients with sex cord–stromal tumors of the ovary is presented in Figure 3.13. Based on multiple studies of patients with granulosa cell tumors and Sertoli–Leydig cell tumors, about 95% of these tumors are unilateral and most are confined to one ovary.101,105–111 Therefore, fertility preservation with unilateral salpingo-oophorectomy seems to be appropriate management for young individuals with disease confined to the ovary. However, for older patients or those with bilateral ovarian involvement, abdominal hysterectomy and bilateral salpingo-oophorectomy is the treatment of choice. The surgical principles are generally similar to those used in management of other ovarian malignancies. The tumor should be submitted for frozen section analysis. If this is consistent with a sex cord–stromal tumor, the entire abdominal cavity and pelvis should be carefully inspected and palpated – any suspicious areas should be resected. If there is no gross extraovarian disease, then systematic staging biopsies, including multiple random peritoneal biopsies from the abdomen and pelvis, omentum, and pelvic and para-aortic lymph nodes, should be performed. In a patient of reproductive age with granulosa cell tumor of the ovary, if the uterus is not removed to maintain
Sex cord–stromal tumor
Grossly confined to ovary
Metastatic disease
USO, staging
TAH-BSO, surgical cytoreduction
Stage 1A (grade 1, 2)
Stage 1, grade 3 or ≥ stage II
Observation
BEP or other platinum-based chemotherapy or adjuvant radiotherapy
BEP or other platinum-based chemotherapy
Figure 3.13 Algorithm for management of ovarian sex cord–stromal tumors. USO, unilateral salpingo-oophorectomy, TAH-BSO, total abdominal hysterectomy–bilateral salpingo-oophorectomy; BEP, bleomycin, etoposide, cisplatin chemotherapy
79
Ch 03 final.qxd
12/18/2006
15:13
Page 80
SURGERY FOR OVARIAN CANCER
fertility, then a dilatation and curettage should be performed to look for possible concurrent endometrial adenocarcinoma.112 Granulosa cell tumors can secrete estrogen and, as a result of this hormonal secretion, an association between granulosa cell tumors with endometrial hyperplasia and adenocarcinoma has been reported.105,106,113–115 Endometrial carcinoma has been reported in 2–27% of patients with granulosa cell ovarian tumors.105,106,115,116 Although there is general agreement that patients with metastatic sex cord–stromal tumors should receive postoperative treatment, other criteria for postoperative treatment are not as well defined. The role for adjuvant chemo- or radiotherapy in stage I–II or completely resected stage III disease has not been defined. For granulosa cell tumors, prognostic factors may include stage, tumor rupture, age at diagnosis, tumor size, mitotic index, cellular atypia and DNA ploidy.105–107,116–126 Determination of these factors has been based on retrospective reviews, mostly based on univariate analyses. Therefore, the importance of individual factors is unknown. Candidates for postoperative treatment among patients with OSCST include patients with stage I poorly differentiated Sertoli–Leydig cell tumors, Sertoli–Leydig cell tumors with heterologous elements, or metastatic tumors of any histology. There are limited data regarding chemotherapeutic management of patients with OSCST. Nonplatinum-based chemotherapy regimens have limited activity against OSCST.88 However, platinumcontaining regimens appear to have the best response rates for patients with OSCST. Overall response rates approaching 63% have been reported with combination chemotherapy consisting of cisplatin, doxorubicin and cyclophosphamide (PAC) in patients with metastatic OSCST.127 Combination chemotherapy regimen of cisplatin, vinblastine and bleomycin (PVB) has been reported to result in response rates ranging from 57 to 92%; however, durable remissions occur in only about 50% of patients with OSCST.128–130 Eventually, PVB therapy was replaced with BEP due to a better toxicity profile. Gershenson
80
et al. reported the first use of this regimen for OSCST. There was an overall response rate of 83%, but only 14% had a durable remission.131 Homesley et al. reported on a phase II Gynecologic Oncology Group study of 75 patients with OSCST.132 Fifty-five patients were assessable for response, and 38 of these patients underwent second-look surgery. Fourteen (37%) of these 38 achieved a pathologic complete response at the time of second-look surgery. There were 17 patients who did not undergo a second-look operation but were clinically free of disease at the end of the study. The authors reported that 69% of patients with advanced tumors and 51% of those with recurrent disease remained progression-free, with a median follow-up of 3 years. Other treatment modalities such as radiotherapy and hormonal therapy with progestins or gonadotropin releasing hormone analogs have shown some activity in small studies, but their overall role in the treatment of OSCST is unclear. Patients with sex cord–stromal ovarian tumors require long-term follow-up because the median time to relapse can be over 4 years after diagnosis.103 The clinical follow-up of these patients should include pelvic examination and tumor marker studies that were elevated at original diagnosis.
CONCLUSION Surgery remains the cornerstone of initial diagnosis and treatment for women with suspected ovarian cancer. The majority of patients will benefit from a thorough staging evaluation, in terms of both determining prognosis and guiding subsequent therapy. The role of conservative surgical treatment for reproductive-age women with cancer confined to the ovary continues to evolve; however, current data suggest that fertility preservation is safe in appropriately selected patients. For the surgeon, an intimate knowledge of the surgical staging techniques and their clinical applications described in the preceding pages are prerequisites for the safe and successful management of patients with apparent early-stage ovarian cancer.
Ch 03 final.qxd
12/18/2006
15:13
Page 81
MANAGEMENT OF EARLY-STAGE OVARIAN CANCER
14.
van ‘t Riet M, Steyerberg EW, Nellensteyn J, et al. Meta-analysis of techniques for closure of midline abdominal incisions. Br J Surg 2002; 89: 1350–6
15.
Colombo M, Maggioni A, Parma G, et al. A randomized comparison of continuous versus interrupted mass closure of midline incisions in patients with gynecologic cancer. Obstet Gynecol 1997; 89: 684–9
16.
Gallup DG, Talledo OE, King LA. Primary mass closure of midline incisions with a continuous running monofilament suture in gynecologic patients. Obstet Gynecol 1989; 73: 675–7
17.
National Institute of Health Consensus Conference on Ovarian Cancer. Screening, treatment, and followup. NIH Consensus Development Panel of Ovarian Cancer. JAMA 1995; 273: 491–7
Soisson AP, Olt G, Soper JT, et al. Prevention of superficial wound separation with subcutaneous retention sutures. Gynecol Oncol 1993; 51: 330–4
18.
Buchsbaum HJ, Brady MF, Delgado G, et al. Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet 1989; 169: 226–32
Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA 1983; 250: 3072–6
19.
Bagley CM Jr, Young RC, Schein PS, et al. Ovarian carcinoma metastatic to the diaphragm – frequently undiagnosed at laparotomy. A preliminary report. Am J Obstet Gynecol 1973; 116: 397–400
Sainz de la Cuesta R, Goff BA, Fuller AF Jr, et al. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994; 84: 1–7
20.
Hart WR, Norris HJ. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer 1973; 31: 1031–45
8.
Piver SM, Barlow J, Lele SB. Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecol 1978; 52: 100–4
21.
9.
Piver SM. Optimal surgical therapy in stage I and II ovarian malignancies. Int J Radiat Oncol Biol Phys 1982; 8: 247–9
Smith JP, Day TG Jr. Review of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute. Am J Obstet Gynecol 1979; 135: 984–93
22.
Sigurdsson K, Alm P, Gullberg B. Prognostic factors in malignant epithelial ovarian tumors. Gynecol Oncol 1983; 15: 370–80
23.
Jadhon ME, Morgan MA, Kelsten ML, et al. Cytologic smears of peritoneal surfaces as a sampling technique in epithelial ovarian carcinoma. Obstet Gynecol 1990; 75: 102–5
REFERENCES 1.
Young RC, Pecorelli S. Management of early ovarian cancer. Semin Oncol 1998; 25: 335–9
2.
Jemal A, Murray T, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2005; 55: 10–30
3.
Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000; 89: 2068–75
4.
5.
6.
7.
10.
Eltabbakh GH, Yadav PR, Morgan A, et al. Clinical picture of women with early stage ovarian cancer. Gynecol Oncol 1999; 75: 476–9
Mayer AR, Chambers SK, Graves E, et al. Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol Oncol 1992; 47: 223–7
11.
McGowan L, Lesher LP, Norris HJ, et al. Misstaging of ovarian cancer. Obstet Gynecol 1985; 65: 568–72
12.
Le T, Krepart GV, Lotocki RJ, et al. Clinically apparent early stage invasive epithelial ovarian carcinoma: should all be treated similarly? Gynecol Oncol 1999; 74: 252–4
24.
International Federation of Gynecology and Obstetrics. Changes in gynecologic cancer staging by the International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 1990; 162: 610–11
13.
Le T, Adolph A, Krepart GV, et al. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 2002; 85: 351–5
25.
Benedetti-Panici P, Greggi S, Maneschi F, et al. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol 1993; 51: 150–4
81
Ch 03 final.qxd
12/18/2006
15:13
Page 82
SURGERY FOR OVARIAN CANCER
26.
Chen SS, Lee L. Incidence of para-aortic and pelvic lymph node metastases in epithelial carcinoma of the ovary. Gynecol Oncol 1983; 16: 95–100
27.
Knapp RC, Friedman EA. Aortic lymph node metastases in early ovarian cancer. Am J Obstet Gynecol 1974; 119: 1013–17
28.
Lanza A, D’Addato F, Valli M, et al. Pelvic and paraaortic lymph nodal positivity in the ovarian carcinoma: its prognostic significance. Eur J Gynaecol Oncol 1988; 9: 36–9
29.
Walter AJ, Magrina JF. Contralateral pelvic and aortic lymph node metastasis in clinical stage I epithelial ovarian cancer. Gynecol Oncol 1999; 74: 128–9
30.
Burghardt E, Pickel H, Lahousen M, et al. Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol 1986; 155: 315–19
31.
Burghardt E, Girardi F, Lahousen M, et al. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991; 40: 103–6
32.
Cass I, Li AJ, Runowicz CD, et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 2001; 80: 56–61
33.
Petru E, Lahousen M, Tamussino K, et al. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 1994; 170: 656–62
34.
Westermann C, Mann WJ, Chumas J, et al. Routine appendectomy in extensive gynecologic operations. Surg Gynecol Obstet 1986; 162: 307–12
35.
Malfetano JH. The appendix and its metastatic potential in epithelial ovarian cancer. Obstet Gynecol 1987; 69: 396–8
36.
Sonnendecker EW. Is appendicectomy mandatory in patients with ovarian carcinoma? S Afr Med J 1982; 62: 978–80
37.
Bese T, Kosebay D, Kaleli S, et al. Appendectomy in the surgical staging of ovarian carcinoma. Int J Gynaecol Obstet 1996; 53: 249–52
38.
Rose PG, Reale FR, Fisher A, et al. Appendectomy in primary and secondary staging operations for ovarian malignancy. Obstet Gynecol 1991; 77: 116–18
39.
Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian can-
82
cer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021–7 40.
Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). Am J Clin Oncol 1995; 6: 887–93
41.
Young RC, Brady MF, Nierberg RM, et al. Randomized clinical trial of adjuvant treatment of women with early (FIGO I-IIA high risk) ovarian cancer – GOG n.95. Int J Gynecol Oncol 1997; 7: 17(Abstr)
42.
Bell J, Brady M, Lage J, et al. A randomized phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2003; 88: 156
43.
Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105–12
44.
Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organization for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003; 95: 113–25
45.
Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003; 95: 125–32
46.
Taylor HC. Malignant and semi-malignant tumors of the ovary. Surg Gynecol Obstet 1929; 48: 701–12
47.
International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand 1971; 50: 1–12
48.
Kaern J, Trope CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993; 71: 1810–20
Ch 03 final.qxd
12/18/2006
15:13
Page 83
MANAGEMENT OF EARLY-STAGE OVARIAN CANCER
49.
Barnhill DR, Kurman RJ, Brady MF, et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13: 2752–6
62.
Gershenson DM, Silva EG, Levy L, et al. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 1998; 82: 1096–103
63.
Hopkins MP, Kumar NB, Morley GW. An assessment of pathologic features and treatment modalities in ovarian tumors of low malignant potential. Obstet Gynecol 1987; 70: 923–9
64.
Buttin BM, Herzog TJ, Powell MA, et al. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol 2002; 99: 11–17
65.
Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer 1988; 62: 2212–22
50.
Link CJ Jr, Reed E, Sarosy G, et al. Borderline ovarian tumors. Am J Med 1996; 101: 217–25
51.
Bostwick DG, Tazelaar HD, Ballon SC, et al. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 1986; 58: 2052–5
52.
Massad LS Jr, Hunter VJ, Szpak CA, et al. Epithelial ovarian tumors of low malignant potential. Obstet Gynecol 1991; 78: 1027–32
53.
Trope C, Kaern J. Management of borderline tumors of the ovary: state of the art. Semin Oncol 1998; 25: 372–80
66.
Leake JF, Currie JL, Rosenshein NB, et al. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 1992; 47: 150–8
Haas JS, Mansfield CM, Hartman GV, et al. Results of radiation therapy in the treatment of epithelial carcinoma of the ovary. Cancer 1980; 46: 1950–6
67.
Houck K, Nikrui N, Duska L, et al. Borderline tumors of the ovary: correlation of frozen and permanent histopathologic diagnosis. Obstet Gynecol 2000; 95: 839–43
68.
Menzin AW, Rubin SC, Noumoff JS, et al. The accuracy of a frozen section diagnosis of borderline ovarian malignancy. Gynecol Oncol 1995; 59: 183–5
69.
Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol 1988; 72: 775–81
70.
Gotlieb WH, Flikker S, Davidson B, et al. Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome. Cancer 1998; 82: 141–6
71.
Morris RT, Gershenson DM, Silva EG, et al. Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol 2000; 95: 541–7
72.
Shiraki M, Otis CN, Donovan JT, et al. Ovarian serous borderline epithelial tumors with multiple retroperitoneal nodal involvement: metastasis or malignant transformation of epithelial glandular inclusions? Gynecol Oncol 1992; 46: 255–8
73.
Duska LR, Chang YC, Flynn CE, et al. Epithelial ovarian carcinoma in the reproductive age group. Cancer 1999; 85: 2623–9
54.
55.
56.
57.
58.
Leake JF, Rader JS, Woodruff JD, et al. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1991; 42: 124–30 Lin PS, Gershenson DM, Bevers MW, et al. The current status of surgical staging of ovarian serous borderline tumors. Cancer 1999; 85: 905–11 Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001; 19: 2658–64 Nikrui N. Survey of clinical behavior of patients with borderline epithelial tumors of the ovary. Gynecol Oncol 1981; 12: 107–19
59.
Gershenson DM, Silva EG. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 1990; 65: 578–85
60.
Manchul LA, Simm J, Levin W, et al. Borderline epithelial ovarian tumors: a review of 81 cases with an assessment of the impact of treatment. Int J Radiat Oncol Biol Phys 1992; 22: 867–74
61.
Crispens MA, Bodurka D, Deavers M, et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002; 99: 3–10
83
Ch 03 final.qxd
12/18/2006
15:13
Page 84
SURGERY FOR OVARIAN CANCER
87.
Manuel M, Katayama PK, Jones HW, Jr. The age of occurrence of gonadal tumors in intersex patients with a Y chromosome. Am J Obstet Gynecol 1976; 124: 293–300
88.
Gershenson DM. Management of early ovarian cancer: germ cell and sex cord–stromal tumors. Gynecol Oncol 1994; 55: S62–72
89.
Gershenson DM. Update on malignant ovarian germ cell tumors. Cancer 1993; 71: 1581–90
90.
Peccatori F, Bonazzi C, Chiari S, et al. Surgical management of malignant ovarian germ-cell tumors: 10 years’ experience of 129 patients. Obstet Gynecol 1995; 86: 367–72
91.
Thomas GM, Dembo AJ, Hacker NF, et al. Current therapy for dysgerminoma of the ovary. Obstet Gynecol 1987; 70: 268–75
92.
Creasman WT, Soper JT. Assessment of the contemporary management of germ cell malignancies